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An integral part of clinical cardiology, echocardiography is becoming a routine 
examination for all cardiac patients. This is due to its role not only in diagnosing 
cardiovascular diseases, but also in clinical decision making, follow-ups and cardiac 
events prediction in these patients. Even though competitive imaging techniques have 
been developed in the last few decades, echocardiography with its techniques remains 
the gold standard of clinical examinations in cardiology.  
The book Echocardiography – In Specific Diseases brings together contributions from 
well- known researchers from around the world, some of them specialized in imaging 
science in their clinical orientation, but also representatives from academic medical 
centers. Each chapter is structured and written to be accessible to those with a basic 
knowledge of echocardiography but also to be stimulating and informative to experts 
and researchers in the field of echocardiography. This book is primarily aimed at 
cardiology fellows during their basic echocardiography rotation, fellows of internal 
medicine, radiology and emergency medicine, but also experts in echocardiography.  
During the past decades technological advancements in echocardiography have been 
developing rapidly, leading to improved echocardiographic imaging using new 
techniques, and the authors of this book acknowledge the most advanced techniques 
used today. The techniques described should be useful in research as well as daily 
clinical practice, not only for detecting different cardiac pathologies in different 
patients, but also with the purpose to contribute to  clinical decision-making, as well as 
follow-ups and outcome predictions. An attempt has been made to explain the role of 
echocardiography in several special pathologies, which the readers may find in 
different chapters of the book. 
Finally, we hope that next few years will bring even greater advances in this field, and 
that this book will motivate other scientists in further enhancing the techniques 
available. The intention is not that these new echo modalities are only implemented in 
daily practice, but that they are used for the development of new techniques so that a 
better assessment of heart structure and its function can contribute to better treatment. 
Readers of Echocardiography – In Specific Diseases will hopefully enjoy this book and 
find the information and expert opinions within very useful to their clinical practice, 
as well as their research work. 
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The Degenerative Mitral Valve Regurgitation: 
From Geometrical Echocardiographic  
Concepts to Successful Surgical Repair 
Gheorghe Cerin, Bogdan Adrian Popa and Marco Diena 
The Cardioteam Foundation / San Gaudenzio Clinic, Novara 
Italy 
1. Introduction 
Echocardiography has become within the last years the main tool in the evaluation of the 
valvulopathies. Surgery plays a key role in the management of the valvular disorders, but it 
must be underlined that the surgical timing, planning and indication are all widely based on 
echocardiography. All the guidelines use the echocardiographic criteria to manage the 
valvular patients. Echocardiography became the main tool for the selection of the patient 
candidate to valve repair or replacement. The echocardiographic assessment is important in 
all the valvulopathies, but becomes crucial in the management of patients with mitral 
insufficiency, candidate to mitral valve repair.  
Still, it should be noted, that there is no randomized study comparing the mitral valve repair 
and mitral valve replacement, and comparisons between the two, using propensity 
matching or other statistical methods are very difficult. On the other hand there are 
numerous studies which suggest that the short and long term outcomes of patients 
undergoing successful mitral valve repair are superior to those undergoing replacement.  
Mitral valve repair has been proved to increase additional operative and long-term survival 
advantages over mitral valve replacement in case of chronic mitral regurgitation. The 
reduction in the left ventricular pump performance that has been observed after 
conventional mitral valve replacement, has not been obvious with mitral valve repair, 
provided that the postoperative contractile state remains pretty similar to the preoperative 
hemodynamic status. Compared to mitral replacement, mitral valve repair has lower 
mortality rates and higher long-term survival.. In addition, the thromboembolic and 
haemorrhagic complications associated with mitral valve reconstruction are also 
significantly decreased compared to mitral valve replacement. Several studies have reported 
that approximately 95% of patients are free from thromboembolic complications at 5 to 10 
years after surgery. In contrast, 10% to 35% of patients with mechanical prostheses have 
thromboembolic events within 5 to 10 years after surgery (Bonow, 2011). Thus, the number 
of mitral valve repairs is expected to increase because the advantages over replacement 
were also clearly demonstrated by daily practice. 
Nowadays, the number of patients undergoing mitral repair surgery is growing worldwide. 
The STS database proves that in the US, the percentage of patients undergoing mitral valve 
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repair has increased from roughly 50% in 2000 to nearly 70% in 2007 (Bonow, 2011), for those 
patients with degenerative mitral regurgitation (excluding mitral stenosis, previous cardiac 
surgery and other types of surgery other than tricuspid valve procedures). The percentage of 
patients is expected to increase, considering that roughly 50% of the symptomatic patients 
with severe mitral regurgitation are still denied surgery. ( Mirabel & colab,) 
2. The role of echocardiography in the management of degenerative mitral 
regurgitation 
First of all, in patients with degenerative mitral regurgitation, Echo identifies the type of 
degeneration: Barlow disease, fibroelastic deficiency (FED), hyper-elastic deficiency in 
Marfan syndrome etc. It is important for the surgeon to know it is important to know the 
aetiology of mitral insufficiency because some types of degenerative mitral regurgitation, 
such as FED, are more difficult to repair. Moreover, echo allows the identification of the 
mechanisms of mitral regurgitation, the alteration of leaflet coaptation and the specific 
geometrical concepts, which will be addressed further on.  
In fact, echocardiography stands out as the only evaluation tool used in mitral valve repair. 
In dedicated centers, the tight collaboration between the echocardiographer and the 
surgeon, transformed the mitral valve repair into the gold standard treatment of mitral 
regurgitation, with over 90-95% of feasibility.  
2.1 Standardization of the echocardiographic evaluation 
The standardization of the perioperative echo exam is a key element; it allows the 
identification of specific patterns of lesions which consequently guide the surgical planning 
and determine the outcome. It may be considered that the standardisation of the 
echocardiographic lesions is, in fact, the first step to achieve a standardised surgical 
technique. At the very beginning, when the echocardiography was less powerful, the mitral 
repair and the surgical strategy were mainly done by direct anatomical assessment 
performed by the surgeon in the operating theatre, after opening of the left atrium. Over the 
last decade, due to to a better resolution of the echo machines and the experience of the 
echocardiographer, the method allowed a reliable assessment of mitral anatomy and lesions, 
and by doing so, permitted a reliable surgical planning before opening of the left atrium.  
During the last decade, ‘Cardioteam’ has developed its own algorithm of mitral assessment, 
in order to standardize the lesions and the mechanisms of regurgitation. It uses some of the 
classically described patterns of lesions, such as mitral valve prolapse, flail, floppy or 
billowing mitral valve, but also new ones, such as ‘undulating mitral valve’, ‘overturned’ 
valve, ‘marginal prolapse’ of the anterior leaflet or ‘pseudo-cleft’ of the posterior leaflet. The 
application of this algorithm allowed a better understanding of the relationship between the 
mitral valve geometry and the valve function. This has significantly modified the surgical 
approach with subsequent improvement of the results. 
Technically speaking, preoperative echocardiographic examination has to consider the 
mitral valve as an eight-component anatomical structure: three pairs of corresponding 
scallops (A1-P1, A2-P2, A3-P3) and the two commissures (Figure 1). This approach guarantees 
a better dialog with the surgical team, by mean of structured lesion localizations and 
standardization of the examination.  
The Degenerative Mitral Valve Regurgitation:  




   
 
   
Fig. 1. The mitral valve scheme. The valve is divided into 8 components: three pairs of 
corresponding scallops (A1-P1, A2-P2, A3-P3) and two commissures. The Echo exam must 
describe the normality or the abnormalities of each component, assessing the pattern of 
mitral valve lesion for each one, focusing the attention on the leaflet coaptation.  
2.2 The first step of standardization: The prolapsing score 
During both transthoracic and intraoperative transesophageal examinations, each scallop 
must be analysed and a lesion code has to be ascribed: 0-normal, 1-elongated chordae, 2-
prolapse, 3-flail and 4-marginal prolapse. The complexity of the valve disorders is expressed 
by the prolapsing score (PS), namely the ratio between the sick scallops and the total 
scallops (eg 1/8; 8/8) per patient (Cerin, 2006, 2010).  
The echocardiographic message contained within the prolapsing score is fundamental for the 
surgeon to set the surgical approach. For example, when the echocardiographer states that the 
prolapsing score is 1/8 or 2/8, the surgical team expects a relatively ‘simple’ repair to be 
performed. Consequently, in such a patient the new surgical approaches such as minimally 
invasive surgery are more likely to be pursued. On the other hand, when the prolapsing score 
is as high as 8/8, the expected surgical approach will be different, more complex from the 
technical point of view, therefore more difficult and more likely to be done in classical 
sternotomy. In the operating theatre, the prolapsing score will be verified and confronted with 
the echo data Based on the experience of our center, around 75-80% of the echo information 
obtained from transthoracic exam fits the reality from the operating room.  
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2.3 The second step of standardization: Evaluation of the mitral valve geometry 
The normal mitral geometry is the concept that guides both the evaluation of the various 
valve lesions and the surgical strategy. This is a key concept, also very helpful in the 
postoperative assessment of surgical result and for the echocardiographic follow up. 
2.3.1 The triangle of coaptation 
The central feature of the normal mitral valve geometry is represented by the triangle of 
coaptation (Cerin, 2006, Tesler 2009). It is usually assessed by two dimensional 
echocardiography and is delimited by the coaptation point, which is normally sited within 
the left ventricular cavity, and two other points placed on the septal and lateral mitral 
annulus (FIG 2). The triangle presents a height, which may be considered the expression of 
the optimal balance between the elastic and collagen fibres of the mitral valve. In patients 
with degenerative mitral valve, the height of the triangle of coaptation, which is usually 
reduced, expresses the excess of elastic fibres.  
 
Fig. 2. The concept of triangle of coaptation. The triangle of coaptation is formed by the two 
points sited on the mitral annulus (A, B) and the coaptation point. The coaptation point (C) 
is normally situated into the left ventricle. LV – left ventricle; LA – left atrium; Ao – aorta;  
At the tip of this triangle, the echocardiographer has to measure the length of leaflet 
coaptation. The coaptation length and the coaptation height are cornerstone elements used 
in order to fully describe the valve geometry and to assess the result of the repair.  
It may be assumed that from a volumetric and a three dimensional geometrical perspective, 
the triangle of coaptation corresponds roughly to an asymmetrical tent. In the course of 
perioperative echocardiographic study, the systematic analysis of the mitral valve apparatus 
is done, focusing on whether the triangle of coaptation is present or not. The main surgical 
purpose of repair is achieving a good leaflet coaptation of at least 6mm in length and 
whenever possible, rebuilding the triangle of coaptation. Due to the increased amount of 
myxomatous tissue and elastic fibres in the mitral apparatus, the degenerative mitral valve 
usually loses its normal geometry progressively, alters the triangle of coaptation, presents 
itself as, elongated chordae or as a truly prolapsing valve. 
The Degenerative Mitral Valve Regurgitation:  
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2.4 The third step of standardization: Check the pattern of mitral valve lesions 
In degenerative mitral insufficiency, many types of mitral valve lesions were classically 
described in the literature: from the classical mitral prolapse or mitral flail, to the billowing 
or floppy mitral valve. For a true dialogue between the echocardiographer, 
anaesthesiologist, and surgeon, all the team has to rigorously know the meaning of the most 
frequent lesions found in these patients. Alongside the well-known classically patterns of 
lesions, our group identifies some other particular patterns of mitral valve injuries, such as: 
elongated chordae, marginal prolapse, overturned mitral valve, undulating mitral valve or 
the mitral valve’s pseudo-cleft. The main echocardiographic pattern used for the 
characterization of the degenerated mitral valve is presented further on.  
2.4.1 The pattern of ‘elongated chordae’ 
This pattern defines the situation when the coaptation point is found to be into the left 
ventricular cavity, immediately below the level of the mitral annulus. It is a borderline 
situation between a normal aspect of the mitral valve and the mitral prolapse. Usually is not 
associated with mitral regurgitation. For the surgical planning, it is important to recognise it 
and indicate it to the surgeon. Sometimes it may interest one or both leaflets (Figure 3), 
involving one or more scallops. The relatives of patients with truly mitral valve prolapse 
may sometimes present ‘elongated chordae’ during the echocardiographic exam, without 
the classical prolapse.  
 
Fig. 3. The pattern of ‘elongated chordae’. In the presence of ‘elongated chordae’, the 
coaptation point (C) is found into the left ventricular cavity, immediately below or at the 
level of the mitral annulus. Note the shape of the triangle of coaptation which is flattened. 
The coaptation height of the triangle has practically disappeared. LV – left ventricle; LA – 
left atrium; Ao – aorta. 
2.4.2 The pattern of ‘prolapsing valve’ 
The pattern of ‘prolapsing valve’ was classically defined as the presence of the coaptation 
point into the left atrium, above the level of the mitral annulus (Figure 4). By definition, the 
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2.4 The third step of standardization: Check the pattern of mitral valve lesions 
In degenerative mitral insufficiency, many types of mitral valve lesions were classically 
described in the literature: from the classical mitral prolapse or mitral flail, to the billowing 
or floppy mitral valve. For a true dialogue between the echocardiographer, 
anaesthesiologist, and surgeon, all the team has to rigorously know the meaning of the most 
frequent lesions found in these patients. Alongside the well-known classically patterns of 
lesions, our group identifies some other particular patterns of mitral valve injuries, such as: 
elongated chordae, marginal prolapse, overturned mitral valve, undulating mitral valve or 
the mitral valve’s pseudo-cleft. The main echocardiographic pattern used for the 
characterization of the degenerated mitral valve is presented further on.  
2.4.1 The pattern of ‘elongated chordae’ 
This pattern defines the situation when the coaptation point is found to be into the left 
ventricular cavity, immediately below the level of the mitral annulus. It is a borderline 
situation between a normal aspect of the mitral valve and the mitral prolapse. Usually is not 
associated with mitral regurgitation. For the surgical planning, it is important to recognise it 
and indicate it to the surgeon. Sometimes it may interest one or both leaflets (Figure 3), 
involving one or more scallops. The relatives of patients with truly mitral valve prolapse 
may sometimes present ‘elongated chordae’ during the echocardiographic exam, without 
the classical prolapse.  
 
Fig. 3. The pattern of ‘elongated chordae’. In the presence of ‘elongated chordae’, the 
coaptation point (C) is found into the left ventricular cavity, immediately below or at the 
level of the mitral annulus. Note the shape of the triangle of coaptation which is flattened. 
The coaptation height of the triangle has practically disappeared. LV – left ventricle; LA – 
left atrium; Ao – aorta. 
2.4.2 The pattern of ‘prolapsing valve’ 
The pattern of ‘prolapsing valve’ was classically defined as the presence of the coaptation 
point into the left atrium, above the level of the mitral annulus (Figure 4). By definition, the 
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lesion has to be present in PSLAx view, otherwise, due to the shaded shape of the mitral 
valve, a false diagnose of mitral prolapse may be possible.  
 
Fig. 4. Prolapsing mitral valve, with both leaflet involvement, shown in the 2D transthoracic 
parasternal long axis view. Notice the coaptation point (C) sited into the left atrium, behind 
the virtual line of the mitral annulus.  
2.4.3 The pattern of mitral valve flail 
It represents the classically loss of leaflet coaptation due to ruptured tendineous chordae. 
(Figure 5).  
  
Fig. 5. Flail of the mitral valve shown in the transthoracic parasternal long axis view using 
real time three-dimensional technique (zoom). The classical lesion usually involves the P2 
scallop of the posterior leaflet, in about 2/3 of the patients with flail mitral valve. LA = left 
atrium, LV = left ventricle, pml = posterior mitral leaflet.  
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2.4.4 The pattern of ‘marginal prolapse’ 
The pattern of ‘marginal prolapse’ is a rare type of mitral lesion, defined as an isolated 
protrusion of the free border area of one scallop, usually up to the insertion of the second 
degree chordae. In case of marginal prolapse, the remaining part of the surface of the scallop 
may be normal, without the displacement of the coaptation point into the left atrium. It is 
never present as isolated lesion; the marginal prolapse, as a rule, is associated with a P2 
scallop prolapse of the posterior leaflet (Figure 6). 
 
Fig. 6. Marginal prolapse of the anterior leaflet, A2 scallop (arrow), shown in 2D (zoom) and 
3 D Echo. Notice the “stair like aspect” of the anterior leaflet due to the regional prolapse 
located between the border of the valve and insertion of the second degree chordae (usually 
strut chordae). This is a hidden and tricky lesion, because its presence may transform the 
simple mitral plasty of one leaflet, in a complex mitral repair of both leaflets.  
2.4.5 The ‘undulating mitral valve’ 
The ‘undulating mitral valve’ is usually a redundant mitral valve, with excessive tissue, 
presenting with diastolic fluttering of the free border of both leaflets. In most cases, the 
prolapsing score is high, approximately 8/8 and as a rule, for the surgeon, it means a 
complex mitral repair. It is important to underline that the border or a normal mitral valve 
opens in a linear manner, without diastolic fluttering of the edge. 
 
Fig. 7. Undulating mitral valve. TEE deep trans-gastric short axis view. Notice the undulating 
aspect of the free borders of the leaflets (much more evident on moving pictures). 
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2.4.6 The pattern of ‘overturned mitral valve’ 
The pattern of ‘overturned mitral valve’: this kind of mitral lesion resembles the mitral valve 
flail as general echocardiographic aspect, but in the ‘overturned mitral valve’ the chordae 
are not ruptured (Figure 8). There is only an excessive elongation of the chordae and an 
obvious prolapse of the mitral valve into the left atrium.  
 
 
Fig. 8. Transthoracic echocardiography 4 chamber view, showing the obvious prolapse of 
the posterior mitral leaflet, due to the ‘eversion’ of the mitral valve. There is a loss of leaflet 
coaptation due to an excessive elongation of the mitral chordae (verified in the operating 
theatre).  
2.4.7 The ‘pseudo-cleft’ of mitral valve 
The ‘pseudo-cleft’ of mitral valve an obvious indentation of the border of the mitral valve, 
which penetrates deeply into the body of the mitral leaflet. It is pretty difficult to diagnose 
being visible only during the diastole and has to be integrated with the analyses of the 
colour Doppler in systole (Figure 9 A,B,C). It is never present as an isolated lesion; it is 
usually found in old mitral valve P2 prolapse. A split which resembles a pseudo-cleft 
develops between the scallops P2 and P3 (or P1).  
 
 
Fig. 9. (A,B,C). Diastolic transthoracic 2D and 3 D echocardiography short axis view (9A,B), 
showing the crack between P2 and P3 in a patient with P2 prolapse. The figure 9C shows a 3 
D transesophageal representation (surgical view) of a pseudo-cleft located between the P3 
and P2 scallops (red arrow).  
The Degenerative Mitral Valve Regurgitation:  
From Geometrical Echocardiographic Concepts to Successful Surgical Repair 
 
11 
2.4.8 The pattern of ‘floppy mitral valve’ 
Represents a redundant mitral valve, usually with both leaflet prolapse. It represents an 
excessive valve leaflet remodelling, with a ‘finger like’ transformation of the valve fabrics 
(Figure 10).  
 
Fig. 10. Transgastric transesophageal intraoperative view of a ‘floppy’ mitral valve (zoom). 
Notice the extensive remodelling of the leaflet fabric.  
2.4.9 The pattern of ‘billowing mitral valve’ 
Is represented by the protrusion of the leaflet body into the left atrium cavity. As a rule, the 
coaptation point still remains into the left ventricular cavity (Figure 11). associated with 
mitral insufficiency, but it is important to indicate it to the surgical team.   
 
Fig. 11. Billowing mitral valve. PSLAx view of transthoracic exam showing the protrusion of 
the posterior leaflet (P2 scallop) into the left atrial cavity. Often the mitral regurgitation may 
be absent or mild due to a pretty good coaptation, with the coaptation point still sited into 
the left ventricular cavity.  
 
Echocardiography – In Specific Diseases 
 
10
2.4.6 The pattern of ‘overturned mitral valve’ 
The pattern of ‘overturned mitral valve’: this kind of mitral lesion resembles the mitral valve 
flail as general echocardiographic aspect, but in the ‘overturned mitral valve’ the chordae 
are not ruptured (Figure 8). There is only an excessive elongation of the chordae and an 
obvious prolapse of the mitral valve into the left atrium.  
 
 
Fig. 8. Transthoracic echocardiography 4 chamber view, showing the obvious prolapse of 
the posterior mitral leaflet, due to the ‘eversion’ of the mitral valve. There is a loss of leaflet 
coaptation due to an excessive elongation of the mitral chordae (verified in the operating 
theatre).  
2.4.7 The ‘pseudo-cleft’ of mitral valve 
The ‘pseudo-cleft’ of mitral valve an obvious indentation of the border of the mitral valve, 
which penetrates deeply into the body of the mitral leaflet. It is pretty difficult to diagnose 
being visible only during the diastole and has to be integrated with the analyses of the 
colour Doppler in systole (Figure 9 A,B,C). It is never present as an isolated lesion; it is 
usually found in old mitral valve P2 prolapse. A split which resembles a pseudo-cleft 
develops between the scallops P2 and P3 (or P1).  
 
 
Fig. 9. (A,B,C). Diastolic transthoracic 2D and 3 D echocardiography short axis view (9A,B), 
showing the crack between P2 and P3 in a patient with P2 prolapse. The figure 9C shows a 3 
D transesophageal representation (surgical view) of a pseudo-cleft located between the P3 
and P2 scallops (red arrow).  
The Degenerative Mitral Valve Regurgitation:  
From Geometrical Echocardiographic Concepts to Successful Surgical Repair 
 
11 
2.4.8 The pattern of ‘floppy mitral valve’ 
Represents a redundant mitral valve, usually with both leaflet prolapse. It represents an 
excessive valve leaflet remodelling, with a ‘finger like’ transformation of the valve fabrics 
(Figure 10).  
 
Fig. 10. Transgastric transesophageal intraoperative view of a ‘floppy’ mitral valve (zoom). 
Notice the extensive remodelling of the leaflet fabric.  
2.4.9 The pattern of ‘billowing mitral valve’ 
Is represented by the protrusion of the leaflet body into the left atrium cavity. As a rule, the 
coaptation point still remains into the left ventricular cavity (Figure 11). associated with 
mitral insufficiency, but it is important to indicate it to the surgical team.   
 
Fig. 11. Billowing mitral valve. PSLAx view of transthoracic exam showing the protrusion of 
the posterior leaflet (P2 scallop) into the left atrial cavity. Often the mitral regurgitation may 
be absent or mild due to a pretty good coaptation, with the coaptation point still sited into 
the left ventricular cavity.  
 
Echocardiography – In Specific Diseases 
 
12
The final echo report contains coaptation height for each pair of scallops. The assessment of 
the triangle of coaptation, coaptation length and coaptation height. It represents an 
integrative scheme which is the synthesis of the various abnormalities found in different 
areas of the valve (Figure 1).  
The mitral annular diameter must be assessed in parasternal long axis view. This 
measurement corresponds to the septo-marginal diameter of the valve, which is the most 
important diameter of mitral valve, because the mitral leaflets work in an anterior-posterior 
plane. The folding of the mitral leaflets depends on this diameter and not on the 
intercommissural diameter (Figure 12). Keep in mind that the TEE intraoperative 
measurement of the mitral annulus tends to underestimate it, due to intraoperative 
hypovolemic status and reduced overload.  
  
Fig. 12. Correct measurement of the mitral valve annulus in PSLAX view. This diameter 
corresponds to the septo-marginal diameter of the valve (red diameter on the anatomical 
photo). The intercommissural diameter (the green diameter in the photo) has to be avoided 
in the algorithm of decision for surgical planning.  
The left ventricular dimensions (as EDØ and EDVolume) and function (LVEF) completes the 
diagnostic echo algorithm. The severity of mitral insufficiency is mainly quantitatively 
assessed by calculating the regurgitating volume using the PISA method (proximal 
isovelocity surface area) and vena contracta. Naturally, all other cardiac structures are 
carefully described, focusing on associated valvular lesions, mainly on the tricuspide valve. 
A special attention is paid to the left atrial volume, which may predict atrial fibrillation 
when measuring around 100ml as volume, or 50mm in diameter (parasternal long axis 
view). The preoperative assessment should also be focused to identify the patients at high 
risk to develop postoperative systolic anterior motion: hypertrophic interventricular 
septum, small left ventricular cavity, hyper dynamic left ventricle (see also 2.6.1 Prepump 
examination).  
The final report, using the Prolapsing Score and the structured anatomical analysis focused 
on mitral geometry, allows the surgeon to be aware of the complexity of the lesions and to 
develop a tailored surgical strategy of repair. In general, the surgical strategy aims to correct 
mitral regurgitation with a single orifice (achieving a coaptation length of at least 6mm) and, 
whenever possible, to rebuild the triangle of coaptation by using the PTFE GoreTex chordae 
and annuloplasty.  
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The transthoracic echocardiography is almost always sufficient to select the patient 
candidate to mitral valve repair or replacement. The preoperative transesophageal exam 
serves to refine the diagnosis, mainly in terms of pseudo-commissures, commissural 
prolapse, ruptured chordae etc. It is mandatory and the only tool used to assess the outcome 
of surgery in postoperative period. The transesophageal three-dimensional 
echocardiography is the best tool in assessing the commissural lesions pre and 
postoperatively. Thus, the echocardiography is an essential tool in the assessment of 
mechanism of mitral regurgitation and in choosing the right timing and the proper planning 
for surgical repair. The surgical strategy is tailored by the prolapsing score and the 
structural echocardiographic algorithm. The successful repair of mitral valve requires a 
skilled team: an expert surgeon in valve repair and a dedicated echocardiographer. 
2.5 Rebuilding the geometry of the mitral valve: Triangle of coaptation and coaptation 
length 
Generally, the main target of the mitral valve repair is to achieve a minimum of 6mm of 
coaptation length. Initially, although not specified, this measure referred to the medial 
corresponding scallops A2-P2. As said before, the triangle of coaptation resembles an 
asymmetrical tent, meaning that the coaptation length varies among different regions of the 
valve. This fact was intuitive until recently, when studies were available in regard to the 
definition of the normal values of the coaptation for each valve region. Once three-
dimensional echocardiography became available, this type of analysis was possible 
exclusively on an automatic base. 
A recent study has defined the normal values of the coaptation length; these results 
indicated that the normal coaptation length in zone 1° (corresponding to the scallops A1/P1) 
is about 3.5mm; in zone 2° (scallops A2/P2) the coaptation length is round 6.2mm and finally 
in zone 3° (scallops A3/P3) the coaptation length seems to be slightly inferior to zone 1°, 
around 3.2mm. The authors also indicated that the contribution at coaptation of the anterior 
and posterior leaflets is not symmetrical. The anterior leaflet seems to have a major 
involvement compared to the posterior one in all the regions of the valve. This underlines 
the importance of the functional reserve of the anterior leaflet (Gogoladze, 2011). 
Another recent study has proposed a new measure for the coaptation length, namely the 
coaptation length index, which represents the ratio between the coaptation length and the 
end-systolic annular septal-lateral diameter (Shudo, 2010). Lately, echocardiographic 
indexation of all measures (generally to the BSA), has gained much consideration. From this 
perspective, the new index looks promising but needs further investigation in order to 
establish its real practical value. 
2.6 Evaluation of mitral regurgitation 
Doppler echocardiography is the most common technique used for detection and evaluation 
of severity of valvular regurgitation. Several indexes have been used to assess the severity of 
regurgitation. The following paragraphs will make a brief description of the main indexes 
used in clinical practice, with their advantages and limitations. Surgery is addressed to 
patients with severe mitral degenerative regurgitation, and the quantification of the mitral 
insufficiency is a crucial point in the algorithm of decision. In the case of moderate mitral 
insufficiency, the surgery is considered only in patients with ischemic mitral regurgitation.  
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2.6.1 Proximal isovelocity surface area (PISA) or flow convergence 
In most patients, PISA was the method of choice for the quantification of mitral 
regurgitation. As already extensively described, the PISA method is derived from the 
hydrodynamic principle stating that, as blood approaches a regurgitant orifice, its velocity 
increases, forming concentric roughly hemispheric shells of increasing velocity and 
decreasing surface area.  
Colour flow mapping offers the ability to visualise one of these hemispheres that 
corresponds to the Nyquist limit of the instrument. If a Nyquist limit can be chosen at which 
the flow convergence becomes hemispheric in shape, the flow rate through the regurgitant 
orifice (ml/s) may be calculated as the product of the surface area of the hemisphere and the 
aliasing velocity. Assuming that the maximal PISA radius occurs at the time of peak 
regurgitant flow and peak regurgitant velocity, the maximal EROA is derived. The 
regurgitant volume can be estimated as EROA multiplied by the velocity time integral of the 
regurgitant jet. Since the PISA calculation provides an instantaneous peak flow rate, EROA 
by this approach is the maximal EROA and may be slightly larger than EROA calculated by 
other methods (Bargiggia, 1991). 
As indicated by the guidelines of evaluation of valve regurgitation, the measurement of 
PISA by Colour Flow Mapping was done by adjustment of the aliasing velocity until a well-
defined hemisphere was apparent. This was generally done by shifting the baseline towards 
the direction of flow, by lowering the Nyquist limit, or both. This has been shown to 
improve the reliability of the measurement (Zoghbi, 2003). 
Despite the fact that it became the preferred method for evaluation of mitral regurgitation, the 
PISA method is far from being perfect. As with any other technique, limitations exist, e.g.: it is 
more accurate for central jets than for eccentric jets and for regurgitation with a circular orifice. 
If the image resolution allows a good visualisation of the flow convergence, and a Nyquist 
limit can be chosen in order to obtain a hemispheric shape of the convergence, it is easy to 
identify the aliasing line of the hemisphere. However, it can be difficult to judge the precise 
location of the orifice and the flow convergence shape. Any error introduced is then squared, 
which can markedly affect the resulting flow rate and EROA. Attention should be paid to 
remain as parallel as possible with the Doppler beam. In every day practice, the main error in 
grading the mitral insufficiency occurs with the eccentric jets. Fig 13 (A,B). 
 
Fig. 13. (A,B). Simultaneous transthoracic PSLAX view and apical three chamber view 
showing an eccentric regurgitant jet in anterior mitral prolapse.  
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2.6.2 Color flow mapping  
Mitral regurgitation has been most frequently evaluated through the Colour Doppler 
method. As all the guidelines use echocardiographic criteria to indicate surgery in valvular 
patients, the echocardiographer must be aware of the drawbacks of the echocardiographic 
criteria used to send the patients in the operating room.  
For example, the maximal jet area correlates well with the semi quantitative angiographic 
grade of severity. However, only limited correlation is observed with quantitative measures 
of regurgitant volume and fraction. In addition, maximal jet area is not predictive of 
hemodynamic abnormalities, such as an elevated pulmonary capillary wedge pressure or 
reduced forward stroke volume. The regurgitant jet geometry, the physiologic variability, 
and the instrument settings are presumably some of the factors that may explain this 
reduced correlation with angiography. 
Given the three-dimensional shape of the regurgitant flow, in all scanning sections, the 
regurgitant jet area will depend on the geometry and direction of the jet. Colour flow 
Doppler mapping of free regurgitant jets that are unbounded by surrounding structures 
may lead to overestimation of severity due to entrainment of adjacent fluid by the high-
velocity jet. In contrast, the area of an eccentric jet is only 40% of the area of a free jet with 
the same regurgitant fraction. Eccentric jets are influenced by adjacent constraining surfaces, 
so that area measurements correlate poorly with regurgitant volume. It is also important to 
remember that the colour flow map of a regurgitant jet represents the spatial distribution of 
velocities and is not a direct measure of volume flow rate. Although colour Doppler jet area 
increases with regurgitant volume, this relationship is not linear because it is highly 
influenced by driving pressure, compliance of the receiving chamber, and the size and shape 
of the regurgitant orifice (Otto, 2002). 
2.6.3 Vena contracta 
It is one of the preferred echocardiographic indexes for its efficacy and its simplicity. The 
vena contracta is the narrowest portion of a jet that occurs at or just downstream from the 
orifice (Baumgartner, 1991). It is characterized by high velocity, laminar flow and is slightly 
smaller than the anatomic regurgitation orifice due to boundary effects.  
The cross-sectional area of the vena contracta represents a measure of the effective 
regurgitant orifice area (EROA), which is the narrowest area of the actual flow. The size of 
the vena contracta is independent of the flow rate and driving pressure for a fixed orifice. 
However, if the regurgitant orifice is dynamic, the vena contracta may change with 
hemodynamics or during the cardiac cycle. Comprised of high velocities, the vena contracta 
is considerably less sensitive to technical factors such as PRF compared to the jet in the 
receiving chamber. To specifically image the vena contracta, it is often necessary to angulate 
the transducer out of the normal echocardiographic imaging planes, such that the area of 
proximal flow acceleration, the vena contracta, and the downstream expansion of the jet can 
be distinguished. It is preferable to use a zoom mode to optimize visualization of the vena 
contracta and facilitate its measurement. The Colour flow sector should also be as narrow as 
possible, with the minimal depth, so as to maximize lateral and temporal resolution. 
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2.6.1 Proximal isovelocity surface area (PISA) or flow convergence 
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regurgitation. As already extensively described, the PISA method is derived from the 
hydrodynamic principle stating that, as blood approaches a regurgitant orifice, its velocity 
increases, forming concentric roughly hemispheric shells of increasing velocity and 
decreasing surface area.  
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regurgitant jet. Since the PISA calculation provides an instantaneous peak flow rate, EROA 
by this approach is the maximal EROA and may be slightly larger than EROA calculated by 
other methods (Bargiggia, 1991). 
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Fig. 13. (A,B). Simultaneous transthoracic PSLAX view and apical three chamber view 
showing an eccentric regurgitant jet in anterior mitral prolapse.  
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2.6.2 Color flow mapping  
Mitral regurgitation has been most frequently evaluated through the Colour Doppler 
method. As all the guidelines use echocardiographic criteria to indicate surgery in valvular 
patients, the echocardiographer must be aware of the drawbacks of the echocardiographic 
criteria used to send the patients in the operating room.  
For example, the maximal jet area correlates well with the semi quantitative angiographic 
grade of severity. However, only limited correlation is observed with quantitative measures 
of regurgitant volume and fraction. In addition, maximal jet area is not predictive of 
hemodynamic abnormalities, such as an elevated pulmonary capillary wedge pressure or 
reduced forward stroke volume. The regurgitant jet geometry, the physiologic variability, 
and the instrument settings are presumably some of the factors that may explain this 
reduced correlation with angiography. 
Given the three-dimensional shape of the regurgitant flow, in all scanning sections, the 
regurgitant jet area will depend on the geometry and direction of the jet. Colour flow 
Doppler mapping of free regurgitant jets that are unbounded by surrounding structures 
may lead to overestimation of severity due to entrainment of adjacent fluid by the high-
velocity jet. In contrast, the area of an eccentric jet is only 40% of the area of a free jet with 
the same regurgitant fraction. Eccentric jets are influenced by adjacent constraining surfaces, 
so that area measurements correlate poorly with regurgitant volume. It is also important to 
remember that the colour flow map of a regurgitant jet represents the spatial distribution of 
velocities and is not a direct measure of volume flow rate. Although colour Doppler jet area 
increases with regurgitant volume, this relationship is not linear because it is highly 
influenced by driving pressure, compliance of the receiving chamber, and the size and shape 
of the regurgitant orifice (Otto, 2002). 
2.6.3 Vena contracta 
It is one of the preferred echocardiographic indexes for its efficacy and its simplicity. The 
vena contracta is the narrowest portion of a jet that occurs at or just downstream from the 
orifice (Baumgartner, 1991). It is characterized by high velocity, laminar flow and is slightly 
smaller than the anatomic regurgitation orifice due to boundary effects.  
The cross-sectional area of the vena contracta represents a measure of the effective 
regurgitant orifice area (EROA), which is the narrowest area of the actual flow. The size of 
the vena contracta is independent of the flow rate and driving pressure for a fixed orifice. 
However, if the regurgitant orifice is dynamic, the vena contracta may change with 
hemodynamics or during the cardiac cycle. Comprised of high velocities, the vena contracta 
is considerably less sensitive to technical factors such as PRF compared to the jet in the 
receiving chamber. To specifically image the vena contracta, it is often necessary to angulate 
the transducer out of the normal echocardiographic imaging planes, such that the area of 
proximal flow acceleration, the vena contracta, and the downstream expansion of the jet can 
be distinguished. It is preferable to use a zoom mode to optimize visualization of the vena 
contracta and facilitate its measurement. The Colour flow sector should also be as narrow as 
possible, with the minimal depth, so as to maximize lateral and temporal resolution. 
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Because of the small values of the width of the vena contracta (usually <1cm), small errors in 
its measurement may lead to a large percentage error and misclassification of the severity of 
regurgitation. Therefore, it is very important to acquire accurate primary data and 
measurement (Zoghbi, 2003).  
The vena contracta method for assessing mitral regurgitation by colour Doppler 
echocardiography overestimates true mitral regurgitant orifice, it is markedly influenced 
by flow rate and the ultrasound system that is used. However, a diameter of a vena 
contracta over 8mm has a very good sensitivity and specificity for discriminating severe 
from non-severe mitral regurgitation (Zoghbi, 2003). The estimation of the diameter of the 
vena contracta is considered to have a good reproducibility of 10-15% (Margulescu, 
Brickner). 
2.7 Intraoperative assessment of mitral regurgitation 
The intraoperative echocardiography may be performed using the transesophageal or 
sometimes the epicardial method. In our practice we used almost exclusively the former. 
The epicardial approach may be used in paediatric cardiac surgery, when the adult TEE 
probe is too large and the paediatric TEE probe is not available.  
2.7.1 Prepump examination  
During the intraoperative transesophageal echocardiography, the evaluation of the severity 
of mitral regurgitation should be performed following the same steps and methodology as 
in all other echocardiographic examinations. It was observed that the degree of mitral 
regurgitation assessed by TEE in the operating theatre appears less severe in respect to the 
transthoracic exam. The team (anaesthesiologist, cardiologist and surgeon) has to be aware 
of the complexity of the changes induced by the general anaesthesia and the opening of the 
thorax and pericardial cavity. It also needs to be taken into account the loading condition of 
the heart, in term of the preload and afterload. Therefore, prepump TEE examination should 
not be used to assess the severity of the regurgitation, but mainly to assess its mechanism 
and the valve anatomy. 
Important items on the preoperative echocardiographic check-list are the valve anatomy and 
the analysis of the coaptation: Does it exists? Is it absent or only reduced? In what valve 
sector is the coaptation missing or reduced? Why? Is there a prolapsed valve or flail? How 
much does each segment prolapse in regard to the mitral annular plane? 
The answer to these final questions is essential for the surgeon who needs to perform a 
mitral valve repair. The correct evaluation of the entity of prolapse in tele-systole and in all 
segments may assist the surgeon in the decision of the length and position of the Gore-Tex 
neochordae they might need to use in order to correct the prolapse. In the operating theatre, 
the echocardiographer should measure the distance between the free border of the 
prolapsing scallop and the mitral annulus plane or the free border of the non-prolapsing 
scallop (Fig 14). This may be of great importance in measuring the length of the artificial 
chordae, but the experience of the surgeon remains the most important factor that will 
determine the final result.  
The Degenerative Mitral Valve Regurgitation:  




Fig. 14. (A,B,C). Intraoperative echocardiographic measurements showing prolapsed with 
flail of the posterior mitral leaflet (14A). The red line indicates the prolapsing plane; the 
green indicates the targeted coaptation plane (14B). Measuring the distance between the 
targeted position of the P2 scallop plane and the tip of the papillary muscle helps the 
surgeon decide the length of the neochordae (14C). 
The preoperative echocardiographic examination must be performed under normal or near 
normal loading conditions. If hypovolemia were present, not only the severity of mitral 
regurgitation might be underestimated, as stated before, but also a false prolapse of various 
segments might erroneously be described. Often, a false prolapse may be encountered at the 
level of the anterior mitral leaflet (scallops A2 and A3) when, in fact, the lesion, usually flail, 
eversion or extreme prolapse, is typically located on the posterior leaflet. In order to avoid 
this risk, the echocardiographer should bear in mind the diagnosis of the preoperative 
transthoracic examination and carefully compare it to his own findings. One should not 
forget that most of the times the transesophageal examination confirms most of the elements 
from the transthoracic exam. By using the new harmonics echocardiographic machines, 
approximately 2/3 of the lesions found in transthoracic examination will be confirmed by 
TEE exam. The mitral annulus might also be underestimated when hypovolemia is present. 
This is the case in the operating room when the prepump exam is performed. In our 
experience the transthoracic measurement of the mitral annulus should always be taken into 
account when the surgical strategy is discussed with the surgeon. 
It is important to remember that mitral regurgitation is dynamic and is affected by loading 
conditions. Reduction of afterload or intravascular volume at the time of the operation may 
reduce the true severity of the regurgitation. When mitral regurgitation is less significant 
than expected, the intravascular blood volume should be expanded and systemic vascular 
resistance should transiently be increased, by using repeated boluses of IV phenylephrine. 
The velocity of mitral regurgitation, and therefore display of its jet by Colour Doppler, 
depends on the pressure difference between the left atrium and left ventricle, which is 
higher in the presence of hypertension. The size of the jet in the left atrium is also very 
sensitive to changes in colour gain (directly proportional) and pulse repetition frequency 
(PRF) (inversely proportional). In any case, remember that the true assessment of the degree 
of mitral regurgitation is done by transthoracic exam.  
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The use of three-dimensional echocardiography for the evaluation of the mitral valve disease 
is rapidly evolving, especially in conjunction with the transesophageal echocardiography. One 
of the explanations of this extensive use is that the mitral valve rends itself to detailed 3D 
imaging from the left atrial perspective, as viewed by the surgeon (Shah & Raney, 2011). In our 
experience, three-dimensional echocardiography allows a reliable ‘volumetric’ evaluation with 
an excellent perspective on the whole mitral valve complex. Moreover, it permits an accurate 
(even more than the 2D echo) localisation of the various lesions. Still, the resolution and 
quality of the 3D images do not match those of the 2D echo.  
2.7.2 Prepump examination: Risk of systolic anterior motion 
Another important mission of the prepump examination is the identification of patients at 
risk for systolic anterior motion (SAM) of the anterior leaflet and subsequent functional 
mitral regurgitation. Fig 15 (A,B,C). The selection of patients at risk for SAM is already 
possible with the transthoracic approach. These patients usually have a small and /or hyper 
dynamic left ventricle, hypertrophy of the inter-ventricular septum, large posterior mitral 
leaflet, small mitral annulus and “narrow” LVOT (revealed by a reduced distance between 
the inter-ventricular septum and the coaptation line). One elegant study has indicated which 
could be the two echocardiographic indexes that may identify the patients at risk for SAM 
after surgery: the first is the ratio between the anterior and the posterior mitral leaflet 
(AL/PL) inferior to 1.3; the second is the distance from the coaptation line to the inter-
ventricular septum (C-Sept) equal or inferior to 2.5cm. (Maslow, 1999).  
 
 
Fig. 15. (A,B,C). Postoperative transesophageal 2D exam showing the presence of SAM at 
the level of the anterior mitral leaflet (15 A, C, arrow) and the presence of severe mitral 
regurgitation (15 B). 
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For this category of patients, in order to avoid SAM, the surgeon must be informed and 
aware of each element stated above (e.g. hypertrophic septum associated or not with large 
posterior leaflet and / or small mitral annulus etc) and the surgical approach should be 
tailored accordingly. If SAM should appear, its management consists of volume expansion, 
withdrawal of positive inotropic agents and sometimes use of short acting betablockers like 
esmolol. However, there is one type of SAM which is irreversible, having a ‘surgical 
mechanism’: in case of large P2 quadrangular resection without sliding plasty. This situation 
calls for a second run pump, to perform the sliding. This is particularly why the 
echocardiographer has to be aware of the surgical technique in the given case.  
Left ventricular outflow tract obstruction caused by SAM has been described as a 
complication of mitral repair. It has generally been attributed to the implantation of an 
annuloplasty ring or to various surgical techniques that alter the normal systolic narrowing 
of the antero-posterior diameter of the mitral annulus, or due to the displacing the mitral 
coaptation level towards the interventricular septum. The period immediately after 
cardiopulmonary bypass is the most crucial time for the development of SAM. This is due to 
reduced peripheral vascular resistance associated with hypovolemia and hypotension, 
which have a particular impact when the left ventricular cavity is small. This adverse effect 
is determined by a hyper dynamic state (increased kinetic energy of blood flow induced by 
catecholamines), associated with left ventricular hypovolemia.  
Mild degrees of LVOT dynamic obstruction after mitral valve repair often respond 
favourably to conservative treatment, as stated before: discontinuing inotropic agents in 
order to decrease contractility and heart rate, volume loading to increase preload, and 
augmenting afterload with pure α-agonists (such as phenylephrine) (Benea, 2005). If these 
measures prove inadequate, reoperation upon the mitral valve—including the performance 
of a sliding plasty or folding reconstruction that reduces the antero-posterior height of the 
posterior leaflet, the implantation of an annuloplasty ring of a larger size or the removal of 
the annuloplasty ring—may prove necessary. In refractory cases, even prosthetic mitral 
valve replacement has been reported. 
2.7.3 Tailored surgical strategy 
Based on the Prolapsed Score and on the structured echocardiographic analyses of the 
mitral valve, the surgical strategy has to be personalised. In order to choose the right 
surgical approach and to be able to interact with the surgeon, the echocardiographer needs 
to know the surgical techniques suitable for the given case. Building a trust-based 
relationship between the surgeon and the echocardiographer is crucial for the surgical 
result. Each case has to be discussed by the surgical team prior to the operation. 
This approach allows the surgeon to make two types of surgical planning, both necessary: 
one is the planning with ‘the closed atrium’, meaning the mental planning based on the 
echocardiographic findings. The other one is performed after the left atrium was opened 
and the valve is directly inspected. In our experience the two coincide in most of the cases, 
due to standardization of the echo exam, to the presence of the echocardiographer in the 
operating room and due to the dialogue with the surgical team.  
Recently, the importance of performing the mitral valve repair using the most 
‘physiological’ approach has become crucial. Single valve orifice but also posterior mitral 
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leaflet mobility became cornerstone principles that guide the mitral repair in our centre. The 
classical techniques of repair included the quadrangular resection of the posterior mitral 
leaflet and ring annuloplasty, which inevitably led to a rigid posterior leaflet (Verma, NYJM 
2009). Lately, many surgeons have chosen to perform the triangular resection (instead of 
quadrangular) in order to guarantee a higher mobility of the posterior leaflet and thus an 
increased anatomical and functional leaflet reserve, convinced that this will subsequently 
achieve a better and longer lasting coaptation.  
In conclusion, we may assume that the importance of the preoperative transesophageal 
examination is given by the accuracy in identifying the mechanism of mitral regurgitation 
and valve anatomy (flail, prolapse, loss of coaptation, perforation and so on), and by 
describing the geometry of the mitral apparatus. There is a close correlation between valve 
geometry and function. The Colour Doppler mapping might underestimate the entity of the 
regurgitant flow; thus, the prepump echocardiographic evaluation needs to rely more on 
valve geometry and regurgitant mechanism, and less on the Colour flow Doppler. 
2.7.4 Postpump examination 
In most cases, with an experienced surgeon, mitral valve repair leads to a competent mitral 
valve with mild or no residual mitral regurgitation. However, there are potential 
complications of mitral valve repair that are readily recognized by postpump intraoperative 
echocardiography. Many of these complications may not be apparent clinically or may take 
longer to accurately diagnose without echocardiography. If left untreated, these 
complications may interfere with the long-term success of the procedure and require early 
re-operation (Otto, 2003). In fact, the trust-based relationship between the 
echocardiographer and the surgeon is tested when a second run pump is needed. In case of 
debatable “moderate” mitral regurgitation, the team has to focus on the mitral coaptation 
(and geometry) rather than on the Colour Doppler analyses. Remember to avoid the 
hypovolemic status. 
Transesophageal echocardiography is practically the only method used immediately after 
weaning from the cardiopulmonary bypass in order to assess the result of the mitral repair. 
It must rapidly answer some essential questions about the repaired valve. The most 
important task of the transesophageal echocardiography is to analyze the postoperative 
mitral valve geometry and function, focusing on leaflet coaptation. 
 It may occur that immediately after weaning the patient off the cardiopulmonary by-pass, 
the echocardiographer declares the success of the repair after analyzing only some of the 
available views, usually the mid-esophageal 0° or distal-esophageal 135°, where only 
scallops A2 and P2 are evaluated. The postoperative transesophageal examination has to be 
performed using the same algorithm that was used during the preoperative evaluation. One 
has to bear in mind that the triangle of coaptation remains the goal of a typically functioning 
reconstructed valve. It should be taken into consideration that the reconstruction of the 
coaptation triangle is not always possible. When present, the echocardiographer has to 
search for it in all the segments of the valve: from the anterior commissure and 
corresponding scallops A1/P1, P2/A2 and of course the medial scallops A3/P3 and the 
posterior commissure.  
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After surgical repair, the essential issue is that the coaptation point must be dragged within 
the left ventricle, underneath the mitral annular plane (Figure 15). In the normal mitral 
valve, this type of coaptation expresses the physiological equilibrium between the collagen 
and elastic fibres, which confers the right balance between the elasticity and resistance of the 
valve. Same should be true about the repaired mitral valves, which will most probably 
remain elastic and long-lasting when their geometry satisfies the mentioned criteria.  
 
Fig. 16. TEE postoperative aspect of complex mitral valve repair. Notice the rebuilding of the 
triangle of coaptation (arrows) and the classical ‘smile’ aspect of the mitral valve on the 
intraoperative photo (middle). LA = left atrium.  
Even if already stated, it should be underlined that the triangle of coaptation and the 
coaptation length need to be carefully assessed in all the regions of the mitral valve before 
expressing the final judgement on the real immediate outcome of the repair. Keep in mind 
possible traps. The surgeon’s “hurry” to know the results of repair; do not express any 
conclusions before appropriate ventricular loading conditions are achieved. Do not start the 
post-operative assessment by Colour Doppler. The most important thing is to assess the 
length of coaptation and valve geometry.  
In order to correctly assess the valve geometry, the loading conditions should be optimal: 
hypovolemia should be avoided as it may underestimate a potential residual mitral 
regurgitation or label as ‘prolapsing’ an otherwise normal valve leaflet. We have stated 
about the prepump exam that the importance of the Doppler techniques for the evaluation 
of the severity of the mitral regurgitation was lower than the importance of the geometrical 
analysis. This does not mean that Color Doppler mapping shouldn’t be performed but it 
should integrate the geometrical analysis and not replace it. These details are essential to the 
surgeon. The outcome depends on that. This statement is also true about the post-pump 
examination. Geometry is more important than colour (meaning Colour Doppler mapping). 
Whenever the result of the repair is suboptimal and there is residual mitral regurgitation, 
the echocardiographer must be able to rapidly identify the true mechanism of mitral 
regurgitation. The problem may vary from residual prolapse or restriction of one or more 
valve sectors - presumably due to incorrect neo-cordal length, residual marginal prolapse if 
left untreated, oversized annuloplasty ring, persistence of pseudo-commissures, etc. In these 
cases further surgery with a second run pump might be needed. Rarely, the mitral valve 
problem may be a consequence of a ventricular dysfunction when a post-pump contractility 
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issue may appear. This should also be clearly pointed out by the post-pump 
echocardiographic examination. In this case, further surgery for the mitral valve might not 
be needed, but only ventricular assistance.  
The main problem with residual mitral regurgitation arises in patients with moderate 
insufficiency. In loose teams, the surgeon tends to underestimates the importance of the 
mitral regurgitation. Because the echocardiography is a semi quantitative method, in every 
day practice the surgeon will go easier to the second run pump only if the 
echocardiographer was able to 100% accurately identify the preoperative lesions, compared 
to the intraoperative findings. Therefore, an excellent preoperative assessment will bond the 
team, creating a trustful relationship between the surgeon and the echocardiographer.  
The evaluation of the outcome after mitral repair has been done mainly using the Colour 
Doppler mapping. When the residual regurgitation is absent or of mild degree, the result is 
judged as adequate. Generally, superior degrees of residual regurgitation, naturally 
correlated with the coaptation and geometrical analysis, indicate the need for a second 
pump run. In selected cases (e.g. old patients or significant comorbidities), moderate or 
more than moderate residual regurgitation might be accepted when the risk of a second 
pump run to correct the valvular problem exceeds the potential benefit for the patient.  
The annuloplasty ring is used in almost all operated patients. From an echocardiographic 
technical perspective this might determine difficulties in the postoperative evaluation of the 
repaired mitral valve when performing the distal esophageal long axis views. Usually, the 
presence of the annuloplasty ring might ‘hide’ the mitral valve leaflets by posterior 
shadowing immediately after surgery. To overcome this problem a valid solution could be 
the evaluation from the deep transgastric short-axis and long axis views.  
3. Conclusion 
The standardization of the preoperative, intraoperative and postoperative 
echocardiographic examination is crucial for the skilled dialogue with the surgical team and 
for the results. As the surgery of degenerative mitral insufficiency is somehow standardised, 
echocardiography should also be as standardised as possible. The use of a specific pattern of 
lesion confers better and tailored surgical planning, adapted to each given case. Use of 
different types of patterns such as mitral valve flail, undulating valve or marginal prolapse 
facilitates the dialog with the surgeon. 
Alongside specific patterns of lesions, a crucial point in surgical repair is the evaluation of 
the mitral geometry. Apart from the three dimensional echo, the main tool in assessing the 
mitral valve geometry by 2 D echocardiography, is the coaptation triangle.  
The echocardiographer must consider the mitral valve as an eight-element anatomical 
structure, and separately assess each segment. The preoperative exam has to be done based 
on a structural echocardiographic algorithm and finally expressed as a prolapsing score.  
By using this strategy, the mitral valve repair is feasible, with excellent results.  
In dedicated centres, the mitral valve repair for degenerative disease is possible with more 
than 95% rate of success. The use of the triangle of coaptation, coaptation length and 
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coaptation height as geometric echocardiographic concepts aiming to restore the mitral 
valve shape and coaptation, is a crucial point to improve the surgical planning and results. 
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Echocardiography in Severe Aortic Stenosis 
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1. Introduction 
Aortic stenosis (AS) is the most frequent valvular heart disease in west developed and 
developing countries, with prevalence between 0.02% in adults under 44 years and 3-9% in 
elderly over 80 years. Patients with this disease may remain asymptomatic for years, 
particularly in elderly with naturally limited exercise. If the patients remain untreated after 
they become symptomatic, the mortality at 10 years follow-up is 80-90%. Based on the 
etiology, mainly are three types of AS: 1) Calcific AS, which is most frequent type in adults 
of advanced age (2–7% of the population), 2) Congenital, which dominates in the younger 
patients, and 3) Rheumatic AS, which is becoming rare in developed countries. 
Patient history and physical examination remain important in the diagnosis of AS. For the 
proper patient management, the evidence of the symptoms characteristic for AS: exertional 
shortness of breath, angina, dizziness, or syncope. Further diagnostic right direction is 
characteristic systolic murmur.  
The disappearance of the second aortic sound is specific to severe AS. 
Aortic valve replacement (AVR) is the only effective treatment for severe aortic AS. It is 
performed either isolated or concomitantly with coronary artery by-pass graft operation, 
which take place in almost 50% of patients with AS. The overall mortality of isolated AVR is 
3-5% in patients below 70 years and 5-15% in elderly. After successful AVR, symptoms and 
quality of live improves significantly. The long term 10 years survival after successful AVR 
is very satisfied and it resulted till 75%. The most important factors that may affect the 
survival are old age, high NYHA functional class, associated aortic regurgitation, 
concomitant coronary aortic by-pass graft and atrial fibrillation.  
2. Echocardiography in aortic stenosis patients  
Echocardiography is the key diagnostic tool, not only to confirm the presence of AS, but also 
to assesses the degree of valve calcification, LV function and wall thickness. Today, 
echocardiography provides prognostic information in patients with AS.  
The severity of AS is provided with a very high sensitivity and specificity by Doppler 
echocardiography. A valve area 1.0 cm2 in a patient with AS is considered severe. The 
indexing of aortic valve area to body surface area is more powerful parameter, and a cut-off 
value of 0.6 cm2/m2 is considered severe AS. However, valve area detected by Doppler 
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echocardiography cannot be the only parameter for clinical decision making for aortic valve 
replacement, and it should be considered in combination with flow rate, pressure gradient 
and ventricular function, as well as functional status of an individual patient.  
In patients with AS and normal left ventricular (LV) ejection fraction (EF) the mean 
pressure gradient of 50 mmHg (Figure 1), was used as a cut-off for the decision making 
for aortic valve replacement. However, in patients with depressed global LV function, 
even in patients with severe AS, Doppler echocardiography may result with low pressure 
gradients (underestimated gradients). In these patients, stress echocardiography using 
low-dose dobutamine may be helpful to distinguish truly severe AS patients from the rare 
cases of pseudosevere AS. In patients with truly severe AS, only small changes in valve 
area, but significant increase in pressure gradients are shown, whereas in pseudosevere 
AS patients are registered significant increase of valve area surface, but only minor 
changes in pressure gradients, before and at peak dose of dobutamine. The dobutamine 
stress-echocardiography is useful also to detect the presence of contractile reserve, which 










Fig. 1. Continues Doppler velocity of the aortic valve, in a patient with high pressure 
gradient and normal EF, before aortic valve replacement. 
 
Echocardiography in Severe Aortic Stenosis 
 
27 
3. Outcome of patients with aortic stenosis 
Aortic stenosis is a chronic progressive disease. Patients with AS may remain 
asymptomatic for a long period of time, and the duration of the asymptomatic phase 
varies widely among individuals. The most frequent cause of death in symptomatic 
patients is sudden cardiac death. However, sudden cardiac death in asymptomatic 
patients with AS is very rare.  
Older age, presence of atherosclerotic risk factors, valve calcification, peak aortic jet velocity, 
low LV EF and increase of transvalvular pressure gradient with exercise, were shown as 
independent predictors of poor outcome in AS patients.  
The development of symptoms on exercise testing, in physically active patients with AS, 
predicts a very high likelihood of symptom development within 12 months. The occurrence 
of symptoms, in these patientsş is a correlate of poor prognosis. The increased of mortality 
in these patients has been reported within months of symptom onset, which is often not 
promptly reported by patients. 
4. Echocardiographic predictors in patients with severe aortic stenosis and 
poor left ventricular systolic function 
Left ventricular systolic function was shown as one of more important predictors of patients 
with AS. Patients with AS and LV systolic dysfunction have a poor prognosis if valve 
replacement is not performed. LV EF, as the most important conventional parameter for the 
LV global systolic function, was consistently reported as a postoperative prognostic factor in 
patients with severe AS. Patients with severe left ventricular dysfunction have increased 
intra-operative mortality, and there are yet contradictions about their improved outcomes 
after the AVR. Generally, the LV systolic dysfunction is not a contraindication to surgery. It 
was shown that patients who underwent AVR have a 5-year survival rate 60–70%, with a 
high operative mortality in the range of 10–15% for patients with LV systolic dysfunction. 
To predict the postoperative outcome of patients with severe AS and impaired LV function, 
the preoperative dobutamine stress echocardiography is useful technique. The presence of 
good contractile reserve in dobutamine stress echocardiography supports potential benefit 
from AVR and better outcome in these patients.  
AVR decreases the LV afterload, through transvalvular pressure drop (Figure 2), resulting 
in regression of LV hypertrophy.  
LV mass regression predominantly occurs within the first 6 months of surgery. Even there 
are few publications regarding the pre-operative echocardiographic predictors of LV 
functional recovery in AS patients with low EF, it justify the statement to consider these 
patients for the operation, after individual assessment of the patient, considering co 
morbidities and general conditions. 
Recovery of LV function was evident after aortic valve replacement in the majority of 
patients with aortic stenosis and pre-operative LV dysfunction. 
Patients with increased LV end-systolic dimension and/or LV systolic volume index seem 
to have less chance for the LV functional recovery. It seems that these patients loosed 
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echocardiography cannot be the only parameter for clinical decision making for aortic valve 
replacement, and it should be considered in combination with flow rate, pressure gradient 
and ventricular function, as well as functional status of an individual patient.  
In patients with AS and normal left ventricular (LV) ejection fraction (EF) the mean 
pressure gradient of 50 mmHg (Figure 1), was used as a cut-off for the decision making 
for aortic valve replacement. However, in patients with depressed global LV function, 
even in patients with severe AS, Doppler echocardiography may result with low pressure 
gradients (underestimated gradients). In these patients, stress echocardiography using 
low-dose dobutamine may be helpful to distinguish truly severe AS patients from the rare 
cases of pseudosevere AS. In patients with truly severe AS, only small changes in valve 
area, but significant increase in pressure gradients are shown, whereas in pseudosevere 
AS patients are registered significant increase of valve area surface, but only minor 
changes in pressure gradients, before and at peak dose of dobutamine. The dobutamine 
stress-echocardiography is useful also to detect the presence of contractile reserve, which 
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contractile reserve, and up to now there is no evidence that they may improve LV systolic 
function after operation, and therefore we should less encourage these patients for the AVR. 
However, there are studies that have shown that even in patients with poor LV systolic 
function, there is still ability for a LV function recovery after AVR, explaining it through the 
mechanism of the markedly reduction of outflow tract resistance.  
Studies have shown that stented and stentless valves have similar effect on the LV mass 
reduction after AVR in all patients that underwent this procedure, despite significant 
differences in indexed effective orifice area and peak flow velocity in favor of the stentless 
valve. However, in patients with AS and markedly reduced ventricular function, there was 
shown more rapid LV mass and function normalization in stentless patients compared to 
similar patients receiving a stented valve. The luck of large randomized studies for these 
prostheses makes even more difficult decision. However, a numerous retrospective studies 
have shown improvement in symptoms and LV EF in about 70% of the survivors after AVR 











Fig. 2. Continues Doppler velocity of the aortic valve, in the same patient, two weeks after 
aortic valve replacement. 
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They suggest that despite increased operative mortality, these patients should not be denied 
aortic valve replacement, given the substantial potential clinical benefit from AVR 
replacement. 
In conclusion, in patients with severe aortic stenosis with impaired LV global systolic 
function, assessed by LV EF, AVR has significantly better outcome compared to those 
treated medically. These patients are likely to carry a high risk operation (up to 10%), than 
to have a very poor prognosis for 10 years survival in medical treatment.  
5. Echocardiographic predictors in patients with severe aortic stenosis and 
preserved left ventricular systolic function 
Global LV function, assessed by conventional EF remains normal in most of AS patients. 
However, the long axis systolic function, assessed by M-mode echocardiography and/or 
tissue Doppler imaging (TDI) velocities, decreases even in patients with preserved EF. In AS 
patients with preserved EF, the longitudinal velocity, strain and strain rate are decreased 
and deteriorate further as AS become severe. These changes reflect that the LV myocardial 
dysfunction beginning at the subendocardium in early stages of AS and progress to mid-
wall and to transmural contraction impairment in patients with severe AS. Recent studies 
have shown also that in patients with AS and preserved LV EF, the apical rotation and LV 
twist are increased and untwist is delayed compared to normals, as compensatory 
mechanisms for the increased intracavitary pressure overload and subendocardial 
ischaemia. Also, it was shown that these LV myocardial correlate with the severity of AS. 
However, these compensatory mechanisms are lost after the LV EF deterioration. 
Strong evidence exists showing beneficial effect of AVR, not only in improving patients’ 
symptoms but also in recovering, even partially, overall cardiac function. Improvement of 
LV ventricular function in these patients is interpreted on the basis of regression of 
myocardial hypertrophy, increased myocardial perfusion and hence overall cavity 
performance, at early and mid-term post-operative periods. While EF is the most popular 
measure of pre-operative LV systolic function in such patients, and surgical risk assessment 
it lacks representing subendocardial component of the LV function.  
Severe aortic stenosis causes significant subendocardial dysfunction despite preserved ejection 
fraction. Aortic valve replacement surgery and removal of left ventricular afterload results in 
recovery of intrinsic subendocardial function within a week of surgery, well before mass 
regression and reverse remodeling. Such degree of pre-operative subendocardial disturbances 
may represent early changes that if ignored may substantiate and become irreversible. Thus, 
the presence of such abnormalities in symptomatic patients, even with normal ejection 
fraction, may suggest further evidence for a need for valve replacement in order to maintain 
overall integral ventricular function and to avoid potential clinical complications.  
In patients with severe aortic stenosis and and maintained LV EF, the left ventricular twist 
is increased as compared with normal subjects suggesting a wall motion compensation for 
the reduced long axis motion in the aim to preserve LVEF. These motions alter towards 
normal values within six months of aortic valve replacement (Figure 3). These findings are 
growing evidence that on LV dysfunction and their improvement after AVR, even in 
asymptomatic patients, and may assist in identifying patients needing surgery before LV 
damage becomes irreversible.  
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Fig. 3. Example of LV rotation and twist in control, pre AVR and post AVR. Purple line 
showing peak of apical rotation and green showing peak basal rotation. AVR, aortic valve 
replacement (Reproduced from Lindqvist P et al. Aortic valve replacement normalizes left 
ventricular twist function. Interact CardioVasc Thorac Surg 2011;12:701-706, 
doi:10.1510/icvts.2010.262303, with permission from the European Association for Cardio-
Thoracic Surgery). 
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1. Introduction 
A considerable burden of cerebral embolism in association with cardiac surgery reflects 
dislodgement of aortic atheroma caused by manipulating the aorta during a surgical 
procedure (Barbut and Gold 1996; Van Zaane, Zuithoff et al. 2008; Whitley and Glas 2008; 
Yamaguchi, Adachi et al. 2009). It clearly makes logical sense to identify and attempt to 
avoid dislodgement of aortic atheroma. This strategy depends on two key elements; the 
accurate detection of atheroma in the aorta, and the surgeons ability to avoid or otherwise 
minimise manipulation of atheromatous disease. 
In this chapter we will describe how epiaortic echocardiography is essential to the complete 
examination of the ascending aorta and aortic arch for the detection of atheroma, and what 
surgical options may be available for the avoidance or minimisation of aortic atheroma 
manipulation. 
2. Background summary of the literature 
2.1 Intraoperative cerebral embolism and brain dysfunction 
Whilst clinical stroke is relatively infrequent in cardiac surgery (1-3%) (Calafiore, Di Mauro 
et al. 2002; Douglas and Spaniol 2009; Rosenberger, Shernan et al. 2008; Shroyer, Coombs et 
al. 2003), such events can be properly viewed as major cerebral injury. Subclinical brain 
injury on the other hand is not often clinically apparent but may be detected by subtle 
neurocognitive testing and this is frequently present (20-60%) (Hammon, Stump et al. 1997; 
Mahanna, Blumenthal et al. 1996; Zamvar, Williams et al. 2002). MRI studies post cardiac 
surgery similarly highlight a far higher frequency of cerebral embolic events then the clinical 
assessment of neurological status would suggest (Deslauriers, Saunders et al. 1996; Djaiani, 
Fedorko et al. 2004; Vanninen, Aikia et al. 1998). Brain injury may be caused by other factors 
related to cardiopulmonary bypass, systemic inflammatory response syndrome, tissue 
oedema, air embolism, post-operative hypotension, anaesthetic agents used, ischaemia and 
reperfusion injury, or alternative causes of embolism. Nevertheless, the predominant cause of 
embolic brain injury reflects surgical manipulation of the atheromatous aorta and thus offers 
the greatest prospect for changing outcome. 
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2.2 Assessment of the aorta 
Surgeons traditionally assess the aorta by manual palpation prior to the placement of the 
cannula and clamp. This is problematic because it relies on the detection of calcified plaques 
in the wall of the aorta that are accessible to the finger; which predominantly reflects the 
anterior and right sides of the ascending aorta, and anterior aspect of the aortic arch. Other 
areas of the aorta are really not accessible or not easily accessible to manual palpation. The 
detection of calcified plaques infers resistance being offered to the surgeon’s finger, and our 
previous data found that detection of such plaques was relatively accurate under these 
circumstances. What are not accurately detected are soft (not calcified) plaques, which do 
not offer counter resistance to the examining finger. However the propensity of these to 
disrupt and embolise the contents or components is potentially greater than for calcified 
plaques. Thus the manual examination of the ascending aorta by the surgeon should be 
considered as frequently inaccurate (Royse, Royse et al. 2000; Royse, Royse et al. 1998; 
Suvarna, Smith et al. 2007; Sylivris, Calafiore et al. 1997; Whitley and Glas 2008). 
Transoesophageal echocardiography is not able to visualise the distal ascending aorta or the 
proximal aortic arch. This is because the distal trachea and right main bronchus lie between 
oesophagus and these structures, and so the ultrasound signal is not transmitted leading to 
poor or absent imaging. Furthermore, the anterior aortic wall is further than near structures 
in relation to the probe, further diminishing resolution. Yet the most frequent locality for 
placement of the aortic cannula for cardiopulmonary bypass is in the distal ascending aorta 
proximal or aortic arch. Equally, the aortic clamp is placed immediately proximal to the 
aortic cannula whereby there is substantial aortic manipulation. Thus, the key areas of aortic 
manipulation related to the use of cardiopulmonary bypass occur in the “blind spot" of 
transoesophageal echocardiography.  
This point was reinforced by a meta-anaylsis performed by van Zaane comparing 
transoesophageal vs. epiaortic echocardiography (Van Zaane, Zuithoff et al. 2008). 
Transoeosphageal had a sensitivity of only 21% (95% confidence interval (CI) 12-32%); but a 
specificity of 99% (95% CI 96-99%). Simply TOE is accurate at assessing the aorta that can be 
visualised, but not all of the aorta can be imaged. Therefore, the accurate assessment of all 
parts of the thoracic aorta require a combination of transoesophageal and epiaortic 
(epivascular) surface ultrasound. 
2.3 The precise anatomical location of aortic atheroma 
Of critical importance to the use of epiaortic ultrasound, is the ability to precisely locate 
atheroma in relation to anatomical landmarks. The use of TOE provides for relative 
anatomical locality by finding lesions relative to the locality of other landmarks seen, such 
as the aortic valve. TOE alone will therefore lead to imperfect localisation of the aortic 
atheroma; whereas use of a handheld probe provides definitive locality of aortic atheroma 
(since the lesion is present immediately beneath the probe). This is crucial when precise 
locality on cannulation or clamping is required in order to avoid atheroma. 
2.4 Prevalence of thoracic aortic atheroma 
Surprisingly, coronary bypass patients do not uniformly have aortic atheroma, even in the 
presence of extensive small vessel arterial disease. But the danger for surgeons (and 
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patients) is assuming that the presence of important aortic atheroma is predictable. Indeed 
the unpredictability of the presence, location and severity of aortic atheroma is the most 
powerful argument in favor of routine comprehensive ultrasound examination of the entire 
thoracic aorta being performed. Specifically, the absence of atheroma seen in the descending 
aorta or proximal aorta by TOE does not always predict the absence of clinically important 
atheroma in the distal ascending aorta or proximal arch (the TOE "blind spot") (Royse, 
Royse et al. 1998). 
We described six zones for the thoracic aorta; three in the ascending aorta, two in the aortic 
arch and the descending aorta. TOE typically images zones 1-2 and 5-6 well; and epiaortic 
echocardiography images zones 1-4 well. For reference, most aortic cannulations and 
clamping occurs in zones 3-4; proximal aortic graft anastomoses in zone 2 and aortic incision 
for valve replacements in zone 1. An intra-aortic balloon pump will be deployed in zone 6. 
Within these zones, the site of the atheroma is further subcategorised into cross sectional 
quadrants of the aorta - anterior, posterior, left or right lateral. 
We found that the prevalence of atheroma increased with distance from the aortic root. 
There was a marked increase in frequency and severity distal to the aortic arch. Increasing 
age resulted in greater prevalence. Considering moderate or severe atheroma in zones 1-4, 
the prevalence was 29% in patients aged 70-79, and 34% in those aged more than 80 years 
(Royse and Royse 2006). 
2.5 Assessment of aortic atheroma severity 
A variety of definitions have been published, but most commonly this simple classification 
is used, Table 1 (Royse, Royse et al. 1998). The greater the severity of atheroma, the greater 
the likelihood that manipulation will result in embolism; excepting that most believe 
embolism is unlikely to arise from "mild" atheroma. In clinical practice the term "clinically 
important atheroma" generally refers to moderate or severe atheroma. 
 
Grade Criteria 
Nil Intimal thickening < 2 mm 
Mild Intimal thickening 2 – 4 mm 
Moderate Flat intimal thickening > 4 mm 
Severe Complex intimal thickening > 4 mm 
or any mobile atheroma 
Table 1. Classification of atheroma grade 
The morphology of the atheromatous plaque may further predict the likelihood of 
embolism. Without good data, it would seem intuitive that a soft friable, frond-like 
atheromatous plaque is more likely to break free and embolise, than a flat, fibrous plaque. 
3. Strategies to avoid aortic atheroma dislogement 
The detection of aortic atheroma does not directly lead to the avoidance of atheroma 
dislodgement and embolism. The actual avoidance of dislodgement requires a change to the 
surgical strategy. Thus the detection of atheroma is the important first step, and allows a 
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decision to be made that then subsequently leads to the avoidance of embolism. This 
highlights one of the key difficulties for surgeons. It may be that a surgical alternative is not 
possible for the patient; or the skill, capability or surgical repertoire of the surgeon 
themselves limits potential alternative strategies being employed. This may vary with 
training, experience and technical capability as well as patient factors such as absence of 
suitable conduits and so forth. Thus there is no commonly applied solution available. 
 
Mild Moderate Severe 
Fig. 1. Ultrasound images of aortic atheroma. 
In principle however, there are few significant options available for surgical alteration. In 
the case of the use of cardiopulmonary bypass, aortic calculation and clamping sites may be 
altered so as to manipulate the aorta near to but not involving the atheroma. Certain 
operations preclude alteration of manipulation position, and so alternative sites for aortic 
cannulation or alternatives for aortic clamping need to be considered. In practice, often the 
surgeon simply accepts the need to manipulate atheromatous segments of the aorta and 
proceeds anyway. An example may be the performance of an aortic valve replacement; 
whereby there is very limited scope for alteration of the aortic incision, and it may not be 
possible to entirely avoid atheroma in this locality.  
Coronary artery bypass surgery provides more opportunity to alter the surgical operation so 
as to avoid atheroma. The construction of proximal aortic anastomoses is predominantly 
situated in the mid ascending aorta; the proximal aorta is rarely used as this will kink the 
grafts and the distal ascending aorta is occupied by the aortic clamp and antegrade cannula. 
So unless the grafting strategy is altered, the detection of aortic atheroma and the need to 
move the site of cannulation and clamping is impeded by the inability to move the proximal 
aortic anastomoses. By performing a composite graft (Y-graft), the aortic anastomoses can be 
eliminated, thereby allowing the freedom to move sites of aortic manipulation (Royse, 
Royse et al. 2000; Royse, Royse et al. 1999), see Fig. 2. Should there be extensive aortic 
atheroma, consideration of "off pump" coronary revascularisation would allow the complete 
avoidance of any aortic manipulation - the ideal solution from this perspective. Many surgeons 
however, are not comfortable or skilled in these techniques, thereby limiting their use.  
 








Fig. 2. Freedom to move sites of aortic manipulation. The sites of aortic manipulation are 
shown for (A) aorta-coronary and (B) Y graft techniques. Construction of aortic anastomosis 
limits movement of aortic cannulation and clamp sites away from detected atheroma 
illustrated in the distal ascending and proximal aortic arch. The atheroma is easily avoided 
by using the exclusive Y graft technique by moving the sites of cannulation and clamping 
away from the atheroma. (Small star (*) is antegrade cardioplegia cannulation site; AV is 
aortic valve.) 
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Fig. 2. Freedom to move sites of aortic manipulation. The sites of aortic manipulation are 
shown for (A) aorta-coronary and (B) Y graft techniques. Construction of aortic anastomosis 
limits movement of aortic cannulation and clamp sites away from detected atheroma 
illustrated in the distal ascending and proximal aortic arch. The atheroma is easily avoided 
by using the exclusive Y graft technique by moving the sites of cannulation and clamping 
away from the atheroma. (Small star (*) is antegrade cardioplegia cannulation site; AV is 
aortic valve.) 
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The technique of aortic clamping itself varies, with the repeated application of the aortic 
clamp rather than the "single clamp" technique; and use of the partial occlusion clamp for 
the construction of proximal aortic coronary anastomoses, further manipulates the aorta and 
will lead to greater propensity for dislodgement of any existing aortic atheroma. In 
particular, the typical Kaye-Lambert partial occlusion ("side biting") clamp will usually 
occupy the majority of the ascending aorta in a vertical plane and about half of the cross 
sectional diameter of the aorta in the horizontal plane, see Fig. 3. This clamp will therefore 
manipulate a considerable part of the ascending aorta even with only one application; and 





Fig. 3. Partial occlusion clamp manipulates most of the ascending aorta 
4. Technique of epiaortic (epivascular) ultrasound examination 
The sequence and technique have been previously published (Royse and Royse 2006) Fig. 4 
or with Guidelines (Glas, Swaminathan et al. 2008). One important point to appreciate is 
that the orientation of the aorta to orthogonal planes is highly variable. For accurate cross-
sectional dimensions, the ultrasound probe needs to be oriented at 90 degrees to the aorta 
irrespective of the relationship to the orthogonal plane, Fig. 5. This is not difficult to achieve, 
and it is obvious as you simply rotate the probe to produce a circle on the screen; yet it is a 
common failing in the early learning experience. 
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Fig. 4. Standardised epiaortic echocardiography examination. (Royse and Royse 2006) 
Intraoperative ultrasound examination of the aorta and proximal coronary arteries 10 standard 
views, 2 supplementary views. LAX, longitudinal axis, SAX, short axis, RCA, right coronary 
artery, SoV, Sinus of Valsalva, AV, aortic valve, RCC, right coronary cusp of aortic valve, LCC, 
left coronary cusp, NCC, non coronary cusp, ST Jn, sinotubular junction of aorta, ALMV, 
anterior leaflet of mitral valve, RV, right ventricle, RVOT, right ventricular outflow tract, MPA, 
main pulmonary artery, PV, pulmonary valve, LA, left atrium, LAD, left anterior descending 
artery, Cx, circumflex coronary artery, SVC, superior vena cava, RA, right atrium, RPA, right 
pulmonary artery, Z1, zone 1 or proximal ascending aorta, Z2, zone 2 or mid ascending, Z3, 
zone 3 or distal ascending, Z4, zone 4 or proximal aortic arch, Z5, zone 5 or distal aortic arch, 
RMB, right main bronchus, LMB, left main bronchus, RBCA, right brachiocephalic artery, 
LCC, left common carotid artery, LSA, left subclavian artery. Reproduced from Royse A and 
Royse C. A standardised intraoperative ultrasound examination of the aorta and proximal 
coronary arteries. Interact CardioVasc Thorac Surg 2006;5:701-704. © 2006 European 
Association of Cardio-Thoracic Surgery with permission from the European Association of 
Cardio-Thoracic Surgery. 
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Fig. 5. Ultrasound images of aorta. A angles of ultrasound probe. B Zone 1, C Zone 2, D 
Zone 3, E Aortic arch, F Cerebral vessels. Other abbreviations as for Fig. 4.Ultrasound probe 
selection is important. A phased, linear array probe with a frequency in the rage 8-12 Mhz is 
preferred. Some attention to the physical size is also important as a large probe may not 
easily fit in the sternotomy wound, and a round probe is difficult to hold or to maintain 
orientation. If the frequency is too high, then the depth of penetration may be sufficiently 
limited so as to preclude adequate imaging of the posterior aortic wall. 
A B C 
D E F
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A variety of ways exist to allow a sterile acoustic interface for the probe. The simplest is to 
partially fill a sterile plastic cover with saline - either a custom made bag or a bag adapted 
from another use such as an endoscopic camera cover. Alternatively, sterile gel may be 
placed within the bag as the internal acoustic couple. Some fill the pericardium with warm 
saline to enhance the external acoustic couple; most do not. One important point that is 
often overlooked is the issue of “near field crowding”. What this refers to is the need to 
maintain some distance between the ultrasound probe and the structure being imaged in 
order for the ultrasound to travel some distance, and then be reflected from the structure 
back to the probe. This is important for visualising the superficial (anterior) aortic wall. This 
wall cannot be adequately imaged when the probe is resting directly on the surface; and in 
order to adequately image this part of the aorta, the probe needs to be moved away from the 
aorta by 0.5-1.0 cm. Of course the acoustic coupling between the probe and the structure in 
question needs to be maintained, but generally this is not a problem when saline has been 
used within the plastic bag in which the probe is suspended. 
There is no rationale or valid reason for any particular order or protocol to be followed 
whilst performing a study. However, it makes logical sense to follow a routine in order to 
efficiently complete a comprehensive study. See Fig. 4 for a proposed sequence. Special-
purpose ultrasound examinations may be performed without the need for a comprehensive 
examination. One example may be to interrogate flow in the right coronary artery following 
an aortic valve replacement where there is some doubt as to whether the prosthesis was 
obstructing the flow to this coronary artery.  
The operator performing the ultrasound examination is (or should be) the surgeon. The 
anaesthetist should be recording sample images or video loops as the examination is being 
performed so that appropriate archiving of the findings occurs. The fascinating thing about 
the subject of atheroma detection and this ultrasound examination is that very little new 
knowledge or new techniques have occurred in the past 10-15 years. The evidence is very 
strong that the performance of this study accurately establishes the presence and location of 
aortic atheroma and provides the surgeon with a greater range treatment options. 
Remarkably, this is not a routine part of every cardiac surgical procedure! Indeed only the 
minority of surgeons actually perform epiaortic ultrasound examinations and even fewer 
still, perform this on a routine basis. 
5. Training 
This ultrasound examination pertains almost exclusively to cardiac surgery. It could quite 
easily be applied to any other forms of surgery involving examination of large arteries or 
veins. At the current time intraoperative transoesophageal echocardiography is routine in 
many parts of the Western world, and becoming more common in the developing world. 
Therefore generally there is a good level of basic ultrasound experience and knowledge 
amongst surgical staff from the general observation of ultrasound being performed. 
However, at present few will be actively performing ultrasound examinations such as 
transthoracic echocardiography, ultrasound guided procedures or venous duplex studies all 
of which are becoming standard practice in advanced cardiac surgical centres. With this 
familiarity, the performance of epiaortic ultrasound examination is extremely simple to 
implement and to teach since there is significant underlying theoretical and practical 
experience. For those who have not performed ultrasound examinations before themselves; 
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or have quite limited theoretical knowledge of ultrasound technologies, learning this 
examination is a little more difficult. The emphasis here is on the word “little”, highlighting 
that this examination is quite straightforward and simple to perform and therefore to learn. 
Also, interpreting the images is equally very simple since it is obvious from first principles 
without any formal training, and the precise locality of atheroma is similarly very easy to 
appreciate since it is always directly beneath the ultrasound probe at the time. Surgeons do 
not require additional anatomy training; indeed the level of anatomy knowledge is the 
greatest of all specialties and even trainees have an extremely good understanding of 
anatomy. It would be expected that an advanced surgical trainee should be able to 
competently and confidently perform and epiaortic ultrasound examination after about 10-
20 supervised cases. With previous practical and theoretical experience in ultrasound or 
echocardiography, it may only be 5-10 cases. 
Learning epiaortic ultrasound examination may be a sufficient enough stimulus to engage in 
a wider use of ultrasound technologies. In the current advanced cardiac surgical 
management, the use of ultrasound by cardiac surgeons should become a matter of routine 
daily practice. Performing transthoracic echocardiography in the pre-and post-operative 
settings, ultrasound guided procedures including pleural drainage and ultrasound lung 
examinations are quite straightforward and simple to learn. However, specific postgraduate 
training in addition to advanced surgical training should be undertaken; specifically it is not 
yet integrated as part of an advanced training program. A variety of postgraduate courses 
are available including university-based courses. These may cater for general (non-cardiac) 
clinical practice, or for an advanced diagnostic (cardiac) practice. Our program may be 
reviewed at www.heartweb.com  
6. Summary and recommendations 
The predominant cause for cerebral atheroma embolism in cardiac surgery using 
cardiopulmonary bypass relates to dislodgement  of aortic atheroma with embolism caused 
by manipulation of the aorta. Transoesophageal echocardiography is not able to visualise 
the distal ascending aorta and proximal aortic arch due to the presence of air in the bronchi 
crossing between aorta and oesophagus. Epiaortic ultrasound is able to assess this portion of 
the aorta; and in addition is far more accurate than manual assessment by the surgeon’s 
finger. Avoiding the atheroma however, requires a change to the surgical strategy. 
A standardised comprehensive echocardiography protocol is proposed. The performance of 
this ultrasound examination is relatively straightforward and is fairly easily taught. It is 
recommended that it be before routinely. 
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Diastolic Heart Failure 
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1. Introduction 
The mortality, hospitalization, and prevalence rates of heart failure (HF) are increasing, in 
spite of decrease in coronary artery and cerebrovascular disease mortality.[1] Importantly, 
heart failure with normal ejection fraction (HFNEF) currently accounts for more than 50% of 
all heart failure patients and as the prevalence of HFNEF in the heart failure population 
rises by 1% a year.[2]  
Approximately half of patients with a diagnosis of heart failure have a normal left 
ventricular (LV) ejection fraction (EF) without valve disease which is defined as diastolic 
heart failure (DHF), because it is attributed to LV diastolic dysfunction.[3] The prevalence of 
DHF increase even more dramatically with age more than HF with a reduced EF and is 
much more common in women than in men at any age. Studies examining prevalence of 
diastolic heart failure in hospitalized patients or in patients undergoing outpatient 
diagnostic screening and prospective community based studies have shown that the 
prevalence of diastolic heart failure approaches 50%.[4-6] Although HF patients with 
preserved systolic function has a slightly better prognosis than HF patients with abnormal 
systolic function, there is a fourfold higher mortality risk compared with subjects free of 
HF.[7] 
2. The mechanism of DHF  
Heart failure is a clinical syndrome characterized by symptoms and signs of increased tissue 
water and decreased tissue perfusion. Definition of the mechanisms that cause this clinical 
syndrome requires measurement of both systolic and diastolic function. When heart failure 
is accompanied by a predominant or isolated abnormality in diastolic function, this clinical 
syndrome is called diastolic heart failure. The pathophysiology is attributed to LV diastolic 
dysfunction, in which LV diastolic chamber size is normal or reduced despite elevated 
filling pressures resulting in decreased cardiac output. DHF occurs when the ventricular 
chamber is unable to accept an adequate volume of blood during diastole, because of a 
decrease in ventricular relaxation and/or an increase in ventricular stiffness,[3] and 
increased circulating blood volume is present. Hypertension, ischemia, aging and diabetes 
mellitus are the major risk factor of a decrease in ventricular relaxation and/or an increase 
in ventricular stiffness. Endocardial biopsies from HF patients without coronary artery 
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disease (CAD) showed structural and functional differences in cardiomyocytes from 
patients with diastolic HF compared to cardiomyocytes from patients with abnormal 
systolic ejection fraction.[8] Myocytes from patients with diastolic HF had increased 
diameter and higher myofibrillar density and developed greater passive force and had 
greater calcium sensitivity. Myocardial collagen volume fraction was equally elevated.  
2.1 Characteristics of medical examination  
Patients with DHF were shown to have similar pathophysiological characteristics, compared 
with HF patients with a reduced EF including reduced exercise capacity and impaired 
quality of life. The Framingham criteria for diagnosis of HF is the following. Major criteria 
are 1) paroxysmal nocturnal dyspnea or orthopnea, 2) jugular venous distention (or central 
venous pressure is more than 16 mmHg), 3) hearing rale or acute pulmonary edema, 4) 
cardiomegaly, 5) hepatojuglar reflex, and 6) response to diuretics (weight loss is more than 
4.5 kg per 5 days). Minor criteria are 1) ankle edema, 2) nocturnal cough, 3) exertional 
dyspnea, 4) pleural effusion, 5) vital capacity lower less than two thirds of normal condition, 
6) hepatomegaly, and 7) tachycardia (more than 120 beats/minute. With diastolic HF, fourth 
heart sounds may be present but third heart sounds are seldom present. Chest radiography 
will show pulmonary congestion during acute exacerbations and for some time following an 
episode, cardiomegaly will be present in systolic HF but may or may not be present in HF 
with preserved ejection fraction. When it is difficult with diagnosing HF, it is important to 
use echocardiography. [9,10] 
2.2 The diagnosis of DHF 
The diagnosis of heart failure with normal left ventricular (LV) ejection fraction (HFNEF) 
requires the following conditions to be satisfied: (1) signs or symptoms of heart failure; (2) 
normal or mildly abnormal systolic LV function; (3) evidence of diastolic LV dysfunction. 
Normal or mildly abnormal systolic LV function implies both an LVEF > 50% and an LV 
end-diastolic volume index (LVEDVI) < 97 mL/m2. Diagnostic evidence of diastolic LV 
dysfunction can be obtained invasively (LV end-diastolic pressure >16 mmHg or mean 
pulmonary capillary wedge pressure >12 mmHg) or non-invasively by tissue Doppler 
(TD) (E/E’ >15) with an echocardiography. If TD yields an E/E’ ratio suggestive of 
diastolic LV dysfunction ( 8 < E/E’ < 15 ), additional non-invasive investigations are 
required for diagnostic evidence of diastolic LV dysfunction. These can consist of blood 
flow Doppler of mitral valve or pulmonary veins, echocardiographic measures of LV mass 
index or left atrial volume index, electrocardiographic evidence of atrial fibrillation, or 
plasma levels of natriuretic peptides. If plasma BNP is more than 200 pg/mL, diagnostic 
evidence of diastolic LV dysfunction also requires additional non-invasive investigations 
(Fig. 1). 
LVEDVI: left ventricular end-diastolic volume index, mPCW: mean pulmonary capillary 
wedge pressure, LVEDP: left ventricular end-diastolic pressure, TD: tissue Doppler, E: early 
mitral valve flow velocity, E’: early TD lengthening velocity, BNP: brain natriuretic peptide, 
E/A: ratio of early (E) to late (A) mitral valve flow velocity, Dct: deceleration time, LVMI: 
left ventricular mass index; LAVI: left atrial volume index, Ard: duration of reverse 
pulmonary vein atrial systole flow, Ad: duration of mitral valve atrial wave flow. 
 








Symptoms or signs of heart failure
Normal or mildly reduced left ventricular systolic function: LVEF > 50% and LVEDVI < 97 mL/m2
Evidence of abnormal LV relaxation, filling, diastolic distensibility, and diastolic stiffness 
Invasive Heamodynamic measurements
mPCW > 12 mmHg
or
LVEDP > 15 mmHg
TD
15< E/E’ 8 < E/E’ <15
Heart failure of normal Ejection Fraction
Biomarkers




BNP > 200 pg/mL E/A < 0.5 and Dct > 280 ms
in more than 50 years old persons
or
Ard-Ad > 30 ms
or
LAVI > 40 mL/m2
or







Fig. 1. How to diagnose HFNEF: Diagnostic flow chart in a patient suspected of HFNEF. 
A similar strategy with focus on a high negative predictive value of successive 
investigations is proposed for the exclusion of HFNEF in patients with breathlessness and 
no signs of congestion. If a patient with breathlessness and no signs of fluid overload has a 
BNP of less than 100 pg/mL, any form of heart failure is virtually ruled out because of the 
high negative predictive value of the natriuretic peptides, and pulmonary disease becomes 
the most likely cause of breathlessness (Fig. 2). [11,12] 
As far as diastolic dysfunctuion, in decompensated patients with advanced systolic heart 
failure (LVEF≦30%, New York Heart Association class Ⅲ to Ⅳ symptoms), tissue Doppler-
derived with E/E’ ratio may not be as reliable in predicting intracardiac filling pressures, 
particularly in those with larger LV volumes, more impaired cardiac indices, and the 
presence of cardiac resynchronization therapy. [13] 
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Fig. 2. How to exclude HFNEF: Diagnostic flow chart in a patient presenting with 
breathlessness and no signs of fluid overload.  
2.3 Echocardiography in diastolic heart failure 
2.3.1 Doppler echocardiographic assessment of diastolic function and filling 
pressures 
Comprehensive Doppler echocardiography is invaluable in the evaluation of HF patients as 
the 2.1. characteristics of medical examination section. Assessment of diastolic function 
begins with the transmitral flow velocity profile. Decreases in the ratio of early to late 
diastolic filling (E/A), increases in the deceleration time, increases in the isovolumic 
relaxation time, or increases in tissue Doppler imagings (E/E’) indicate impaired relaxation. 
However, in the presence of impaired relaxation, increases in filling pressure progressively 
modify the transmitral gradient and mitral inflow pattern. A comprehensive Doppler 
assessment must be used to determine diastolic function from filling pressures and tissue 
Doppler imagings. [12] Patients studied at various times during their presentation will 
display a spectrum of filling patterns, including abnormal relaxation and psuedonormal or 
restrictive patterns. Such a spectrum has also been reported in patients with HF with a 
depressed EF and reflects the potent effect of filling pressures and blood pressure and their 
interaction with underlying diastolic dysfunction on the Doppler patterns. Thus, depending 
on their level of compensation and their filling pressures and whether they have exertional 
or rest symptoms, patients with HF preserved EF may display any of the filling patterns.[14]  
 








Fig. 3. Normal pattern in LV inflow: Panel A shows long axis view. Panel B shows 4 




Fig. 4. Abnormal relaxation pattern in LV inflow: Panel A shows long axis view. Panel B 
shows 4 chamber view. Panel C shows LV inflow. Panel D shows tissue Doppler imaging. 
2.3.2 Left ventricle in diastolic heart failure  
Most patients with HF preserved EF have normal chamber dimensions, although a small 
subset may have variable degrees of LV enlargement. 
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Although HF preserved EF has been thought to occur primarily inpatients with LVH, 
studies that have carefully quantified LV mass report that echocardiographic criteria for 
LVH are met in less than 50% of patients. [15-18]  
2.3.3 Left atrium in diastolic heart failure 
Increases in the left atrial dimension or volume are commonly present in patients with HF 
preserved EF. [19-21]  
2.3.4 Pulmonary hypertension in diastolic heart failure 
Just as chronic pulmonary venous hypertension leads to pulmonary arterial hypertension in 
HF with reduced EF, the same can occur in HF preserved EF, and an elevated tricuspid 
regurgitant velocity indicative of pulmonary hypertension is extremely common in HF 
preserved EF.[19, 22]  
2.3.5 Other echocardiographic findings in diastolic heart failure 
Regional wall motion abnormalities with preserved EF and right ventricular dilatation, 
either from ischemic disease or secondary to chronic pressure overload from chronic 
pulmonary venous hypertension, can also be present at echocardiography in patients with 
HF preserved EF. Additional negative findings at echocardiography include the absence of 
valvular disease, pericardial tamponade, pericardial constriction, the presence of congenital 
heart diseases such as atrial septal defect, other more extensive structural abnormalities are 
important enough to cause the HF symptoms. 
2.4 The treatment of DHF 
Almost randomized, double-blind studies of therapy for HF are studies of systolic 
dysfunction. Guidelines for the management of patients with chronic HF have been 
published by several organizations. The management of patients with DHF is not different 
from that of HF patients with a reduced EF. They include daily monitoring of weight, 
attention to patient education, and close medical follow-up. The role of cardiac 
rehabilitation in patients with DHF has also been explored.[23]  
The treatment of diastolic heart failure can be demonstrated the following 3 strategies. First, 
treatment should target symptom reduction by decreasing pulmonary venous pressure at 
rest and during exertion. Second, treatment should target the pathological disease that 
caused the diastolic heart failure. For example, coronary artery disease, hypertensive heart 
disease and diabetes mellitus provide relatively specific therapeutic targets, such as 
lowering of blood pressure, induction of hypertrophy regression, blood sugar control and 
treatment of ischemia by increasing myocardial blood flow and reducing myocardial oxygen 
demand. Third, treatment should target the underlying mechanisms that are altered by the 
disease processes.  
Diuretics are advised for therapy of diastolic HF in the ACC/AHA Guidelines for 
Evaluation and Management of Heart Failure. The use of diuretics may improve 
breathlessness in patients with diastolic HF, because circulating blood volume is a major 
 
Diastolic Heart Failure 
 
55 
determinant of ventricular filling pressure. In spite of chronic data are lacking on nitrates, 
they are effective on the diastolic HF in the acute phase, because of deceasing central blood 
volume by vasodilating. In spite of chronic data are also lacking on human atrial natriuretic 
peptides, they are effective on the diastolic HF in the acute phase, because of deceasing 
central blood volume by natriuretic and vasodilating effect. Digoxin was reported to yield 
symptomatic improvement and decreased hospitalizations without mortality benefit in the 
DIG study in patients with DHF.[24]  
We treat with angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor 
blockers (ARBs) and aldosterone antagonists in the chronic systolic heart failure patients, 
because the rennin-angiotensin- aldosterone system (RAAS) plays the pivotal roles on the 
left ventricular remodeling in HF patients.[25] Recent studies of HF patients with preserved 
LV function suggest that ACE inhibitors or ARBs may improve functional class, exercise 
duration, ejection fraction, diastolic filling and LV hypertrophy. In the large randomized 
trial of perindopril (an ACE inhibitor) for patients older than 70 years with chronic HF and 
normal or near-normal EF, event rates were lower than anticipated. Some trends toward 
benefit, primarily driven by reduction in HF-related hospitalizations, were observed at 1 
year (PEP-CHF trial).[26] In the CHARM-Preserved Trial, [27] HF patients with an EF higher 
than 40% were randomized to candesartan ( an angiotensin receptor antagonist ) or placebo 
in addition to standard therapy. Fewer patients in the candesartan group than in the placebo 
group reached the primary endpoint of cardiovascular death or HF hospitalization, a 
finding that reached statistical significance only after adjustment for nonsignificant 
differences in baseline characteristics. Then, irbesartan (an ARB) did not improve the 
outcomes of DHF patients (I-PRESERVE).[28] Although candesartan and irbesartan are 
angiotensin receptor blockers, the results of the trials are different. These pleiotropic effects 
may be different. The trial of aldosterone antagonists for DHF patients is going on in DHF 
patients (TOPCAT trial). Beta blocker has been shown to improve morbidity with diastolic 
and systolic HF. [29,30] Although calcium channel antagonists can improve measures of 
diastolic function during short-term use, definitive data with chronic administration for 
diastolic HF are not available. Recent reports show statins reduce the number of 
cardiovascular hospitalizations in patients with systolic heart failure, although they did not 
reduce the primary outcome which is the composite of death from cardiovascular causes, 
non fatal myocardial infarction and nonfatal stroke.[31,32] A few trials of statins have 
shown to improve the mortality in patients with DHF [33]. Further investigations are 
needed. 
3. Conclusions 
Heart failure with normal left ventricular ejection fraction (HFNEF) currently accounts for 
more than 50% of all heart failure patients. The updated strategies for the diagnosis and 
exclusion of HFNEF are useful not only for individual patient management but also for 
patient recruitment in future clinical trials exploring therapies for HFNEF. 
4. Acknowledgments 
The authors thank Dr. Takahiro Shiota, MD (Professor, Cedars-Sinai Heart Institute, Cedars-
Sinai Medical Center and UCLA, Los Angels, USA), Dr. Homma Shunichi, MD, FACC (the 
 
Echocardiography – In Specific Diseases 
 
54
Although HF preserved EF has been thought to occur primarily inpatients with LVH, 
studies that have carefully quantified LV mass report that echocardiographic criteria for 
LVH are met in less than 50% of patients. [15-18]  
2.3.3 Left atrium in diastolic heart failure 
Increases in the left atrial dimension or volume are commonly present in patients with HF 
preserved EF. [19-21]  
2.3.4 Pulmonary hypertension in diastolic heart failure 
Just as chronic pulmonary venous hypertension leads to pulmonary arterial hypertension in 
HF with reduced EF, the same can occur in HF preserved EF, and an elevated tricuspid 
regurgitant velocity indicative of pulmonary hypertension is extremely common in HF 
preserved EF.[19, 22]  
2.3.5 Other echocardiographic findings in diastolic heart failure 
Regional wall motion abnormalities with preserved EF and right ventricular dilatation, 
either from ischemic disease or secondary to chronic pressure overload from chronic 
pulmonary venous hypertension, can also be present at echocardiography in patients with 
HF preserved EF. Additional negative findings at echocardiography include the absence of 
valvular disease, pericardial tamponade, pericardial constriction, the presence of congenital 
heart diseases such as atrial septal defect, other more extensive structural abnormalities are 
important enough to cause the HF symptoms. 
2.4 The treatment of DHF 
Almost randomized, double-blind studies of therapy for HF are studies of systolic 
dysfunction. Guidelines for the management of patients with chronic HF have been 
published by several organizations. The management of patients with DHF is not different 
from that of HF patients with a reduced EF. They include daily monitoring of weight, 
attention to patient education, and close medical follow-up. The role of cardiac 
rehabilitation in patients with DHF has also been explored.[23]  
The treatment of diastolic heart failure can be demonstrated the following 3 strategies. First, 
treatment should target symptom reduction by decreasing pulmonary venous pressure at 
rest and during exertion. Second, treatment should target the pathological disease that 
caused the diastolic heart failure. For example, coronary artery disease, hypertensive heart 
disease and diabetes mellitus provide relatively specific therapeutic targets, such as 
lowering of blood pressure, induction of hypertrophy regression, blood sugar control and 
treatment of ischemia by increasing myocardial blood flow and reducing myocardial oxygen 
demand. Third, treatment should target the underlying mechanisms that are altered by the 
disease processes.  
Diuretics are advised for therapy of diastolic HF in the ACC/AHA Guidelines for 
Evaluation and Management of Heart Failure. The use of diuretics may improve 
breathlessness in patients with diastolic HF, because circulating blood volume is a major 
 
Diastolic Heart Failure 
 
55 
determinant of ventricular filling pressure. In spite of chronic data are lacking on nitrates, 
they are effective on the diastolic HF in the acute phase, because of deceasing central blood 
volume by vasodilating. In spite of chronic data are also lacking on human atrial natriuretic 
peptides, they are effective on the diastolic HF in the acute phase, because of deceasing 
central blood volume by natriuretic and vasodilating effect. Digoxin was reported to yield 
symptomatic improvement and decreased hospitalizations without mortality benefit in the 
DIG study in patients with DHF.[24]  
We treat with angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor 
blockers (ARBs) and aldosterone antagonists in the chronic systolic heart failure patients, 
because the rennin-angiotensin- aldosterone system (RAAS) plays the pivotal roles on the 
left ventricular remodeling in HF patients.[25] Recent studies of HF patients with preserved 
LV function suggest that ACE inhibitors or ARBs may improve functional class, exercise 
duration, ejection fraction, diastolic filling and LV hypertrophy. In the large randomized 
trial of perindopril (an ACE inhibitor) for patients older than 70 years with chronic HF and 
normal or near-normal EF, event rates were lower than anticipated. Some trends toward 
benefit, primarily driven by reduction in HF-related hospitalizations, were observed at 1 
year (PEP-CHF trial).[26] In the CHARM-Preserved Trial, [27] HF patients with an EF higher 
than 40% were randomized to candesartan ( an angiotensin receptor antagonist ) or placebo 
in addition to standard therapy. Fewer patients in the candesartan group than in the placebo 
group reached the primary endpoint of cardiovascular death or HF hospitalization, a 
finding that reached statistical significance only after adjustment for nonsignificant 
differences in baseline characteristics. Then, irbesartan (an ARB) did not improve the 
outcomes of DHF patients (I-PRESERVE).[28] Although candesartan and irbesartan are 
angiotensin receptor blockers, the results of the trials are different. These pleiotropic effects 
may be different. The trial of aldosterone antagonists for DHF patients is going on in DHF 
patients (TOPCAT trial). Beta blocker has been shown to improve morbidity with diastolic 
and systolic HF. [29,30] Although calcium channel antagonists can improve measures of 
diastolic function during short-term use, definitive data with chronic administration for 
diastolic HF are not available. Recent reports show statins reduce the number of 
cardiovascular hospitalizations in patients with systolic heart failure, although they did not 
reduce the primary outcome which is the composite of death from cardiovascular causes, 
non fatal myocardial infarction and nonfatal stroke.[31,32] A few trials of statins have 
shown to improve the mortality in patients with DHF [33]. Further investigations are 
needed. 
3. Conclusions 
Heart failure with normal left ventricular ejection fraction (HFNEF) currently accounts for 
more than 50% of all heart failure patients. The updated strategies for the diagnosis and 
exclusion of HFNEF are useful not only for individual patient management but also for 
patient recruitment in future clinical trials exploring therapies for HFNEF. 
4. Acknowledgments 
The authors thank Dr. Takahiro Shiota, MD (Professor, Cedars-Sinai Heart Institute, Cedars-
Sinai Medical Center and UCLA, Los Angels, USA), Dr. Homma Shunichi, MD, FACC (the 
 
Echocardiography – In Specific Diseases 
 
56
Department of Cardiology, Columbia University, USA) and Jae K Oh, MD (Professor of 
Medicine, Mayo Clinic College of Medicine, Consultant in Cardiovascular Disease, Mayo 
Clinic, Rochester, Minnesota,USA) for the education of the diastology. 
5. References 
[1] Braunwald, E. (1997) Shattuck lecture--cardiovascular medicine at the turn of the 
millennium: triumphs, concerns, and opportunities. N Engl J Med 337 (19), 1360-
1369 
[2] Owan, T.E. et al. (2006) Trends in prevalence and outcome of heart failure with 
preserved ejection fraction. N Engl J Med 355 (3), 251-259 
[3] Redfield, M.M. (2004) Understanding "diastolic" heart failure. N Engl J Med 350 (19), 
1930-1931 
[4] Aurigemma, G.P. et al. (2001) Predictive value of systolic and diastolic function for 
incident congestive heart failure in the elderly: the cardiovascular health study. J 
Am Coll Cardiol 37 (4), 1042-1048 
[5] Gottdiener, J.S. et al. (2000) Predictors of congestive heart failure in the elderly: the 
Cardiovascular Health Study. J Am Coll Cardiol 35 (6), 1628-1637 
[6] Kitzman, D.W. et al. (2001) Importance of heart failure with preserved systolic function 
in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health 
Study. Am J Cardiol 87 (4), 413-419 
[7] Vasan, R.S. et al. (1999) Congestive heart failure in subjects with normal versus reduced 
left ventricular ejection fraction: prevalence and mortality in a population-based 
cohort. J Am Coll Cardiol 33 (7), 1948-1955 
[8] van Heerebeek, L. et al. (2006) Myocardial structure and function differ in systolic and 
diastolic heart failure. Circulation 113 (16), 1966-1973 
[9] Prasad, A. et al. (2005) Abnormalities of Doppler measures of diastolic function in the 
healthy elderly are not related to alterations of left atrial pressure. Circulation 111 
(12), 1499-1503 
[10] Zile, M.R. and Brutsaert, D.L. (2002) New concepts in diastolic dysfunction and diastolic 
heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. 
Circulation 105 (11), 1387-1393 
[11] Paulus, W.J. et al. (2007) How to diagnose diastolic heart failure: a consensus statement 
on the diagnosis of heart failure with normal left ventricular ejection fraction by the 
Heart Failure and Echocardiography Associations of the European Society of 
Cardiology. Eur Heart J 28 (20), 2539-2550 
[12] Redfield, M.M. et al. (2003) Burden of systolic and diastolic ventricular dysfunction in 
the community: appreciating the scope of the heart failure epidemic. JAMA 289 (2), 
194-202 
[13] Mullens, W. et al. (2009) Tissue Doppler imaging in the estimation of intracardiac filling 
pressure in decompensated patients with advanced systolic heart failure. 
Circulation 119 (1), 62-70 
[14] Bursi, F. et al. (2006) Systolic and diastolic heart failure in the community. JAMA 296 
(18), 2209-2216 
 
Diastolic Heart Failure 
 
57 
[15] Chen, H.H. et al. (2002) Diastolic heart failure in the community: clinical profile, natural 
history, therapy, and impact of proposed diagnostic criteria. J Card Fail 8 (5), 279-
287 
[16] Kawaguchi, M. et al. (2003) Combined ventricular systolic and arterial stiffening in 
patients with heart failure and preserved ejection fraction: implications for systolic 
and diastolic reserve limitations. Circulation 107 (5), 714-720 
[17] Kitzman, D.W. et al. (2002) Pathophysiological characterization of isolated diastolic 
heart failure in comparison to systolic heart failure. JAMA 288 (17), 2144-2150 
[18] Zile, M.R. et al. (2004) Diastolic heart failure--abnormalities in active relaxation and 
passive stiffness of the left ventricle. N Engl J Med 350 (19), 1953-1959 
[19] Lam, C.S. et al. (2009) Pulmonary hypertension in heart failure with preserved ejection 
fraction: a community-based study. J Am Coll Cardiol 53 (13), 1119-1126 
[20] Lam, C.S. et al. (2007) Cardiac structure and ventricular-vascular function in persons 
with heart failure and preserved ejection fraction from Olmsted County, 
Minnesota. Circulation 115 (15), 1982-1990 
[21] Melenovsky, V. et al. (2007) Cardiovascular features of heart failure with preserved 
ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the 
urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll 
Cardiol 49 (2), 198-207 
[22] Kjaergaard, J. et al. (2007) Prognostic importance of pulmonary hypertension in patients 
with heart failure. Am J Cardiol 99 (8), 1146-1150 
[23] Pina, I.L. et al. (2003) Exercise and heart failure: A statement from the American Heart 
Association Committee on exercise, rehabilitation, and prevention. Circulation 107 
(8), 1210-1225 
[24] Ahmed, A. et al. (2006) Effects of digoxin on morbidity and mortality in diastolic 
heart failure: the ancillary digitalis investigation group trial. Circulation 114 (5), 
397-403 
[25] Schrier, R.W. and Abraham, W.T. (1999) Hormones and hemodynamics in heart failure. 
N Engl J Med 341 (8), 577-585 
[26] Cleland, J.G. et al. (2006) The perindopril in elderly people with chronic heart failure 
(PEP-CHF) study. Eur Heart J 27 (19), 2338-2345 
[27] Yusuf, S. et al. (2003) Effects of candesartan in patients with chronic heart failure and 
preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362 
(9386), 777-781 
[28] Massie, B.M. et al. (2008) Irbesartan in patients with heart failure and preserved ejection 
fraction. N Engl J Med 359 (23), 2456-2467 
[29] Flather, M.D. et al. (2005) Randomized trial to determine the effect of nebivolol on 
mortality and cardiovascular hospital admission in elderly patients with heart 
failure (SENIORS). Eur Heart J 26 (3), 215-225 
[30] Ghio, S. et al. (2006) Effects of nebivolol in elderly heart failure patients with or without 
systolic left ventricular dysfunction: results of the SENIORS echocardiographic 
substudy. Eur Heart J 27 (5), 562-568 
[31] Khush, K.K. et al. (2007) Effect of high-dose atorvastatin on hospitalizations for heart 
failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation 
115 (5), 576-583 
 
Echocardiography – In Specific Diseases 
 
56
Department of Cardiology, Columbia University, USA) and Jae K Oh, MD (Professor of 
Medicine, Mayo Clinic College of Medicine, Consultant in Cardiovascular Disease, Mayo 
Clinic, Rochester, Minnesota,USA) for the education of the diastology. 
5. References 
[1] Braunwald, E. (1997) Shattuck lecture--cardiovascular medicine at the turn of the 
millennium: triumphs, concerns, and opportunities. N Engl J Med 337 (19), 1360-
1369 
[2] Owan, T.E. et al. (2006) Trends in prevalence and outcome of heart failure with 
preserved ejection fraction. N Engl J Med 355 (3), 251-259 
[3] Redfield, M.M. (2004) Understanding "diastolic" heart failure. N Engl J Med 350 (19), 
1930-1931 
[4] Aurigemma, G.P. et al. (2001) Predictive value of systolic and diastolic function for 
incident congestive heart failure in the elderly: the cardiovascular health study. J 
Am Coll Cardiol 37 (4), 1042-1048 
[5] Gottdiener, J.S. et al. (2000) Predictors of congestive heart failure in the elderly: the 
Cardiovascular Health Study. J Am Coll Cardiol 35 (6), 1628-1637 
[6] Kitzman, D.W. et al. (2001) Importance of heart failure with preserved systolic function 
in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health 
Study. Am J Cardiol 87 (4), 413-419 
[7] Vasan, R.S. et al. (1999) Congestive heart failure in subjects with normal versus reduced 
left ventricular ejection fraction: prevalence and mortality in a population-based 
cohort. J Am Coll Cardiol 33 (7), 1948-1955 
[8] van Heerebeek, L. et al. (2006) Myocardial structure and function differ in systolic and 
diastolic heart failure. Circulation 113 (16), 1966-1973 
[9] Prasad, A. et al. (2005) Abnormalities of Doppler measures of diastolic function in the 
healthy elderly are not related to alterations of left atrial pressure. Circulation 111 
(12), 1499-1503 
[10] Zile, M.R. and Brutsaert, D.L. (2002) New concepts in diastolic dysfunction and diastolic 
heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. 
Circulation 105 (11), 1387-1393 
[11] Paulus, W.J. et al. (2007) How to diagnose diastolic heart failure: a consensus statement 
on the diagnosis of heart failure with normal left ventricular ejection fraction by the 
Heart Failure and Echocardiography Associations of the European Society of 
Cardiology. Eur Heart J 28 (20), 2539-2550 
[12] Redfield, M.M. et al. (2003) Burden of systolic and diastolic ventricular dysfunction in 
the community: appreciating the scope of the heart failure epidemic. JAMA 289 (2), 
194-202 
[13] Mullens, W. et al. (2009) Tissue Doppler imaging in the estimation of intracardiac filling 
pressure in decompensated patients with advanced systolic heart failure. 
Circulation 119 (1), 62-70 
[14] Bursi, F. et al. (2006) Systolic and diastolic heart failure in the community. JAMA 296 
(18), 2209-2216 
 
Diastolic Heart Failure 
 
57 
[15] Chen, H.H. et al. (2002) Diastolic heart failure in the community: clinical profile, natural 
history, therapy, and impact of proposed diagnostic criteria. J Card Fail 8 (5), 279-
287 
[16] Kawaguchi, M. et al. (2003) Combined ventricular systolic and arterial stiffening in 
patients with heart failure and preserved ejection fraction: implications for systolic 
and diastolic reserve limitations. Circulation 107 (5), 714-720 
[17] Kitzman, D.W. et al. (2002) Pathophysiological characterization of isolated diastolic 
heart failure in comparison to systolic heart failure. JAMA 288 (17), 2144-2150 
[18] Zile, M.R. et al. (2004) Diastolic heart failure--abnormalities in active relaxation and 
passive stiffness of the left ventricle. N Engl J Med 350 (19), 1953-1959 
[19] Lam, C.S. et al. (2009) Pulmonary hypertension in heart failure with preserved ejection 
fraction: a community-based study. J Am Coll Cardiol 53 (13), 1119-1126 
[20] Lam, C.S. et al. (2007) Cardiac structure and ventricular-vascular function in persons 
with heart failure and preserved ejection fraction from Olmsted County, 
Minnesota. Circulation 115 (15), 1982-1990 
[21] Melenovsky, V. et al. (2007) Cardiovascular features of heart failure with preserved 
ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the 
urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll 
Cardiol 49 (2), 198-207 
[22] Kjaergaard, J. et al. (2007) Prognostic importance of pulmonary hypertension in patients 
with heart failure. Am J Cardiol 99 (8), 1146-1150 
[23] Pina, I.L. et al. (2003) Exercise and heart failure: A statement from the American Heart 
Association Committee on exercise, rehabilitation, and prevention. Circulation 107 
(8), 1210-1225 
[24] Ahmed, A. et al. (2006) Effects of digoxin on morbidity and mortality in diastolic 
heart failure: the ancillary digitalis investigation group trial. Circulation 114 (5), 
397-403 
[25] Schrier, R.W. and Abraham, W.T. (1999) Hormones and hemodynamics in heart failure. 
N Engl J Med 341 (8), 577-585 
[26] Cleland, J.G. et al. (2006) The perindopril in elderly people with chronic heart failure 
(PEP-CHF) study. Eur Heart J 27 (19), 2338-2345 
[27] Yusuf, S. et al. (2003) Effects of candesartan in patients with chronic heart failure and 
preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362 
(9386), 777-781 
[28] Massie, B.M. et al. (2008) Irbesartan in patients with heart failure and preserved ejection 
fraction. N Engl J Med 359 (23), 2456-2467 
[29] Flather, M.D. et al. (2005) Randomized trial to determine the effect of nebivolol on 
mortality and cardiovascular hospital admission in elderly patients with heart 
failure (SENIORS). Eur Heart J 26 (3), 215-225 
[30] Ghio, S. et al. (2006) Effects of nebivolol in elderly heart failure patients with or without 
systolic left ventricular dysfunction: results of the SENIORS echocardiographic 
substudy. Eur Heart J 27 (5), 562-568 
[31] Khush, K.K. et al. (2007) Effect of high-dose atorvastatin on hospitalizations for heart 
failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation 
115 (5), 576-583 
 
Echocardiography – In Specific Diseases 
 
58
[32] Kjekshus, J. et al. (2007) Rosuvastatin in older patients with systolic heart failure. N 
Engl J Med 357 (22), 2248-2261 
[33] Fukuta, H. et al. (2005) Statin therapy may be associated with lower mortality in 
patients with diastolic heart failure: a preliminary report. Circulation 112 (3), 357-
363 
5 
Effects of Eptifibatide on the Microcirculation 
After Primary Angioplasty in Acute ST-Elevation 
Myocardial Infarction: A Trans-Thoracic 
Coronary Artery Doppler Study 
Dawod Sharif1,2, Amal Sharif-Rasslan2,3 and Uri Rosenschein1,2 
1Cardiology Department, Bnai Zion Medical Center, Haifa 
2Technion, Israel Institute of Technology, Haifa 
3Mathematics Departmant,The Academic Arab College, Haifa 
Israel 
1. Introduction 
1.1 Extent of disease 
Cardiovascular atherosclerosis is the most common disease in the industrial countries. In the 
United States of America more than 1 million patients every year are admitted to the 
coronary care unit with suspected acute myocardial infarction (Yusuf et al, 2004; American 
Heart Association, 2007). The incidence of acute myocardial infarction in USA is 865000, 
565000 of them new infarctions annually. In Europe, the situation is similar to the USA, 
however in northern countries the incidence is higher than in southern countries (Lopez et 
al, 2006). In the emerging market economies in Eastern Europe, higher cardiovascular 
mortality is found. The burden of cardiovascular and coronary heart disease in developing 
countries is approaching that in developed countries. Thus the problem is a worldwide 
problem and international joint efforts are needed in order to treat this still prevalent 
disease.  
Mortality of acute myocardial infarction is decreasing steadily. This decrease is related to 
reduction in the prevalence of disease in some countries, improvement of primary 
prevention and secondary prevention as well as treatment of the acute event (Hunink et al, 
1997; Cooper et al, 2000).   
1.2 Contemporary treatment 
Primary percutaneous coronary intervention (PCI) is the treatment of choice in acute ST 
elevation myocardial infarction (Grines et al, 1993; Zijlstra et al, 1993; GUSTO, 1997; De 
Luca et al, 2004).The objective of primary PCI is to restore myocardial perfusion in the 
coronary bed distal to the occluded culprit artery. The TIMI classification (Chesebro et al, 
1987) and myocardial blush grades (van't Hof, 1998; Gibson et al, 2000; Stone et al, 2002) 
used to assess epicardial coronary artery flow and myocardial perfusion after primary PCI 
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predict outcome after the procedure. However, the TIMI flow and myocardial blush 
grades are semi-quantitative, invasive, not easily repeatable, and do not reflect 
subsequent events and processes at the level of the coronary artery and microcirculation. 
Thus, even with successful primary PCI and the high rate of patency of the culprit artery, 
left ventricular functional recovery is limited and not well predicted (Stone et al, 1997; 
Zijlstra et al, 1997).  
1.3 Limitations and problems of contemporary treatment 
The main goal of primary PCI is to open the occluded epicardial coronary artery, and thus 
to re-establish blood flow to the jeopardized myocardium. In order to nourish the 
myocardium, blood must flow through the epicardial coronary artery segments, resistance 
vessels, arterioles and capillaries before reaching venules and veins. The epicardial coronary 
arteries are larger than 400 um, serve as conduit vessels and their diameter is regulated by 
shear stress and do not contribute significantly to pressure drop. Coronary resistance vessels 
with diameter between 100 and 400 um are affected myogenically mainly by shear stress 
and luminal pressure. Resistance coronary vessels with diameter less than 100um are 
sensitive to local tissue metabolism and directly control perfusion to the low pressure 
capillary bed nourishing the myocardium. Myocardial capillary density is 3500/mm2 with 
inter-capillary distance of 17 um , greater in the subendocardium than in the subepicardium 
(Canty, 2008).  
Microvascular injury is the leading cause for the decreased myocardial perfusion 
observed in about 80% of patients after successful PCI (Gibson et al, 2000; Stone et al, 
1997; Zijlstra et al, 1997; Kondo et al, 1998). Various factors contribute to the limited 
myocardial perfusion, including micro-emboli, platelets, white blood cells, ischemic 
necrosis, and reperfusion injury(Chesebro et al, 1987; van't Hof, 1998; Gibson et al, 2000; 
Stone et al, 2002).  
1.4 Detection of dysfunction of the microcirculation 
As already mentioned, myocardial blush grade as assessed in the catheterization laboratory 
evaluates the function of the microcirculation.  
Extent of resolution of ST-segment elevation after primary angioplasty is an adequate 
indicator of the function of the microcirculation and myocardial perfusion. 
Measurement of coronary flow velocities using Doppler wire and pressure recordings to 
assess severity of coronary artery stenoses are invasive procedures in addition to other 
disadvantages (Iliceto et al 1991; Erbel et al, 1991; Kozakova et al, 1994; Donohue et al, 1993; 
Miller et al, 1994; Di Carli et al, 1995). 
Trans-esophageal echocardiography visualizes only the proximal coronary arteries and 
Doppler sampling is feasible in less than 70% of patients (Joye et al, 1994; Kern et al 1995; 
Abizaid et al, 1998). 
Recent technologic advances in trans-thoracic echocardiography made Doppler sampling of 
coronary artery velocities possible (Voci et al, 1998; Caiati et al, 1999; Hildick-Smith et al, 
2000; Higashiue et al, 2001; Pizzuto et al, 2001; Takeuchi et al, 2001). Contrast agents may 
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enhance the detection rate of coronary velocities (Abizaid et al, 1998; Caiati et al, 1999), 
however, an experienced operator is essential. 
Sampling of blood velocities in the left anterior descending coronary artery is successful 
almost in all patients. The advantages of Doppler sampling of coronary artery blood 
velocities is that it is non-invasive and can be repeated easily in the coronary care unit. As 
we demonstrated recently using transthoracic Doppler, the function of the microcirculation 
is dynamic and changes after primary angioplasty (Sharif et al, 2008; 2010). After primary 
coronary intervention in acute myocardial infraction the microcircirculation may improve or 
deteriorate. Therefore, transthoracic Doppler sampling of coronary artery velocities is even 
more important than other methods for the evaluation of the function of coronary 
microcirculation.   
1.5 Possible solution for coronary microvascular dysfunction 
After having the epicardial coronary artery treated and well open, according to the 
mechanisms of microcirculatory dysfunction, platelet micro-emboli and changes in platelet 
activity may have an impact on myocardial perfusion. Therefore, in the present study we 
examine the effects adjuvant treatment with glycoprotein 2b3a receptor blockers on the 
function of the microcirculation after primary angioplasty in the setting of acute anterior ST-
elevation myocardial infarction. 
2. Methods 
Forty five consecutive patients with acute ST elevation anterior myocardial infarction 
undergoing primary PCI were enrolled in the study. All fulfilled the following criteria: 1) 
First anterior wall ST segment elevation myocardial infarction (STEMI). 2) Primary PCI 
within 12 hours of the onset of symptoms. 3) Routine informed consent to perform primary 
PCI. Anterior STEMI was defined as continuous chest pain for at least 30 minutes and ST 
elevation of at least 2.0mm in ≥2 contiguous precordial ECG leads. Exclusion criteria 
included one of the following clinical or angiographic findings: Prior bypass surgery, 
previous anterior STEMI, significant left main artery disease, failed primary PCI. 
2.1 Primary PCI 
Primary PCI was performed in standard fashion. All subjects were treated with oral 
clopidogral (600 mg) and aspirin (300 mg) in the emergency department. Thirty one patients 
were treated with an intravenous bolus injection of heparin (50-70 U/Kg) to achieve 
coagulation time of ≥ 250msec, Fourteen patients were treated before angioplasty with 
intravenous eptifibatide as 2 boluses of 180ug/kg, ten minutes apart, and a maintenance 
infusion at a rate of 2ug/kg/min for 24 hours, and 500 units heparin/hour. Coronary 
angiography and primary PCI were performed subsequently. Bare metal stents were 
deployed by high-pressure implantation techniques. Low magnification angiogram at either 
the right 30 º or 90 º lateral projections with prolonged cine was performed to optimize 
myocardial blush grade (MBG) documentation at the end of the intervention as previously 
described ( van't Hof et al, 1998). All patients were treated with clopidogrel and aspirin for 
12 months after the procedure.  
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All patients had complete Doppler echcardiographic studies, within the first 6 hours after 
primary PCI, 48 hours later, and 5 days after the intervention. 
Siemens, Acuson Sequoia echocardiographic system, California, equipped with 3.5-7MHZ 
transducers was used. All patients had complete Doppler echcardiographic studies, within 
the first 6 hours after primary PCI, 48 hours after primary PCI, and 5 days after primary 
PCI. 
In order to obtain LAD flows, the color Doppler Nyquist limit was set at 17 cm/sec or 
power Doppler modality was applied. Systematic attempt to get LAD-color flow were 
performed. From low parasternal short axis view, search for diastolic color flow in the 
anterior interventricular groove followed by clockwise rotation was performed, while form 
apical foreshortened two chamber views LAD diastolic flow was located in the 
interventricular groove and the counterclockwise rotation of the transducer was performed. 
Colour Doppler sampling was easy to achieve, branches could be seen (figure 1) and 
margins of colour jet well delineated allowing measurement of jet width (figure 2).  
 
Fig. 1. Colour Doppler of the LAD and diagonal branch 
 
Fig. 2. Colour Doppler of the LAD allowing measurement of jet width 
Pulsed-wave Doppler sampling was consistent (figure 3), with dominant diastolic 
component and clear envelope easy to trace (figure 4) and well demonstrated systolic 
component (figure 5). 
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Fig. 5. Pulsed-wave Doppler of LAD blood velocity with prominent systolic flow 
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margins of colour jet well delineated allowing measurement of jet width (figure 2).  
 
Fig. 1. Colour Doppler of the LAD and diagonal branch 
 
Fig. 2. Colour Doppler of the LAD allowing measurement of jet width 
Pulsed-wave Doppler sampling was consistent (figure 3), with dominant diastolic 
component and clear envelope easy to trace (figure 4) and well demonstrated systolic 
component (figure 5). 
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Fig. 5. Pulsed-wave Doppler of LAD blood velocity with prominent systolic flow 
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2.3 Echocardiographic measurements 
Chamber diameters and usual measurements were performed according to 
recommendations of American Society of Echocardiography. Ejection fraction of LV (LVEF) 
was measured from biplane apical views. 




score of segmentsLV WMSI    (1) 
assigning a value of 1 for normal LV wall motion, 2 for hypokinesis and 3 for akinesis. Using 




score of segmentsLAD WMSI    (2) 
2.4 Velocity of the LAD and measurements 
In order to obtain LAD flows, the color Doppler Nyquist limit was set at 17 cm/sec. From 
low parasternal short axis view, search for diastolic color flow in the anterior 
interventricular groove followed by clockwise rotation was performed, while form apical 
foreshortened two chamber views LAD diastolic flow was located in the interventricular 
groove and the counterclockwise rotation of the transducer was performed. 
Parameters of LAD velocity patterns were averaged from 3 beats, all in sinus rhythm. 
Diastolic LAD deceleration Time (DDT) was measured as the time from peak diastolic 
velocity to the intercept of tangent of the velocity envelope with baseline. Pressure half time 
(P1/2T) (msec) was determined as the time for peak diastolic velocity to decrease to 1 2  of 
its initial value. In addition, search for LAD early systolic flow reversal with early systolic 
negative velocity (ESFR) was performed. 
2.5 LAD Flow measurements 
Diameter of the jet of blood velocity through the LAD (D), heart rate (HR) and diastolic time 
velocity integral (TVIDiastole) of the pulsed-wave Doppler were used to calculate blood flow 





DaistoleDiastolic LAD Flow HR TVI    (3) 
2.6 Angiographic analysis 
Coronary angiograms were reviewed by two experienced interventional cardiologists. TIMI 
(thrombolysis in myocardial infarction) and MBG (myocardial blush grade) were evaluated 
pre and post- PCI. TIMI-0: no antigrade flow beyond the occlusion; TIMI-1: contrast passes 
through the occlusion but do not opacify the distality entirely; TIMI-2: contrast passes 
through the obstruction and opacify the distal coronary bed slower than normal or clears 
slower than normal; TIMI-3: prompt contrast opacification and clearance of the distal 
coronary bed (Chesebro et al, 1987). MBG was evaluated as: MBG-0: minimal or no 
Effects of Eptifibatide on the Microcirculation After Primary Angioplasty in  
Acute ST-Elevation Myocardial Infarction: A Trans-Thoracic Coronary Artery Doppler Study 
 
65 
myocardial blush; MBG-1: myocardial staining persists on the next injection; MBG-2: 
myocardial staining with slow washout and persists markedly at the end of injection; MBG-
3: normal myocardial staining and clearance with only mild staining at end of injection 
(van't Hof, 1998; Gibson et al, 2000; Stone et al, 2002).  
2.7 Statistical analysis 
Statistical analyses wee conducted using SPSS software version 13. All values were 
expressed as means and standard deviations. Two-tailed student's-t test was performed to 
compare changes in DDT and P1/2T, considering p<0.05 as statistically significant. 
Assessment of clinical utility of flow parameters was done by calculating sensitivity, 
specificity, positive and negative predictive values as well as diagnostic accuracy. 
Correlation coefficients and their p value were calculated to evaluate the relation of LAD 
flow parameters with LV systolic function parameters pre-discharge (5 days after PCI). 
3. Results 
3.1 Angiographic results 
Average TIMI and myocardial blush grades (MBG) before angioplasty were not different 
between patient who were treated with epitifibatide compared to those in whom the 
medicine was not administrated (table 1). However, TIMI=0, was observed in 33% with 
eptifibatide compared to 55% in those without. In both groups TIMI and MBG grades 
improved after the PCI. TIMI grade after the intervention was higher in subjects who were 
treated with epifibatide, however, MBG was not different.  
 
















EPT-Yes 1.07±1.07 2.43±0.5 0.0004 0.71±1.07 1.93±0.73 0.002 49±26 
EPT-NO 0.94±1.2 2.28±0.6 1.3×10-9  0.52±1.06 2.25±0.9 6×10-9  35±17 
P 
(Yes/No) 0.7 0.049  0.57 0.22  0.09 
Table 1. Pre and Post PCI, TIMI and MBG and Diastolic LAD Flow 
3.2 Feasibility and examples of LAD Doppler velocity sampling 
Sampling of LAD blood velocities was possible at all occasions in all the patients. Colour-
Doppler jet of blood velocity through the LAD had distinct boarders and measurement of 
diameters was possible with inter and intra-observer variability of 0.1±0.05mm and 
0.15±0.07mm. Inter and intra-observer variability of LAD velocities were 2±0.4 and 1.5±0.2 
cm/sec and of time velocity integrals 0.4±0.1 and 0.3±0.1cm, and of pressure half time 10±3 
and 8±3 msec In figure 6, an example of a patient with acute anterior STEMI after primary 
angioplasty and bare metal stent implantation in the LAD. The velocity profile demonstrates 
prolonged diastolic deceleration time (more than 600msec) and forward systolic flow. In this 
patient left ventricular systolic function improved and left ventricular ejection fraction at 
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discharge was normal. In figure 7, an example of a patient with unfavorable LAD blood 
velocity profile after primary angioplasty and bare metal stent implantation in a patient 
with acute anterior STEMI. Short diastolic deceleration time (less than 600msec) and early 
systolic flow reversal are demonstrated. In this patient left ventricular ejection fraction was 
reduced at admission and did not improve later.  
 
 
Fig. 6. Favourable LAD blood velocity profile with prolonged diastolic deceleration time 
and forward systolic flow. 
 
 
Fig. 7. Unfavourable LAD blood velocity profile with reduced diastolic deceleration time 
and early systolic flow reversal. 
3.3 LAD velocity profiles 
Early systolic flow reversal did not occur with eptifibatide while it was noticed in 6 (17%) in 








EPT-Yes 0 0 0 
EPT-No 6 4 2 
 
Table 2. LAD Systolic Flow Reversal  
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Diastolic deceleration time of LAD flow averaged 629±238 msec in patients treated with 
eptifibatide and 593±344 msec in those without, p=0.7 (figure 8). Short (<600msec) diastolic 
deceleration time occurred in 6 (40%) of those treated with eptifibatide, compared to 12 
(39%) in those not treated, p=ns (figure 8).  
 
Fig. 8. Histogram of diastolic deceleration time and pressure half time of LAD blood velocity 
profiles in patients with and those without eptifibatide treatment. 
Patients treated with eptifibatide had higher diastolic velocities, 39±11 cm/sec, vs 31±9 
cm/sec, p=0.043 and tended to have higher diastolic LAD flows, 49±26 ml/min, vs 35±17 
ml/min, p=0.09 (figure 9). 
 
Fig. 9. Histogram of diastolic and systolic velocities of LAD blood velocity profiles in 
patients with and those without eptifibatide treatment. 
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3.4 LAD Flow 
LAD flow tended to be higher early after primary angioplasty in subjects pre-treated with 
eptifibatide, however on the following evaluations during mid-hospital stay and pre-
discharge diastolic flow in the LAD was similar in both groups.  
 
Fig. 10. Histogram of diastolic flow in the LAD in patients with and those without 
eptifibatide treatment. 
3.5 Left ventricular systolic function 
LVEF with epifibatide at baseline 37±6.5% was similar to that in those without, 36.7±4.4%, 
and at discharge, with epifibatide 43.8±8.2% and in those without 45±8.9%, p=ns. 
 














EPT-Yes 37±6.49 43.8±8.2 1.68±0.17 1.49±0.295 2.15±0.2 1.83±0.43 
EPT-NO 36.7±4.4 45±8.9 1.6±0.24  1.39±0.32 2±10.4 1.63±0.55 
P 
(Yes/No) 0.79 0.687 0.296 0.282 0.165 0.258 
Table 3. LV Systolic Function 
4. Discussion 
4.1 Brief summary of results 
In this study, per-treatment of patients with acute anterior STEMI undergoing primary 
coronary angioplasty prevented severe dysfunction of the coronary microcirculation as 
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evidenced by absence of early systolic flow reversal in subjects treated with epitifibatide; 
however, less severe dysfunction of the microcirculation was not different between the 
groups since diastolic deceleration times by Doppler, and myocardial blush grades were 
similar. Moreover, diastolic maximal blood velocities early after PCI were higher in patients 
treated with eptifibatide but similar later on. Eptfibatide treatment was associated with a 
tendency of larger diastolic blood flow through the LAD but not later. All these changes 
with eptifibatide treatment did not affect left ventricular systolic function which was similar 
in both treatment groups, early after PCI and pre-discharge. 
4.2 Applicability of sampling of LAD blood velocities 
Transthoracic Doppler sampling of coronary blood velocities is not mentioned or not 
stressed sufficiently in most textbooks of echocardiography. Thus, the importance of this 
study is related not only to the treatment of patients with acute STEMI. We found that 
sampling of LAD blood velocities was possible in all the patients and at all occasions. We 
believe that sampling of LAD blood velocities should be applied widely and repeated when 
needed and in all echocardiographic studies. In fact, electrocardiographic recording is 
performed when patients have chest pain, and in a similar fashion, echocardiography and 
sampling of coronary blood velocity may be performed in such patients in coronary care 
units.  
4.3 Transthoracic Doppler sampling of LAD blood velocities and other methods 
Measurement of coronary flow velocities using Doppler wire and pressure recordings to 
assess severity of coronary artery and microcirculation are invasive procedures in addition 
to other disadvantage (Iliceto et al 1991; Erbel et al, 1991; Kozakova et al, 1994; Donohue et 
al, 1993; Miller et al, 1994; Di Carli et al, 1995). Normal peak diastolic velocities in the 
present study were similar to those reported previously by invasive Doppler flowires (Ofili 
et al, 1993). 
Trans-esophageal echocardiography visualizes only the proximal coronary arteries and 
Doppler sampling is feasible in less than 70% of patients (Joye et al, 1994; Kern et al 1995; 
Abizaid et al, 1998). Recent technologic advances in trans-thoracic echocardiography made 
Doppler sampling of coronary artery velocities possible (Voci et al, 1998; Caiati et al, 1999; 
Hildick-Smith et al, 2000; Higashiue et al, 2001; Pizzuto et al, 2001; Takeuchi et al, 2001). 
Contrast agents may enhance the detection rate of coronary velocities (Abizaid et al, 1998; 
Caiati et al, 1999), however, with increasing experience of the operator contrast agents are 
not needed. 
4.4 Validity of LAD blood velocities and flow calculations  
The range of the value of LAD blood velocities and time velocity integrals (Sharif et al, 2010) 
is similar to those found through cardiac valves with similar reproducibility and 
applicability. The diameter of the LAD and of the colour jet of blood flow through the vessel 
is in the range of diameter of vena contracta of regurgitant jets through cardiac valves. 
Moreover, LAD-colour jet diameter is similar to that of proximal iso-velocity surfaces of 
regurgitant jets through the mitral valve, so it can be applied in a similar fashion and 
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squared to calculate areas. Thus if blood velocities, and colour jet diameters of the LAD are 
similar to those of cardiac valves, then flow calculations should be of the same degree of 
validity.  
4.5 Need for coronary blood velocity sampling in acute STEMI 
Restoration of epicardial coronary artery flow by primary PCI in the setting of acute STEMI 
improves outcome (Shah et al, 2000), however optimization of myocardial tissue perfusion 
improves the prediction of outcome (van't Hof et al, 1998; Shah et al, 2000; van't Hof et al, 
1997; Claeys et al, 1999; The TIMI Study Group, 19985; Gibson et al, 1996; 1999; 2001; de 
Lemos, 2001; Dörge et al, 2000). Despite these findings, still even with successful primary 
PCI and the high rate of patency of the culprit artery, left ventricular functional recovery is 
limited and not well predicted (Stone et al, 1997; Zijlstra et al, 1997). 
 Despite the value of myocardial blush grade in the evaluation of myocardial perfusion it is 
not repeatable because of its invasive nature. Resolution of ST-elevation also correlates with 
better myocardial perfusion, however it reflects only the stage immediately following the 
emergency PCI. As we have shown (Sharif et al, 2008) the function of coronary 
microcirculation is variable and may improve or worsen during the hospital stay after 
primary coronary angioplasty in patients with acute STEMI. Therefore, Doppler 
transthorcaic sampling of LAD blood velocities is important in such patients.  
4.6 Diastolic deceleration time of LAD blood velocity curve (DDT) and the 
microcirculation 
To understand the relation between DDT and coronary microcirculation, consider normal 
subjects where the intra-myocardial blood capacitance vessels fill during diastole without 
significant increase in intramural pressure, therefore the DDT is prolonged. When the 
capacitance vessels are partially obstructed with miroemboli there is impedance to flow in 
diastole, therefore the DDT is abbreviated (Kawamoto et al, 1999; Yamamaro et al, 2002). 
When the blockage of the microcirculation is more severe, the milking of blood in systole 
cannot proceed to the venules; instead, it is pushed back into the coronary artery and results 
in early systolic flow reversal (Kawamoto et al, 1999; Yamamaro et al, 2002).  
4.7 Mechanisms of dysfunction of coronary microcirculation after primary coronary 
angioplasty 
After primary PCI, dysfunction of the microcirculation may develop as a result of 
periprocedural microembolization to the distal coronary artery bed. In addition, recently, 
evidence for the hypothesis that in situ inflammation and thrombosis contributes to 
dysfunction of the microcirculation after primary PCI was provided (Dörge et al, 2000). 
Despite the tendency of microemboli to dissolve after they developed during primary 
PCI, in situ microcirculatory thrombosis may account for worsening of microcirculatory 
function late after primary PCI. Thus not only early evaluation of the coronary 
microcirculation is important; in fact the worst coronary microcirculatory status like 
minimal diastolic deceleration time of LAD blood velocity seems to be even more 
important.  
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4.8 The logic and need for intense antiplatelet treatment in acute STEMI 
Plaque disruption is considered to be the common substrate of acute coronary syndromes 
(Boersma et al, 2003). Consequently, the blood is exposed to a significant quantity of 
thrombogenic materials initiating platelet aggregation and the lumen of the coronary artery 
become obstructed by a combination of platelets, fibrin and red blood cells. Moreover, as 
mentioned previously, primary coronary angioplasty in patients with acute STEMI is 
associated with microembilzation rich with platelets to the distal coronary circulation. 
Therefore, the administration of rapidly acting powerful antiplatelet agent seems logical. 
Glycoprotein IIbIIIa receptor blockers fulfil these requirements.  
4.9 The evidence of effectiveness of Glycoprotein IIbIIIa receptor blockers in acute 
STEMI 
Thus, Abciximab (Neumann et al, 1998) maintained patency of large coronary arteries, but 
in addition was associated with higher coronary artery peak blood velocities and better left 
ventricular wall motion score index and higher left ventricular ejection fraction compared to 
heparin. Abciximab (de Lemos et al, 2000) was shown to improve both epicardial coronary 
artery flow and myocardial reperfusion as evidenced by resolution of ST elevation in 
patients with acute STEMI. Eptifibatide and tirofiban- small molecule Glycoprotein IIbIIIa 
receptor blockers- in a meta-analysis study were shown to be non-inferior to abciximab in 
patients with acute STEMI undergoing PPCI (Ottani et al, 2010). Eptifibatide was shown to 
be equal to abciximab as an adjunct to PPCI in acute STEMI and as effective in causing 
resolution of ST elevation ( Zeymer et al, 2010) and reduced the rate one year mortality and 
re-infarction ( Akerblom et al, 2010). Eptifibatide improved clinical outcome in patients with 
STEMI undergoing PPCI (Mahmoudi et al, 2011). In our study eptifibatide prevented severe 
dysfunction of coronary microcirculation after PPCI in acute STEMI which was not 
translated into better left ventricular systolic function. A larger number of patients may 
reveal such benefit in recovering left ventricular systolic function.  
5. Summary and look to the future 
Thus, transthoracic Doppler echocardiography is feasible and provides important 
information about the function of coronary microcirculation in patients with acute STEMI 
undergoing PPCI. Treatment with eptifibatide before primary angioplasty, prevented early 
LAD systolic flow reversal indicative of severe dysfunction of the microcirculation, 
increased diastolic LAD velocities and flows but did not increase left ventricular systolic 
function. Understanding mechanisms of dysfunction of the coronary microcirculation and 
implementation of newer strategies to treat microcirculatory dysfunction with transthoracic 
Doppler evaluation may improve the treatment of patients with acute STEMI undergoing 
primary angioplasty.  
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squared to calculate areas. Thus if blood velocities, and colour jet diameters of the LAD are 
similar to those of cardiac valves, then flow calculations should be of the same degree of 
validity.  
4.5 Need for coronary blood velocity sampling in acute STEMI 
Restoration of epicardial coronary artery flow by primary PCI in the setting of acute STEMI 
improves outcome (Shah et al, 2000), however optimization of myocardial tissue perfusion 
improves the prediction of outcome (van't Hof et al, 1998; Shah et al, 2000; van't Hof et al, 
1997; Claeys et al, 1999; The TIMI Study Group, 19985; Gibson et al, 1996; 1999; 2001; de 
Lemos, 2001; Dörge et al, 2000). Despite these findings, still even with successful primary 
PCI and the high rate of patency of the culprit artery, left ventricular functional recovery is 
limited and not well predicted (Stone et al, 1997; Zijlstra et al, 1997). 
 Despite the value of myocardial blush grade in the evaluation of myocardial perfusion it is 
not repeatable because of its invasive nature. Resolution of ST-elevation also correlates with 
better myocardial perfusion, however it reflects only the stage immediately following the 
emergency PCI. As we have shown (Sharif et al, 2008) the function of coronary 
microcirculation is variable and may improve or worsen during the hospital stay after 
primary coronary angioplasty in patients with acute STEMI. Therefore, Doppler 
transthorcaic sampling of LAD blood velocities is important in such patients.  
4.6 Diastolic deceleration time of LAD blood velocity curve (DDT) and the 
microcirculation 
To understand the relation between DDT and coronary microcirculation, consider normal 
subjects where the intra-myocardial blood capacitance vessels fill during diastole without 
significant increase in intramural pressure, therefore the DDT is prolonged. When the 
capacitance vessels are partially obstructed with miroemboli there is impedance to flow in 
diastole, therefore the DDT is abbreviated (Kawamoto et al, 1999; Yamamaro et al, 2002). 
When the blockage of the microcirculation is more severe, the milking of blood in systole 
cannot proceed to the venules; instead, it is pushed back into the coronary artery and results 
in early systolic flow reversal (Kawamoto et al, 1999; Yamamaro et al, 2002).  
4.7 Mechanisms of dysfunction of coronary microcirculation after primary coronary 
angioplasty 
After primary PCI, dysfunction of the microcirculation may develop as a result of 
periprocedural microembolization to the distal coronary artery bed. In addition, recently, 
evidence for the hypothesis that in situ inflammation and thrombosis contributes to 
dysfunction of the microcirculation after primary PCI was provided (Dörge et al, 2000). 
Despite the tendency of microemboli to dissolve after they developed during primary 
PCI, in situ microcirculatory thrombosis may account for worsening of microcirculatory 
function late after primary PCI. Thus not only early evaluation of the coronary 
microcirculation is important; in fact the worst coronary microcirculatory status like 
minimal diastolic deceleration time of LAD blood velocity seems to be even more 
important.  
Effects of Eptifibatide on the Microcirculation After Primary Angioplasty in  
Acute ST-Elevation Myocardial Infarction: A Trans-Thoracic Coronary Artery Doppler Study 
 
71 
4.8 The logic and need for intense antiplatelet treatment in acute STEMI 
Plaque disruption is considered to be the common substrate of acute coronary syndromes 
(Boersma et al, 2003). Consequently, the blood is exposed to a significant quantity of 
thrombogenic materials initiating platelet aggregation and the lumen of the coronary artery 
become obstructed by a combination of platelets, fibrin and red blood cells. Moreover, as 
mentioned previously, primary coronary angioplasty in patients with acute STEMI is 
associated with microembilzation rich with platelets to the distal coronary circulation. 
Therefore, the administration of rapidly acting powerful antiplatelet agent seems logical. 
Glycoprotein IIbIIIa receptor blockers fulfil these requirements.  
4.9 The evidence of effectiveness of Glycoprotein IIbIIIa receptor blockers in acute 
STEMI 
Thus, Abciximab (Neumann et al, 1998) maintained patency of large coronary arteries, but 
in addition was associated with higher coronary artery peak blood velocities and better left 
ventricular wall motion score index and higher left ventricular ejection fraction compared to 
heparin. Abciximab (de Lemos et al, 2000) was shown to improve both epicardial coronary 
artery flow and myocardial reperfusion as evidenced by resolution of ST elevation in 
patients with acute STEMI. Eptifibatide and tirofiban- small molecule Glycoprotein IIbIIIa 
receptor blockers- in a meta-analysis study were shown to be non-inferior to abciximab in 
patients with acute STEMI undergoing PPCI (Ottani et al, 2010). Eptifibatide was shown to 
be equal to abciximab as an adjunct to PPCI in acute STEMI and as effective in causing 
resolution of ST elevation ( Zeymer et al, 2010) and reduced the rate one year mortality and 
re-infarction ( Akerblom et al, 2010). Eptifibatide improved clinical outcome in patients with 
STEMI undergoing PPCI (Mahmoudi et al, 2011). In our study eptifibatide prevented severe 
dysfunction of coronary microcirculation after PPCI in acute STEMI which was not 
translated into better left ventricular systolic function. A larger number of patients may 
reveal such benefit in recovering left ventricular systolic function.  
5. Summary and look to the future 
Thus, transthoracic Doppler echocardiography is feasible and provides important 
information about the function of coronary microcirculation in patients with acute STEMI 
undergoing PPCI. Treatment with eptifibatide before primary angioplasty, prevented early 
LAD systolic flow reversal indicative of severe dysfunction of the microcirculation, 
increased diastolic LAD velocities and flows but did not increase left ventricular systolic 
function. Understanding mechanisms of dysfunction of the coronary microcirculation and 
implementation of newer strategies to treat microcirculatory dysfunction with transthoracic 
Doppler evaluation may improve the treatment of patients with acute STEMI undergoing 
primary angioplasty.  
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1. Introduction 
The role of echocardiography in patients with atrial fibrillation (AF) has been changing 
gradually according with recent advance in echocardiographic instruments and better 
understanding for AF. Historically, M-mode echocardiography applied to AF patients has 
focused on the diagnosis of underlying organic heart diseases and on the detection of left 
atrial (LA) thrombi. These are not surprising because AF had been the highest risk of 
ischemic stroke in the era of incomplete anticoagulation therapy. Thereafter, LA size, 
volume and functions have been foci assessed by echocardiography. These 
echocardiographic procedures have been conducted for prediction and prevention of 
recurrence of AF paroxysms (Barbier et al, 1994; Verdecchia et al, 2003; Vasan et al, 2003). 
Spontaneous echo contrast has also been an established B-mode echocardiographic finding 
with highly predictive value of ischemic stroke. After the development of Doppler 
echocardiography, pulmonary venous flow (PVF) evaluation is a routine laboratory 
investigation for patients with and without AF. The usefulness of PVF evaluation is not 
limited to assess LA or left ventricular (LV) functions, but has expanded to investigation of 
various aspects of AF (Tabata et al., 2003). PVF recording increases its usefulness when it is 
combined with recordings of Doppler LV inflow pattern. This article reviews the established 
usefulness of PVF estimation in patients with permanent AF, and then focuses on the 
potential usefulness of PVF assessment in AF progression, i.e., during sinus rhythm (i.e., 
interval of paroxysms of AF), during ongoing paroxysmal AF, and further during the long-
term AF management. 
2. Clinical Perspectives of AF 
AF is one of the most common sustained arrhythmias in daily clinical practice. There has 
been a great advance in the exploration of the etiologies of AF. These are the subject of 
several overlapping schemes of individual pathogenesis, i.e., atrial overload and stretch, 
myocardial ischemia and inflammation, degeneration and subsequent fibrosis of atrial 
myocardium, neurohumoral or metabolic factors, and other unknown factors. Therefore, 
clinical presentations of AF are very broad. This arrhythmia occurs in a variety of clinical 
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clinical presentations of AF are very broad. This arrhythmia occurs in a variety of clinical 
 
Echocardiography – In Specific Diseases 
 
78
settings such as valvular heart diseases, postoperative conditions, heart failure, 
hypertension, metabolic syndrome, thyrotoxicosis, and so on (Fig. 1). Since valvular heart 
diseases were historically a main etiology of AF, echocardiographic attention to AF patients 
was mainly rheumatic valvular lesions and detection of LA thrombi or spontaneous echo 
contrast which is based on the local hemostatic changes due to rheologic abnormalities 
(Kwaan et al, 2004; Topaloglu et al, 2007). In relation to thrombus formation, LA appendage 
function was highlighted in that impaired appendage function leads to thrombus formation 
and high risk of embolic event (Donal et al, 2005). According to an increased prevalence of 
coronary artery diseases, AF has been encountered in acute myocardial infarction, after 
coronary artery bypass grafting surgery and chronic phase of ischemic heart disease and 
subsequent heart failure. On the other hand, AF is often observed in patients with another 
kind of arrhythmias (e.g., preexcitation syndrome) or noncardiac disorders (e.g., 
thyrotoxicosis, chronic obstructive pulmonary disease). AF is often encountered in subjects 
without systemic or organic heart diseases (so-called ‘lone’ AF). According with relative 
decline of rheumatic valvular diseases, terminology of ‘nonvalvular’ or ‘nonrheumatic’ AF 
becomes familiar. Wide spectrum in clinical features of AF sometimes makes the therapeutic 
decision-making difficult (Wyse & Gersh, 2004). 
AF is classified by the duration in which this arrhythmia sustains (e.g., paroxysmal, 
persistent and permanent). Paroxysmal AF is characterized as rare or repetitive paroxysms 
of short-lasting AF, which often undergoes spontaneous conversion to sinus rhythm, but 
rhythm-control treatment is required depending on symptom and hemodynamic 
deterioration. Persistent AF has the possibility of termination either by antiarrhythmic drugs 
or by electrical defibrillation. Permanent AF does not restore to sinus rhythm 
spontaneously, and hence conservative therapeutic option is the rate-control strategy. AF is 
not only responsible for substantial morbidity and mortality, but also impairs quality of life 
by limited capacities of physical activity and heart rate regulation. To date, the most 
effective treatment for drug-refractory AF is radiofrequency catheter ablation. Pulmonary 
vein (PV) isolation by circumferential ablation of PV-LA junction is a promising technique to 
terminate AF. Despite the introduction of novel and sophisticated ablation techniques such 
as irrigation catheters, pericardial approach and ganglionated plexi ablation, periprocedural 
complications are not negligible. 
AF is characterized to date as an age-dependent, progressive disease, i.e., AF prevalence 
increases steeply from 0.5% at age 50 to 59 years to 9.0% at age 80 to 89 years (Kannel et al., 
1998). Progressive nature of this arrhythmia is evident in that AF becomes refractory to 
pharmacologic treatment and electrical defibrillation in proportion with the duration of 
sustaining AF. This is the main feature that distinguishes AF from many other kinds of 
clinical arrhythmia (Wijffels et al., 1995). In a few decades, the mechanisms of such 
progression of AF have been clarified by many basic experiments using AF animal models 
and clinical studies of AF patients. Remodeling of LA plays an important role in the genesis, 
maintenance and perpetuation of AF. LA remodeling is a concept including electrical, 
contractile and structural aspects. Electrical remodeling induces abbreviated and dispersed 
electrical refractoriness and inhomogeneous slow conduction of electrical impulse. These are 
considered to be an arrhythmogenic substrate, prerequisite of AF development. 
Electrocardiograms (ECG) in patients with AF demonstrate characteristic fibrillation (f) 
waves that are evident in right precordial leads. According to the progression of AF, 
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characteristic f-waves become gradually small in amplitude and high in frequency. On the 
other hand, contractile remodeling provides poor LA contraction and structural remodeling 
causes LA dilatation. Histologically, LA myocardium in patients with AF shows infiltration 
of inflammatory cells, interstitial fibrosis and loss of contractile myocytes, leading to slow, 
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Atrial degeneration and progressive remodeling
 
Fig. 1. Mechanisms favoring atrial fibrillation (AF).  
3. Physiology of PVF 
PVF recording is feasible not only by transesophageal echocardiography (TEE) but also by 
transthoracic echocardiography (TTE). According with the prevalence of PVF estimation by 
TTE, there have been investigations comparing the PVF recorded by TTE with that recorded 
by TEE. To date, TTE estimation of PVF is reported to provide reliable quantitation of PVF 
recorded by TEE in patients with and without organic heart diseases (Masuyama et al., 
1995).  Fig. 2 is an actual Doppler PVF pattern during an entire cardiac cycle recorded by 
TTE. When ultrasound probe is positioned at the apex of chest wall, a four-chamber apical 
view is obtained. Then color jet is visualized in the upper LA of real-time, B-mode image. 
This color image is forward blood flow signals in right superior PV (Fig. 2, upper). After 
overall color Doppler interrogation, Doppler velocimetry is obtained by positioning the 
sampling gate 2-3 cm distal from the orifice of right superior PV (Fig. 2, lower). 
The PVF profile is characterized as forward flows during LV systolic (S) and early diastolic 
(D) phases, and as reversed flow during late diastole when LA contracts (Ar). There are 
strictly two components within the S wave of PVF, i.e., S1 is caused by active LA relaxation 
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and S2 is ascribed to passive LA wall stretching caused by vigorous LV contraction toward 
apical direction. Peak velocity and velocity-time integral of the S wave are usually greater 
than those of the D wave. Gentile et al (1997) investigated Doppler PVF parameters in 143 
healthy individuals aged from 20 to 80 years by TTE. Age-dependent Doppler parameters 
are reported to be as follows; peak amplitude and time integral of both S and D waves, and 
S/D peak amplitude and integral ratios, whereas Ar wave is reported to be age-
independent. These findings indicate the possibility of Ar wave as a diagnostic tool of 




Fig. 2. Representative Doppler imaging of transthoracic echocardiography applied to a 
patient with hypertension. Upper image is an apical four chamber view with color flow 
indicating blood flow returning from right superior pulmonary vein (PV) into left atrium 
(LA). Middle is an ECG tracing (standard limb lead II). Lower is a continuous-wave Doppler 
PV flow velocimetry during an entire cardiac cycle. Upward direction indicates forward 
flow, whereas downward direction means reverse flow. 
LA plays three different roles periodically in an entire cardiac cycle, i.e., LA acts as a 
‘booster pump’ when LA contracts in late LV diastole, then as a ‘reservoir’ during LV 
systole, and finally as a ‘conduit’ during early LV diastole (Fig. 3). These three kinds of LA 
functions correspond with Ar, S and D waves respectively, and are estimated also by LA 
volume curve during an entire cardiac cycle using automatic boundary detection (Zhang et 
al, 1998), manual tracking (Ogawa et al, 2009), and speckle tracking techniques (Mori et al, 
2011). The PVF pattern, especially S and D wave components, is influenced originally by 
many physiologic factors such as age, heart rate, respiration, LV function and loading 
conditions (Bollmann, 2007). These factors should be taken into account when evaluating 
PVF recording. 
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and S2 is ascribed to passive LA wall stretching caused by vigorous LV contraction toward 
apical direction. Peak velocity and velocity-time integral of the S wave are usually greater 
than those of the D wave. Gentile et al (1997) investigated Doppler PVF parameters in 143 
healthy individuals aged from 20 to 80 years by TTE. Age-dependent Doppler parameters 
are reported to be as follows; peak amplitude and time integral of both S and D waves, and 
S/D peak amplitude and integral ratios, whereas Ar wave is reported to be age-
independent. These findings indicate the possibility of Ar wave as a diagnostic tool of 
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4. Myocardial sleeves in PV 
In the PVF profile, Ar wave reflects physiologic PV regurgitation during LA contraction due 
to the absence of an anatomic valve at the PV-LA junction. Interestingly, PV wall contains 
myocardial sleeves instead of anatomic valve. Fig. 4 is a schematic illustration of human 
atria and adjacent great veins. Posterior LA wall contains complicated myocardial layers for 
myocardial sleeves running longitudinally, cross-sectionally and obliquely within the PV 
walls. Histologically, myocardial sleeves exist in the mid-layer of PV walls (Fig. 5A). The 
myocardial sleeves are, therefore, considered to function as a ‘sphincter’, which minimizes 
the PV regurgitation caused by LA contraction. PV contraction is actually confirmed, and 
this phenomenon is mainly due to the presence of myocardial sleeves contracting 
synchronously with LA myocardium. This is validated by radiofrequency catheter ablation, 
i.e., perfect PV isolation (e.g., electrical disconnection of PV-LA junction) is reported to 
abolish the PV contraction (Atwater et al, 2011). These sleeves also function as ‘throttle’ 
valve that regulates cardiac output for systemic circulation (Burch & Romney, 1954). The 
myocardial sleeves show characteristic electrophysiological properties prone to yield 
spontaneous repetitive firings which propagate to LA and cause frequent ectopic beats. Fig. 
5B is the microelectrode recording of the intracellular potentials of guinea-pig LA and 
myocardial sleeve in PV. Resting membrane potential in myocardial sleeve is less negative 
relative to that of LA. Moreover, myocardial sleeve in PV show the tendency of spontaneous 
electrical activity leading to the abnormal automaticity initiating AF. These arrhythmogenic 
foci act as a ‘driver’ to trigger and maintain paroxysms of AF. Highly compliant PV wall 
allows own cyclic stretching due to physiological PV regurgitation. This phenomenon is 
considered to accentuate intracellular Ca2+ dynamics mediated by stretch-activated ion 
channels, which is a prerequisite of repetitive electrical firing (de Bakker et al., 2002; Honjo 
et al., 2003; Chou et al., 2005, Takahara et al, 2011). Moreover, the myocardial sleeves within 
PV show a complicated anisotropic orientation of myocardial fibers separated by fibrotic 
tissues causing impaired electrotonic interactions, which accentuates intrinsic spontaneous 
firing and triggered activity (Nathan & Eliakim, 1966). 
Since Haïssaguerre et al (1998) demonstrated the ectopic and spontaneous electrical 
activities in the myocardial sleeves located in PV responsible for triggering AF, main stream 
of the AF research has been changed over the past decade, in that recent AF study focused 
on many areas which had not been given much attention. Importance of the myocardial 
sleeves as arrhythmogenic foci in AF is confirmed also in the human postmortem studies. 
Tagawa et al (2001) investigated myocardial sleeve distribution in patients with AF or 
without AF. They showed that the significantly longer distance of sleeves extending to the 
peripheral end of PV in AF patients relative to the distance in control patients was 
confirmed  in inferior but not superior PV. In addition, myocytes in PV of AF patients were 
not uniform and surrounded by fibrous tissues compared with those in controls. Moreover, 
Steiner et al (2006) reported that amyloid deposition and scarring in myocardial sleeves 
tended to be observed more frequently in AF patients relative to control patients. 
Interestingly, the incidence of atrial myocardium extending beyond the PV-LA junction up 
to the PV periphery in all the examined PV specimens is commonly reported to be 88 to 89% 
(Tagawa et al, 2001; Steiner et al, 2006). 
According with an advance of immunohistochemical techniques, autonomic nervous 
innervation in PV has been elucidated. Ganglionated plexi are reported to be abundant 
around the great vessels of the human heart including PV (Armour et al, 1997). 
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Furthermore, both cholinergic and adrenergic nerve endings are found together within a 
single neural plexus of PV, and nerve density is highest in the PV antrum (Tan et al, 2006). 
The physiological meaning of these ganglionated plexi remains to be speculative. 
Considering the ‘throttle’ valve function of myocardial sleeves, ganglionated plexi located in 
PV-LA junctions may play a role of neural control of cardiac output by regulating proximal 
PV tonus. Elevated PV tonus associated with pathological condition such as heart failure 
(e.g., ganglionated plexi out of neural control) may lead to the occasion of acute pulmonary 
edema leading to severe dyspnea or orthopnea. AF per se also shows potential autonomic 
influence (Fig. 1). The correlations between the neural aspect of AF and the ganglionated 
plexi possibly influencing PV tonus or contraction are the subjects of future study. 
5. PVF during ongoing AF 
PVF is visualized by Doppler echocardiography not only in sinus rhythm but also during 
AF. AF is characterized by electrophysiological and mechanical properties such as rapid, 
irregular and fragmented electrical activities and absence of complete LA contraction and 
relaxation. Therefore, PVF during AF is known as loss of Ar wave, blunted S wave and 
relatively dominant D wave. Loss of synchronous LA contraction is reflected by 
disappearance of Ar wave. Similarly, loss of complete LA relaxation causes a delayed onset 
of S wave. 
LAA RAA
 
Fig. 4. Schematic illustration of human atria and adjacent great veins. Myocardial sleeves 
run in PV wall longitudinally, obliquely and cross-sectionally. Myocardial sleeve in superior 
PV is usually longer than that in inferior PV. IVC, inferior vena cava; LAA, left atrial 
appendage; LIPV, left inferior PV; LSPV, left superior PV; RAA, right atrial appendage; 
RIPV, right inferior PV; RSPV, right superior PV; SVC, superior vena cava. 
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Fig. 5. A: Microscopic findings of PV obtained from guinea pig (upper: masson trichrome 
staining, lower: immunostaining for α-smooth muscle actin). B: Electrophysiological 
characteristics of PV and LA. (From Takahara, A.; Sugimoto, T.; Kitamura, T.; Takeda, K.; 
Tsuneoka, Y.; Namekata, I. & Tanaka, H. Electrophysiological and pharmacological 
characteristics of triggered activity elicited in guinea-pig pulmonary vein myocardium. 
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This phenomenon is due to loss of S1 wave that reflects forward PV flow under the active 
LA relaxation. Moreover, early systolic reversed PVF is sometimes observed (Tabata et al., 
2003; Bollmann, 2007). This is reflected by reversed PV-LA pressure gradient at this moment 
of the early systolic phase. S2 per se is also blunted under the increased LA stiffness during 
AF. LA functions of ‘reservoir’ and ’booster pump’ are impaired profoundly under the 
presence of AF. Impaired LA functions result in the reduction of stroke volume by 38% even 
in AF patients without organic heart diseases (Alboni et al, 1995). Therefore, only the 
‘conduit’ function of LA remains, which leads to the greater D wave relative to S2 wave 
(Chao et al., 2000). These echocardiographic findings are important predictors of progressive 
LA remodeling. 
6. PVF during sinus rhythm in AF patients 
AF is a progressive disease showing electrical, contractile and structural LA remodeling 
(Wijffels et al., 1995). It is well known that paroxysms of AF gradually become refractory to 
pharmacologic treatment and electrical defibrillation. Accordingly, paroxysmal AF becomes 
persistent AF, and finally converts to permanent AF, although individual difference in such 
time course exists. For sonographers and cardiologists, one of the greatest 
echocardiographic interests during sinus rhythm in AF patients is to predict future 
paroxysms and progression of AF. Conventionally, prediction of AF progression is based 
mainly on LA size, volume, and functions (Barbier et al, 1994; Verdecchia et al, 2003; Vasan 
et al, 2003). Such evaluations have been performed historically by various 
echocardiographic techniques such as M-mode measurement, LV inflow Doppler 
velocimetry, strain-rate imaging, three-dimensional echocardiography speckle tracking 
technique and so on. Two-dimensional speckle tracking echocardiography monitors LA 
volume curve during an entire cardiac cycle, which enables accurate evaluations of 
aforementioned three kinds of LA functions (e.g., ‘reservoir’, ‘conduit’ and ‘booster pump’ 
functions). This technique showed reduced ‘reservoir’ and ‘booster pump’ functions in 
patients with paroxysmal AF (Mori et al., 2011). 
PVF recording in sinus rhythm of AF patients has been receiving increasing attention, 
because ‘focal’ AF originates predominantly from PV (Haïssaguerre et al., 1998), and wide 
spectrum of paroxysmal to persistent AF associated with and without organic heart diseases 
shows similar characteristics of ‘focal’ AF. PV orifice morphologies in conjunction with AF 
progression have been investigated over the years by various modalities such as TEE 
(Knackstedt et al, 2003), magnetic resonance (MR) imaging (Tsao et al, 2001; Takase et al., 
2004) and multislice computed tomography (Scharf et al, 2003). These investigations have 
been conducted under the uniform hypothesis that largest PV is the main source of ectopic 
electrical activities triggering and sustaining AF. Fig. 6 demonstrates the PV images 
obtained by MR angiography applied to the patients with paroxysmal (Fig. 6A) or 
permanent (Fig. 6B) AF and with sinus rhythm (Fig. 6C). Four PV diameters are reported to 
be greater in the order of patients with permanent AF > those with paroxysmal AF > those 
with sinus rhythm (Takase et al., 2004). Moreover, PV branching pattern observed in AF 
patients is complicated compared with that of patients with sinus rhythm. These indicate 
that most permanent and paroxysmal AF stems from ‘focal’ AF, and that progressive 
structural remodeling caused by AF affects both LA and PV. With respect to the PV/LA 
diameter ratio, there has been a controversy, i.e., this ratio in patients with AF tended to be 
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LA remodeling. 
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time course exists. For sonographers and cardiologists, one of the greatest 
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mainly on LA size, volume, and functions (Barbier et al, 1994; Verdecchia et al, 2003; Vasan 
et al, 2003). Such evaluations have been performed historically by various 
echocardiographic techniques such as M-mode measurement, LV inflow Doppler 
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volume curve during an entire cardiac cycle, which enables accurate evaluations of 
aforementioned three kinds of LA functions (e.g., ‘reservoir’, ‘conduit’ and ‘booster pump’ 
functions). This technique showed reduced ‘reservoir’ and ‘booster pump’ functions in 
patients with paroxysmal AF (Mori et al., 2011). 
PVF recording in sinus rhythm of AF patients has been receiving increasing attention, 
because ‘focal’ AF originates predominantly from PV (Haïssaguerre et al., 1998), and wide 
spectrum of paroxysmal to persistent AF associated with and without organic heart diseases 
shows similar characteristics of ‘focal’ AF. PV orifice morphologies in conjunction with AF 
progression have been investigated over the years by various modalities such as TEE 
(Knackstedt et al, 2003), magnetic resonance (MR) imaging (Tsao et al, 2001; Takase et al., 
2004) and multislice computed tomography (Scharf et al, 2003). These investigations have 
been conducted under the uniform hypothesis that largest PV is the main source of ectopic 
electrical activities triggering and sustaining AF. Fig. 6 demonstrates the PV images 
obtained by MR angiography applied to the patients with paroxysmal (Fig. 6A) or 
permanent (Fig. 6B) AF and with sinus rhythm (Fig. 6C). Four PV diameters are reported to 
be greater in the order of patients with permanent AF > those with paroxysmal AF > those 
with sinus rhythm (Takase et al., 2004). Moreover, PV branching pattern observed in AF 
patients is complicated compared with that of patients with sinus rhythm. These indicate 
that most permanent and paroxysmal AF stems from ‘focal’ AF, and that progressive 
structural remodeling caused by AF affects both LA and PV. With respect to the PV/LA 
diameter ratio, there has been a controversy, i.e., this ratio in patients with AF tended to be 
 
Echocardiography – In Specific Diseases 
 
86
greater than that of patients without AF (Knackstedt et al, 2003), whereas this ratio was the 
same among the patient groups of paroxysmal AF, permanent AF and sinus rhythm (Tsao et 
al, 2001). These discrepant results may be attributed in part to the different imaging 
modalities and AF patients’ enrollment. 
In spite of accumulated morphological investigations of PV-LA junction in AF patients, 
there have been controversies in echocardiographic PVF patterns during sinus rhythm in 
patients susceptible to AF. Kosmala et al (2006) reported that an abnormal PVF pattern was 
observed in patients with AF, i.e., abbreviated acceleration time and prolonged deceleration 
time in S wave, indicating impaired LA relaxation and compliance. Similarly, Lindgren et al 
(2003) reported the reduced S wave amplitude as a predictor of AF progression. These are 
compatible to the findings reported by two-dimensional speckle tracking method (Mori et 
al, 2011). On the other hand, increased Ar wave amplitude in sinus rhythm is reported to be 
a potential marker of AF progression in hypertensive patients in our laboratory (Fig. 7). Ar 
amplitude and velocity-time integral of Ar wave are supposed to be linked closely to the 
sphincter function of myocardial sleeves located in PV (Fig. 4, Fig. 5A), i.e., impaired 
sphincter function theoretically allows more PV regurgitation and Ar wave augmentation. 
Surprisingly, increased Ar amplitude is associated with reduced, but not increased, LA 
contractility in our study (Maruyama et al, 2008). These findings imply that PV sphincter 
dysfunction is linked to the contractile LA remodeling responsible for AF progression. LA 
contractile performance is usually quantified as LA fractional shortening (LAFS), which is 
calculated by the following equation (Fig. 8), 
 LAFS = (LADa – LADd) / LADa (1) 
where, LADa is an LA diameter at the beginning of LA contraction, and LADd is a 
minimum LA diameter during active LA contraction (Barbier et al, 1994). This is a simple 
measure of LA contractility obtained by M-mode echocardiography, although it is a 
parameter estimated only in the anteroposterior LA direction. Ar wave augmentation is 
associated with reduced LAFS, and predictive values of PV regurgitation (e.g., peak PV 
backflow velocity: PVBV), LA contractile function (e.g., LAFS) and LA size (e.g., LADd) for 
AF progression are assessed. Consequently, receiver-operating curve (ROC) indicated that 
the amplitude of age-independent Ar wave (e.g., PVBV) showed the greatest predictive 
value for the perpetuation of AF (Fig. 9). So far, the reason for discrepant results showing 
the importance of impaired forward flow (S wave) vs. augmented backward flow (Ar wave) 
in AF progression is unknown. PV regurgitation reflected by augmented Ar wave 
amplitude (e.g., PVBV) is determined by LA-PV pressure gradient (e.g., balance between LA 
contractile function and PV ‘sphincter’ function). These structures are under the influence of 
continuous remodeling according to the AF progression, which differs in individual AF 
patient. There are so many echocardiographic indices with different sensitivities and 
specificities. Echocardiography recorded during sinus rhythm at different stages of long-
term AF progression may have resulted in such discrepant outcomes. Therefore, in personal 
opinion, it seems uncertain whether or not such comparisons of echocardiographic 
investigations are meaningful or fruitful. 
Ar  wave augmentation indicating an extent of PV regurgitation is considered to be a PV 
remodeling based on the impaired ‘sphincter’ function of the myocardial sleeves 
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surrounding the PV-LA junction (Fig. 4, Fig. 5A). This is considered to be due to the 
histological, electrical and mechanical abnormalities of the myocardial sleeves. On the other 





Fig. 6. Representative magnetic resonance angiography of patients with paroxysmal (A) or 
permanent (B) AF and with sinus rhythm (C). Diameters of pulmonary veins in AF patients 
are greater than those in patients with sinus rhythm. Landmark (*) showing the center of 
posterior wall of left atrium was indicated. (From Takase, B.; Nagata, M.; Matsui, T.; Kihara, 
T.; Kameyama, A.; Hamabe, A.; Noya, K.; Satomura, K.; Ishihara, M.; Kurita, A. & Ohsuzu, 
F. Pulmonary vein dimensions and variation of branching pattern in patients with 
paroxysmal atrial fibrillation using magnetic resonance angiography. Japanese Heart Journal 
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in part the structural LA remodeling.  It is, therefore, of interest which part of remodeling 
shows the greatest influence on the AF progression and perpetuation. In our study, PV 
remodeling demonstrated the greatest influence on the perpetuation of AF by the ROC 
analysis (Fig. 9). Knackstedt et al (2003) reported no correlation between PV diameter and 
LA size in patients with or without AF. Considering their TEE study, PV remodeling (e.g., 
dilation and regurgitation) plays a key role in AF progression (Scharf et al, 2003), although it 
is uncertain whether PV remodeling is a cause or a consequence of AF progression. PV wall 
is relatively more compliant and hence more susceptible to hemodynamics altered by 
paroxysms of AF than LA wall. Therefore, in personal opinion, these vessel properties of PV 
relates to susceptibility to AF-induced remodeling. 
 
Fig. 7. Representative pulsed-wave Doppler findings of time-matched LV inflow (upper) 
and right superior pulmonary vein (PV) flow patterns (lower) during sinus rhythm in 
patients with AF which became permanent (A) or remained paroxysmal (B). Peak velocity 
of PV backflow (Ar wave) during left atrial (LA) contraction in A (left white arrow) was 
obviously greater than that in B (right white arrow). Time-integral of PV backflow in A is 
also greater than that in B. Note that scale in LV inflow is different from that in PV flow. 
(From Maruyama, T.; Kishikawa, T.; Ito, H.; Kaji, Y.; Sasaki, Y. & Ishihara, Y. Augmentation 
of pulmonary vein backflow velocity during left atrial contraction: a novel phenomenon 
responsible for progression of atrial fibrillation in hypertensive patients. Cardiology Vol. 109, 
No. 1, 2008, pp. 33-40, with permission.) 
After the termination of AF episode, LA contractile function is briefly impaired. This 
impairment is gradually restored, and this reversible phenomenon is well known as LA 
stunning. One of the main causes of this stunning is considered to be based on the intracellular 
handling of cytosolic Ca2+, which is important in cardiac performance but disturbed during 
AF. The aspects of atrial cardiomyopathy induced by tachycardia and atrial hibernation or 
fibrosis are also involved in the genesis of LA stunning (Khan, 2003). Recovery from LA 
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stunning depends on the duration of AF, mode of defibrillation, and LA size, i.e., AF lasting 10 
to 20 minutes does not cause observable stunning (Sparks et al, 1999) and recovery of LA 
contractile function is early in the order of spontaneous conversion to sinus rhythm > 
pharmacological defibrillation > electrical defibrillation. AF patients with normal LA size are 
also apt to show earlier LA functional recovery (Mattioli et al, 1998; Khan, 2003). 
Thromboembolic event is a major complication of AF. This complication after defibrillation has 
been attributed to the dislodgement of LA thrombi during the recovery from LA stunning. 
Therefore, serial echocardiographic investigation and optimal anticoagulation treatment are 
necessary during this period. LA stunning is observed also in the case of AF treated with 
radiofrequency catheter ablation. Stavrakis et al (2011) investigated the acute changes of LA 
function and PVF pattern following PV isolation associated with ganglionated plexi ablation 
by TEE. They reported augmentation of both D and S waves, decrease of S/D ratio, and trend 
toward an increase in LA appendage emptying velocities after the ablation. LA appendage 
emptying velocity closely relates to LA stunning, and reduced S/D ratio reflects impaired LA 
relaxation in the postablative period. These TEE findings are consistent with those reported by 













Fig. 8. Schematic illustration of the M-mode estimation of left atrial (LA) contractile 
function. LA dimension is variable depending on cardiac cycle. LADa, LA dimension 
immediately prior to the onset of LA contraction; LADd, minimal LA dimension at the end 
of the active LA contraction; LADs, maximal LA dimension at the end-systole. LA fractional 
shortening (LAFS) is calculated by equation (1) in the text. LA plays three kinds of 
hemodynamic function during an entire cardiac cycle (text). Aortic valve opening time 
corresponds to the left ventricular ejection period. Ao, aortic root; ECG, electrocardiogram; 
RVOT, right ventricular outflow tract; UCG, ultrasound cardiogram. 
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in part the structural LA remodeling.  It is, therefore, of interest which part of remodeling 
shows the greatest influence on the AF progression and perpetuation. In our study, PV 
remodeling demonstrated the greatest influence on the perpetuation of AF by the ROC 
analysis (Fig. 9). Knackstedt et al (2003) reported no correlation between PV diameter and 
LA size in patients with or without AF. Considering their TEE study, PV remodeling (e.g., 
dilation and regurgitation) plays a key role in AF progression (Scharf et al, 2003), although it 
is uncertain whether PV remodeling is a cause or a consequence of AF progression. PV wall 
is relatively more compliant and hence more susceptible to hemodynamics altered by 
paroxysms of AF than LA wall. Therefore, in personal opinion, these vessel properties of PV 
relates to susceptibility to AF-induced remodeling. 
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7. PVF in AF management 
Pharmacological AF management is mainly divided into rhythm control and rate control 
strategies, both of which show equivalent outcomes in long-term prognosis of AF patients 
provided that appropriate anticoagulation therapy is conducted (Wyse, 2005). However, 
choice of better strategy based only on electrophysiologic or electrocardiographic 
perspectives seems insufficient. PVF evaluation has the potential to play a role in this 
decision-making process, i.e., PVF recording enables evaluation of contractile LA and PV 
functions, which vary during the long period of AF remodeling affecting both LA and PV. 
For AF management, it is important to assess the stage of AF progression in individual AF 
patient with different clinical background. For this purpose, assessment of LA stiffness or 
contractility and severity of PV regurgitation by PVF profile is important for AF 
management in individual patient. 
Radiofrequency catheter ablation is widely conducted in many electrophysiologic 
laboratories. It is a first line therapy for ‘focal’ AF originating from PV, and is currently 
applied not only to paroxysmal AF but also to persistent AF. Remodeling makes AF drug-
refractory. Moreover, antiarrhythmic drugs often suppress cardiac performance (negative 
inotropism) and are sometimes arrhythmogenic (proarrhythmic effects). The main  
 
Fig. 9. Receiver-operating curve (ROC) discriminated PV backflow velocity (PVBV) as the 
best predictor of the progression of AF.  Areas under the ROC for PVBV, left atrial fractional 
shortening (LAFS) and left atrial diameter at end-diastole (LADd) are 0.873, 0.740 and 0.623, 
respectively. Cut-off PVBV for predicting future AF perpetuation is 21.8 cm/sec (sensitivity 
84.6%, specificity 78.3%). LAFS is calculated by equation (1) in the text. (From Maruyama, T.; 
Kishikawa, T.; Ito, H.; Kaji, Y.; Sasaki, Y. & Ishihara, Y. Augmentation of pulmonary vein 
backflow velocity during left atrial contraction: a novel phenomenon responsible for 
progression of atrial fibrillation in hypertensive patients. Cardiology Vol. 109, No. 1, 2008, pp. 
33-40, with permission.) 
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procedure for ablation is electrical isolation of PV-LA junctions, i.e., disconnection of 
arrhythmogenic PV and adjacent antrum. Although recent advance in navigation system 
and new catheter device have enabled safe and effective PV isolation, PV stenosis remains a 
major complication especially of circumferential PV isolation. Pulmonary veno-occlusive 
syndrome associated with secondary pulmonary hypertension is a serious late-onset 
complication. During this procedure, mild-to-moderate forward PVF (e.g., S and D waves) 
acceleration is recorded, but this acceleration is transient and well tolerated (Ren et al., 2002). 
PVF monitoring is a practical and cost-effective method for early detection of this serious 
complication (Tabata et al., 2003; Bollmann 2007). When considering PVF is influenced by 
heart rate and autonomic tone (Ren et al., 2004), computed tomography or MR imaging is 
required to determine the therapeutic indication for balloon dilatation of PV stenosis. 
8. PVF and AF progression 
All the components of PVF have the potential role to evaluate AF progression, i.e., S wave 
attenuation and consequent relative D wave augmentation indicate impaired LA relaxation 
and compliance. Considering increased D and Ar wave amplitudes during sinus rhythm in 
AF patients, PVF increases exclusively during LV diastole, whichever PVF direction is 
forward (e.g., D wave) or backward (e.g., Ar wave). If ectopic beats originating from PV are 
mechanically triggered, these echocardiographic findings indicate that ectopic beats are 
prone to occur during diastole. Therefore, repetitive PV ectopic beats easily capture 
ventricles that are out of refractory period, and induce rapid ventricular response during 
‘focal’ AF. This is important because rapid AF is easy to promote electrical remodeling 
(Wijffels et al., 1995). 
PV backflow during 
LA contraction        
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Fig. 10. Possible mechanisms of reversed PV flow (Ar wave) augmentation contributing to 
the AF progression. 
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acceleration is recorded, but this acceleration is transient and well tolerated (Ren et al., 2002). 
PVF monitoring is a practical and cost-effective method for early detection of this serious 
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AF progression is reported to be associated with greater PV diameter (Knackstedt et al., 
2003; Tsao et al., 2001) as a consequence of PV remodeling (Scharf et al., 2003). Although the 
relation of AF and PV contraction remains to be fully investigated, augmentation of Ar wave 
(e.g., PVBV) may cause cyclic stretching of highly compliant myocardial sleeves in PV, 
repetitive ectopic beats and loss of ‘sphincter’ function, which underlie further PV 
regurgitation. Therefore, D and Ar waves augmentation, PV myocardial sleeve stretching 
and ectopic beats form a vicious cycle leading to PV remodeling. A possible mechanism by 
which PV characteristics contribute to AF progression is demonstrated in Fig. 10. 
9. Conclusion 
AF is the most common clinical arrhythmia showing progressive features. There has been 
evidence to suggest PV as a source of abnormal electrical activities initiating and sustaining 
AF. Currently, PVF recording is feasible in routine Doppler echocardiography, and is 
essential for evaluation of LA functioning three roles during an entire cardiac cycle such as 
‘booster pump’, ‘reservoir’ and ‘conduit’. This flow pattern recognition is of clinical 
importance not only in assessing global cardiac performance but also for obtaining 
considerable information with respect to the pathophysiology and management of AF. 
There has been a consensus with respect to the PVF pattern during ongoing AF or in 
patients with permanent AF. However, there has been a controversy concerning PVF profile 
during sinus rhythm in patients with paroxysmal AF. This indicates the anatomical and 
pathophysiological complexities of PV-LA junction and AF itself. Time-dependent recovery 
of LA contractile function (LA stunning) and neuroanatomical modification of PV-LA 
junction by radiofrequency catheter ablation make this controversy further complicated. In 
spite of such controversy and complexity, PVF recording has potential benefits to assess 
various stages of long-term AF progression and to manage the AF patients. 
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1. Introduction 
Impaired systolic performance and/or diastolic function have long been detrimental 
consequences of acute myocardial infarction (AMI), which remains a major cause of 
morbidity and mortality worldwide. Despite considerable therapeutic improvements, left 
ventricular dysfunction secondary to infarction continues to pose serious health 
complications, including heart failure (HF), wherein the heart is unable to maintain a cardiac 
output appropriate for the requirements of the body. Several factors contribute to HF, 
including adverse ventricular remodeling, progressive hypertrophy and sustained cell death 
by apoptosis. Therefore, the search for a therapeutic strategy to overcome or mitigate the 
progression of HF is of paramount importance. 
1.1 PDE-5 Inhibitors 
Sildenafil citrate (ViagraTM) is the first PDE-5 inhibitor approved for treatment of erectile 
dysfunction. The discovery of this drug in 1989 was the result of extensive research on 
chemical agents that hold potential promise in the treatment of coronary heart disease. 
Initial clinical studies on sildenafil in the early 1990s were not promising with respect to its 
anti-anginal potential. However, a remarkable side effect was reported by a number of 
volunteers participating in these investigations; sildenafil seemed to enhance penile 
erections, which soon thereafter became the main focus of further studies. More than 10 
million men worldwide have been treated with sildenafil since its market debut in 1998. 
Sildenafil is highly specific for PDE-5 inhibition with relatively minor cross-reactivity with 
PDE-6 (Laties & Fraunfelder, 1999). It has a chemical structure similar to cGMP and inhibits 
PDE-5 by binding to the cGMP-catalytic sites (Corbin & Francis, 2002) thereby allowing the 
accumulation of cGMP in the erectile tissue. Two additional agents in this class (vardenafil 
[LevitraTM] (Porst et al., 2001) and tadalafil [CialisTM]) have also been developed and 
approved by the FDA for treatment of erectile dysfunction and recently sildenafil and 
tadalafil were approved for treatment of pulmonary arterial hypertension (PAH) (Corbin & 
Francis, 2002). PDE-5 inhibitors are structurally similar to cGMP and therefore compete with 
cGMP for binding to PDE-5 at the catalytic site (reviewed in Kukreja et al., 2005). 
Interestingly, PDE expression has been reported to change in pathologic conditions. For 
instance, in patients with cardiovascular disease or diabetes, nitric oxide (NO) levels are 
 
Echocardiography – In Specific Diseases 
 
96
Vasan, RS.; Larson, MG.; Levy, D.; Galderisi, M.; Wolf, PA. & Benjamin, EJ. (2003). Doppler 
transmitral flow indexes and risk of atrial fibrillation (the Framingham Heart 
Study). American Journal of Cardiology Vol. 91, No. 9, (May 2003), pp. 1079-1083, 
ISSN 0002-9149 
Verdecchia, P.; Reboldi, G.; Gattobigio, R.; Bentivoglio, M.; Borgioni, C.; Angeli, F.; 
Carluccio, E.; Sardone, MG. & Porcellati, C. (2003). Atrial fibrillation in 
hypertension: predictors and outcome. Hypertension Vol. 41, No. 2, (February 2003), 
pp. 218-223, ISSN 0194-911X 
Wijffels, MC.; Kirchhof, CJ.; Dorland, R. & Allessie, MA. (1995). Atrial fibrillation begets 
atrial fibrillation: a study in awake chronically instrumented goats. Circulation Vol. 
92, No. 7, (October 1995), pp. 1954-1968, ISSN 0009-7322 
Wyse, DG. (2005). Rate control vs. rhythm control strategies in atrial fibrillation. Progress in 
Cardiovascular Diseases Vol. 48, No. 2, (September-October 2005), pp. 125-138, ISSN 
0033-0620 
Wyse, DG. &  Gersh, BJ. (2004). Atrial fibrillation: a perspective: thinking inside and outside 
the box. Circulation Vol. 109, No. 25, (June 2004), pp. 3089-3095, ISSN 0009-7322 
Zhang, GC.; Tsukada, T.; Nakatani, S.; Uematsu, M.; Yasumura, Y.; Tanaka, N.; Masuda, Y.; 
Miyatake, K. & Yamagishi, M. (1998). Comparison of automatic boundary detection 
and manual tracking technique in echocardiographic determination of left atrial 
volume. Japanese Circulation Journal Vol. 62, No. 10, (October 1998), pp. 755-759, 
ISSN 1346-9843 
7 
Phosphodiesterase-5 Inhibitors Improve Left 
Ventricular Function in Failing Hearts 
Fadi N. Salloum and Rakesh C. Kukreja 
Virginia Commonwealth University  
Medical Center Richmond, Virginia 
USA 
1. Introduction 
Impaired systolic performance and/or diastolic function have long been detrimental 
consequences of acute myocardial infarction (AMI), which remains a major cause of 
morbidity and mortality worldwide. Despite considerable therapeutic improvements, left 
ventricular dysfunction secondary to infarction continues to pose serious health 
complications, including heart failure (HF), wherein the heart is unable to maintain a cardiac 
output appropriate for the requirements of the body. Several factors contribute to HF, 
including adverse ventricular remodeling, progressive hypertrophy and sustained cell death 
by apoptosis. Therefore, the search for a therapeutic strategy to overcome or mitigate the 
progression of HF is of paramount importance. 
1.1 PDE-5 Inhibitors 
Sildenafil citrate (ViagraTM) is the first PDE-5 inhibitor approved for treatment of erectile 
dysfunction. The discovery of this drug in 1989 was the result of extensive research on 
chemical agents that hold potential promise in the treatment of coronary heart disease. 
Initial clinical studies on sildenafil in the early 1990s were not promising with respect to its 
anti-anginal potential. However, a remarkable side effect was reported by a number of 
volunteers participating in these investigations; sildenafil seemed to enhance penile 
erections, which soon thereafter became the main focus of further studies. More than 10 
million men worldwide have been treated with sildenafil since its market debut in 1998. 
Sildenafil is highly specific for PDE-5 inhibition with relatively minor cross-reactivity with 
PDE-6 (Laties & Fraunfelder, 1999). It has a chemical structure similar to cGMP and inhibits 
PDE-5 by binding to the cGMP-catalytic sites (Corbin & Francis, 2002) thereby allowing the 
accumulation of cGMP in the erectile tissue. Two additional agents in this class (vardenafil 
[LevitraTM] (Porst et al., 2001) and tadalafil [CialisTM]) have also been developed and 
approved by the FDA for treatment of erectile dysfunction and recently sildenafil and 
tadalafil were approved for treatment of pulmonary arterial hypertension (PAH) (Corbin & 
Francis, 2002). PDE-5 inhibitors are structurally similar to cGMP and therefore compete with 
cGMP for binding to PDE-5 at the catalytic site (reviewed in Kukreja et al., 2005). 
Interestingly, PDE expression has been reported to change in pathologic conditions. For 
instance, in patients with cardiovascular disease or diabetes, nitric oxide (NO) levels are 
 
Echocardiography – In Specific Diseases 
 
98
suboptimal due to endothelial dysfunction [damaged NO synthase (NOS)], and recently 
myocardial PDE-5 expression has been shown to increase in patients with heart failure 
(Pokreisz et al., 2009). In this regard, targeting PDE-5 is a promising therapeutic approach 
for treatment of cardiovascular disease and dysfunction. 
2. PDE-5 Inhibitors preserve myocardial function following infarction 
A number of pioneering investigations from our laboratory have demonstrated that PDE-5 
inhibitors attenuate ischemic injury in animal and cell models (Ockaili et al., 2002; Salloum 
et al., 2003). In animal models, sildenafil and vardenafil exerted an infarct-sparing effect 
when given before ischemia (Ockaili et al., 2002; Salloum et al., 2003; Salloum et al., 2006) or 
at the time of reperfusion (Salloum et al., 2007). Furthermore, chronic treatment with 
sildenafil immediately after permanent occlusion of the left descending coronary artery 
(LAD) in mice attenuated ischemic cardiomyopathy (Salloum et al., 2008a). These 
cardioprotective effects are mediated by activation of protein kinase G (PKG), increased 
expression of endothelial and inducible nitric oxide synthase (eNOS & iNOS), and 
augmented Bcl-2/Bax ratio. Due to their powerful anti-ischemic effects, PDE-5 inhibitors 
became promising candidates for the preservation of cardiac function following AMI. In 
fact, several studies demonstrated that PDE-5 inhibition preserved left ventricular (LV) 
function in failing hearts as discussed in the following sections. 
2.1 Sildenafil attenuates left ventricular dysfunction in ischemic heart failure 
Salloum et al. showed that chronic treatment with sildenafil preserves cardiomyocytes post 
AMI through reduction of myocardial necrosis, apoptosis and hypertrophy thereby limiting 
the progression of HF (Salloum et al., 2008a). This study used a murine model of post-MI 
remodeling by permanent ligation of the left coronary artery. The experimental protocol is 


















Sildenafil (0.71 mg/kg; ip; BID)
or
Saline (volume matched; ip; BID)





Daily monitoring: Pain, appetite/drinking, behavior and responsiveness  
Fig. 1. Experimental protocol illustrating various parameters studied at different time points 
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was evaluated by echocardiography using the Vevo770TM imaging system (VisualSonics, 
Inc., Toronto, Canada). A 30-MHz probe was utilized to obtain two-dimensional, M-mode 
and Doppler imaging from parasternal short-axis view at the level of the papillary muscles 
and the apical four-chamber view (Schiller et al., 1989). M-mode images of the LV were 
obtained and systolic and diastolic wall thickness (anterior and posterior) and LV end-
systolic and end-diastolic diameters (LVESD and LVEDD, respectively) were measured.  
Figure 2 is representative of M-mode images from mice on day 28 post MI. The hearts from 
sham and sildenafil-treated mice exhibited a smaller LV cavity and thicker infarct wall 
compared to the saline-treated mice. Increase in LVEDD, LVESD and a decrease in anterior 
wall diastolic thickness (AWDT), anterior wall systolic thickness (AWST) and fractional 
shortening (FS) in saline- and sildenafil-treated mice (vs. baseline and sham) were observed 
on day 7 and 28.  
Sham 28 days Saline 28 days





Fig. 2. M-mode images from mouse LV treated with sildenafil or vehicle 28 days after MI 
Sildenafil-treated mice had smaller LVEDD, LVESD, greater FS, and lower Tei index 
(reflecting better myocardial performance) on day 7 and 28 as compared to saline-treated 
group (P<0.05, Figure 3). Sildenafil-treated animals also had a shorter isovolumetric 
relaxation time (reflective of lower LV end-diastolic pressure) 28 days after AMI when 
compared to saline-treated animals (11±3 vs. 27±7 ms, respectively, P=0.03), which was not 
different from sham operated animals (10±3, P=NS). AWDT and AWST were also greater in 
sildenafil-treated animals (vs. saline-treated animals, P<0.05) on day 7 and 28 post MI 
showing a protective effect in the peri-infarct region, while no differences in PWDT and 
PWST were seen. Aneurysmatic dilatation of the anterior wall and apex was observed on 
day 28 in 90% of saline-treated mice and 62% of sildenafil treated animals (P>0.05). 
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suboptimal due to endothelial dysfunction [damaged NO synthase (NOS)], and recently 
myocardial PDE-5 expression has been shown to increase in patients with heart failure 
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expression of endothelial and inducible nitric oxide synthase (eNOS & iNOS), and 
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Fig. 1. Experimental protocol illustrating various parameters studied at different time points 
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was evaluated by echocardiography using the Vevo770TM imaging system (VisualSonics, 
Inc., Toronto, Canada). A 30-MHz probe was utilized to obtain two-dimensional, M-mode 
and Doppler imaging from parasternal short-axis view at the level of the papillary muscles 
and the apical four-chamber view (Schiller et al., 1989). M-mode images of the LV were 
obtained and systolic and diastolic wall thickness (anterior and posterior) and LV end-
systolic and end-diastolic diameters (LVESD and LVEDD, respectively) were measured.  
Figure 2 is representative of M-mode images from mice on day 28 post MI. The hearts from 
sham and sildenafil-treated mice exhibited a smaller LV cavity and thicker infarct wall 
compared to the saline-treated mice. Increase in LVEDD, LVESD and a decrease in anterior 
wall diastolic thickness (AWDT), anterior wall systolic thickness (AWST) and fractional 
shortening (FS) in saline- and sildenafil-treated mice (vs. baseline and sham) were observed 
on day 7 and 28.  
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Fig. 2. M-mode images from mouse LV treated with sildenafil or vehicle 28 days after MI 
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relaxation time (reflective of lower LV end-diastolic pressure) 28 days after AMI when 
compared to saline-treated animals (11±3 vs. 27±7 ms, respectively, P=0.03), which was not 
different from sham operated animals (10±3, P=NS). AWDT and AWST were also greater in 
sildenafil-treated animals (vs. saline-treated animals, P<0.05) on day 7 and 28 post MI 
showing a protective effect in the peri-infarct region, while no differences in PWDT and 
PWST were seen. Aneurysmatic dilatation of the anterior wall and apex was observed on 
day 28 in 90% of saline-treated mice and 62% of sildenafil treated animals (P>0.05). 
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Moreover, the number of aneurysmatic segments [based on a 16-segment map (Schiller et 




























































































Fig. 3. Echocardiography results of LV function at 28 days post-MI in sildenafil- and saline-
treated mice 
2.2 Tadalafil preserves left ventricular function following MI through PKG-dependent 
generation of hydrogen sulfide 
We also studied the effect of a longer acting PDE-5 inhibitor, tadalafil, on cardiac function in 
an acute model of myocardial infarction (Salloum et al., 2009). After baseline transthoracic 
echocardiography, adult male mice were injected i.p. with vehicle (10% DMSO) or tadalafil (1 
mg/kg) with or without KT5823 (KT, PKG blocker, 1 mg/kg) or dl-propargylglycine [PAG, 
Cystathionine-γ-lyase (CSE, H2S-producing enzyme) blocker; 50 mg/kg] 1 h prior to coronary 
artery ligation for 30 min and reperfusion for 24 h, whereas C57BL-wild type and CSE-
knockout mice were treated with either vehicle or tadalafil. After reperfusion, repeat 
echocardiography was performed. Similar to sildenafil, tadalafil preserved cardiac 
performance following MI as compared to vehicle. In this study, since ischemia was limited to 
30 minutes, none of the groups presented with significant LV dilatation at 24 h post infarction, 
however, tadalafil preserved fractional shortening (FS: 31±1.5%) compared to control (FS: 
22±4.8%, P<0.05, Figure 4). Baseline FS was 44±1.7%. KT and PAG abrogated the preservation 
of LV function with tadalafil by a decline in FS to 17±1% and 23±3%, respectively.  
 








Fig. 4. Tadalafil preserves LV function at 24 hours following MI through PKG and H2S 
signaling  
2.3 Sildenafil treatment 3 days following MI mitigates the progression of heart failure 
In the previous studies, PDE-5 inhibitors were administered either shortly prior to or 
immediately after infarction. This raises the question whether the preservation of cardiac 
function observed was a true phenomenon, or it was simply secondary to the anti-infarct 
effect of these drugs. Specially, little is known about the effects of PDE-5 inhibition on 
limiting adverse remodeling independent of its ability to modulate infarct size. This concept 
is clinically relevant, particularly in patients with advanced ischemic HF, because necrosis 
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has a negligible role in a post-infarct setting (Anversa et al., 1993). To address this question, 
we administered sildenafil 3 days following MI (Chau et al., 2011). Specifically, we sought to 
determine if sildenafil treatment following LV dysfunction, defined as FS less than 25% at 
day 3 post-MI, could prevent the progression of HF in a permanent LAD occlusion model. 
At 3 days post MI, mice receiving sildenafil or saline (control) treatment had similar FS 
(18±1% and 19±1%, respectively, P>0.05) as compared to baseline value of 47±1%. At days 7 
and 28 post-MI, sildenafil-treated group had a significantly higher FS than saline-treated 
mice (P<0.05). Both LVEDD and LVESD were increased in saline-treated mice as compared 
to sildenafil-treated mice (P<0.05), indicating more dilatation. Moreover, AWDT was greater 
in sildenafil-treated animals versus saline-treated animals (P<0.05) on day 28 post-MI. 
Fractional shortening of sham-operated mice was 43±1.0% at 28 days post left thoracotomy. 
An increase in LVEDD from a baseline value of 3.5±0.1 mm and a decrease in FS in saline- 
and sildenafil-treated mice as compared to baseline and sham-operated mice (P<0.05) was 
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Fig. 5. Late sildenafil treatment preserves LV function and attenuates the progression of 
ischemic heart failure 
2.4 Sildenafil preserves LV function in infant rabbits 
Although we previously showed that PDE-5 inhibitors induce powerful preconditioning-
like protective effects in the ischemic heart, it is not known whether sildenafil exerts similar 
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protective effects against ischemia/reperfusion injury in the infant rabbit hearts as well. In 
this study, we used the model of coronary artery occlusion and reperfusion in infant rabbits 
(Bremer et al., 2005), which is similar to our previously described adult rabbit model of 
myocardial infarction. The benefits of this work are immense since this model may be 
applicable in pediatrics, and especially in pediatric cardiovascular surgery where there may 
be periods of ischemia/reperfusion injury. Also, we used two-dimensional (2D) and 
Doppler trans-esophageal echocardiography (TEE) for the estimation of LV cardiac output 
(LVCO) and aortic velocity time integral (VTI) in this model. A 10-Fr AcuNav diagnostic 
ultrasound probe (Acuson Corp., Siemens, Iselin, NJ) was inserted into the esophagus, at 
baseline, after the 30 min period of ischemia, and after 3 h of reperfusion in both the control 
and sildenafil groups. Standardized 2D imaging in a long axis view of the LV to show LV 
inflow across the mitral valve and LV outflow tract (LVOT) was obtained. Aortic flow 
Doppler across the aortic valve was performed in a long axis view of the LV and LVOT to 
obtain LVCO. The standard equation: mean velocity (cm/s) × flow area (cm2) × 60 (s/min), 
where mean velocity (cm/s) = VTI (in cm/beat) ÷ RR interval (s/beat), was used to obtain 
LVCO, expressed in milliliters per minute. Laminar Doppler flow across the aortic valve 
confirmed the absence of aortic stenosis. Color Doppler assessment was made of both the 
aortic and mitral valves again in the long axis view at baseline, after the ischemic period, 
and after 3 h of reperfusion for the presence or absence of mitral or aortic regurgitation. 
Subjective functional assessment was also made after ischemia and reperfusion to 
demonstrate at least left ventricular apical diminished contractility to confirm infarction. In 
this study, we showed that both the control and sildenafil-treated groups had comparable 
LVCO and aortic VTI at baseline. The controls had a decline in LVCO and aortic VTI 
immediately after the 30-min period of ischemia (28% and 27% lower than baseline values, 
respectively, p < 0.05), whereas the LVCO and aortic VTI increased in the sildenafil group 
after ischemia (43% and 45% higher than baseline values, respectively, n = 6 per group, p < 
0.05). Both groups, however, had significant decline in LVCO after 3 h of reperfusion (54% 
of baseline in the sildenafil group, p < 0.05, and 62% of baseline in the control group, p < 
0.05), and were not statistically significantly different from each other (n = 4–6 per group). 
Both groups demonstrated a decrease in aortic VTI after 3 h of reperfusion. However, this 
decline was only statistically significant in the control group compared with baseline values. 
None of the rabbits had aortic stenosis or developed aortic regurgitation for the duration of 
the study. Moreover, both the control and sildenafil groups demonstrated a comparable 
amount of mitral regurgitation (no more than mild) after ischemia/reperfusion, and none of 
the rabbits had baseline mitral regurgitation. 
2.5 Sildenafil and vardenafil preserve LV function in female mice 
Since the impact of PDE-5 inhibitors on the female cardiovascular system following 
ischemia remains unknown, we interrogated the effect of sildenafil and vardenafil on 
ischemia/reperfusion injury in female mice. In this study, adult female mice were 
pretreated (ip, bid) with sildenafil (0.7 mg/kg), vardenafil (0.14 mg/kg) or saline one hour 
before left coronary artery ligation for 30 minutes and reperfusion for 24 hours (Salloum et 
al., 2008b). Cardiac function, evaluated using echocardiography, showed that LV end-
diastolic and end-systolic diameters increased 7 days post myocardial infarction with saline 
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has a negligible role in a post-infarct setting (Anversa et al., 1993). To address this question, 
we administered sildenafil 3 days following MI (Chau et al., 2011). Specifically, we sought to 
determine if sildenafil treatment following LV dysfunction, defined as FS less than 25% at 
day 3 post-MI, could prevent the progression of HF in a permanent LAD occlusion model. 
At 3 days post MI, mice receiving sildenafil or saline (control) treatment had similar FS 
(18±1% and 19±1%, respectively, P>0.05) as compared to baseline value of 47±1%. At days 7 
and 28 post-MI, sildenafil-treated group had a significantly higher FS than saline-treated 
mice (P<0.05). Both LVEDD and LVESD were increased in saline-treated mice as compared 
to sildenafil-treated mice (P<0.05), indicating more dilatation. Moreover, AWDT was greater 
in sildenafil-treated animals versus saline-treated animals (P<0.05) on day 28 post-MI. 
Fractional shortening of sham-operated mice was 43±1.0% at 28 days post left thoracotomy. 
An increase in LVEDD from a baseline value of 3.5±0.1 mm and a decrease in FS in saline- 
and sildenafil-treated mice as compared to baseline and sham-operated mice (P<0.05) was 
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Fig. 5. Late sildenafil treatment preserves LV function and attenuates the progression of 
ischemic heart failure 
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protective effects against ischemia/reperfusion injury in the infant rabbit hearts as well. In 
this study, we used the model of coronary artery occlusion and reperfusion in infant rabbits 
(Bremer et al., 2005), which is similar to our previously described adult rabbit model of 
myocardial infarction. The benefits of this work are immense since this model may be 
applicable in pediatrics, and especially in pediatric cardiovascular surgery where there may 
be periods of ischemia/reperfusion injury. Also, we used two-dimensional (2D) and 
Doppler trans-esophageal echocardiography (TEE) for the estimation of LV cardiac output 
(LVCO) and aortic velocity time integral (VTI) in this model. A 10-Fr AcuNav diagnostic 
ultrasound probe (Acuson Corp., Siemens, Iselin, NJ) was inserted into the esophagus, at 
baseline, after the 30 min period of ischemia, and after 3 h of reperfusion in both the control 
and sildenafil groups. Standardized 2D imaging in a long axis view of the LV to show LV 
inflow across the mitral valve and LV outflow tract (LVOT) was obtained. Aortic flow 
Doppler across the aortic valve was performed in a long axis view of the LV and LVOT to 
obtain LVCO. The standard equation: mean velocity (cm/s) × flow area (cm2) × 60 (s/min), 
where mean velocity (cm/s) = VTI (in cm/beat) ÷ RR interval (s/beat), was used to obtain 
LVCO, expressed in milliliters per minute. Laminar Doppler flow across the aortic valve 
confirmed the absence of aortic stenosis. Color Doppler assessment was made of both the 
aortic and mitral valves again in the long axis view at baseline, after the ischemic period, 
and after 3 h of reperfusion for the presence or absence of mitral or aortic regurgitation. 
Subjective functional assessment was also made after ischemia and reperfusion to 
demonstrate at least left ventricular apical diminished contractility to confirm infarction. In 
this study, we showed that both the control and sildenafil-treated groups had comparable 
LVCO and aortic VTI at baseline. The controls had a decline in LVCO and aortic VTI 
immediately after the 30-min period of ischemia (28% and 27% lower than baseline values, 
respectively, p < 0.05), whereas the LVCO and aortic VTI increased in the sildenafil group 
after ischemia (43% and 45% higher than baseline values, respectively, n = 6 per group, p < 
0.05). Both groups, however, had significant decline in LVCO after 3 h of reperfusion (54% 
of baseline in the sildenafil group, p < 0.05, and 62% of baseline in the control group, p < 
0.05), and were not statistically significantly different from each other (n = 4–6 per group). 
Both groups demonstrated a decrease in aortic VTI after 3 h of reperfusion. However, this 
decline was only statistically significant in the control group compared with baseline values. 
None of the rabbits had aortic stenosis or developed aortic regurgitation for the duration of 
the study. Moreover, both the control and sildenafil groups demonstrated a comparable 
amount of mitral regurgitation (no more than mild) after ischemia/reperfusion, and none of 
the rabbits had baseline mitral regurgitation. 
2.5 Sildenafil and vardenafil preserve LV function in female mice 
Since the impact of PDE-5 inhibitors on the female cardiovascular system following 
ischemia remains unknown, we interrogated the effect of sildenafil and vardenafil on 
ischemia/reperfusion injury in female mice. In this study, adult female mice were 
pretreated (ip, bid) with sildenafil (0.7 mg/kg), vardenafil (0.14 mg/kg) or saline one hour 
before left coronary artery ligation for 30 minutes and reperfusion for 24 hours (Salloum et 
al., 2008b). Cardiac function, evaluated using echocardiography, showed that LV end-
diastolic and end-systolic diameters increased 7 days post myocardial infarction with saline 
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(3.5±0.1 mm and 2.4±0.2 mm, respectively). In contrast, no dilatation was detected in 
sildenafil (3.0±0. mm and 1.4±0.1 mm, respectively) and vardenafil (2.9±0.3 mm and 1.4±0.2 
mm, respectively) groups. Fractional shortening decreased at 7 days post infarction with 
saline (30±4%; P<0.05), but was preserved with sildenafil (52±2%) and vardenafil (53±5%). 
These data clearly suggest that PDE-5 inhibitors induce powerful cardioprotection in female 
mice as well. For this reason, PDE-5 inhibition may be a novel therapeutic strategy against 
ischemia/reperfusion injury in women with coronary artery disease. 
3. PDE-5 Inhibitors protect against doxorubicin-induced cardiac dysfunction 
A number of pioneering investigations from our laboratory have demonstrated that PDE-5 
inhibitors attenuate doxorubicin-induced cardiomyopathy in animal and cell models (Koka 
et al., 2010; Das et al., 2010). In a recent study, we tested whether sildenafil potentiates the 
antitumor efficacy of doxorubicin in prostate cancer. Our results show that doxorubicin and 
sildenafil induce a potent antitumor effect in prostate cancer while simultaneously 
providing a cardioprotective effect. This study was an elegant sequel to our previous work 
demonstrating that sildenafil attenuated doxorubicin-induced cardiomyopathy in mice 
(Fisher et al., 2005). In that study, we showed that treatment with sildenafil attenuates the 
decline in LV developed pressure caused by doxorubicin treatment. An important question, 
however, was whether sildenafil interferes with the anti-tumor effect of doxorubicin. Our 
recent study showed that sildenafil ameliorates doxorubicin-induced cardiac dysfunction 
without interfering with its chemotherapeutic benefits (Das et al., 2010). Cardiac function in 
nude mice with tumor xenografts was monitored by Doppler echocardiography using the 
Vevo770 imaging system (VisualSonics, Toronto, Canada) as previously reported (Salloum 
et al., 2008a). A slight increase in LVEDD and LVESD were observed with doxorubicin. 
LVFS and LVEF declined in doxorubicin-treated mice. Sildenafil co-treatment with 
doxorubicin improved LVFS and LVEF compared with the doxorubicin-treated group (P < 
0.05). No differences in heart rate were observed between control, doxorubicin, and 
doxorubicin and sildenafil groups. Sildenafil-treated animals showed lower heart rates 
compared with other groups (P < 0.01; n = 8). These data suggest that changes in LVFS or 
LVEF were independent of heart rate.  
In a separate study, tadalafil improved left ventricular function and prevented 
cardiomyocyte apoptosis in doxorubicin-induced cardiomyopathy through mechanisms 
involving upregulation of cGMP, PKG activity, and MnSOD level without interfering with 
the chemotherapeutic benefits of doxorubicin (Koka et al., 2010). In these studies, adult male 
CF-1 mice were randomized to receive saline (0.2 ml i.p.), doxorubicin (15 mg/kg i.p.), or 
doxorubicin + tadalafil (4 mg/kg p.o. daily) for 9 days starting 3 days before doxorubicin 
treatment. We chose to use a single dose of doxorubicin at 15 mg/kg i.p., which has been 
reported to be cardiotoxic. LV function was significantly impaired 5 days after doxorubicin 
treatment. However, mice treated with doxorubicin + tadalafil showed preserved fractional 
shortening and ejection fraction compared with those treated with doxorubicin as shown in 
Figure 6 (n = 6, p < 0.05). In addition, the LV systolic pressure decreased 36%, +dp/dtmax 
decreased 63%, −dp/dtmax decreased 57%, and heart rate decreased 30% as compared with 
the controls (P < 0.05). In contrast, mice treated with doxorubicin + tadalafil showed improved 
LV function (i.e., LV systolic pressure, 33%; +dp/dtmax, 35%; −dp/dtmax, 46%, and heart 
rate, 27%) as compared with the group treated with doxorubicin alone (n = 6, p < 0.05). 
 




Fig. 6. Tadalafil attenuates doxorubicin-induced LV dysfunction 
4. PDE-5 inhibitors protect against hypertrophy-induced cardiac dysfunction 
Sustained pressure overload leads to cellular and molecular changes that are initially 
activated as compensatory mechanisms but later become maladaptive and contribute to 
progressive cardiac dysfunction and heart failure. This response involves a combination of 
complex signaling and transcription pathways that induce hypertrophic remodeling (Frey & 
Olson, 2003; Frey et al., 2004). The heart appears to have an intrinsic signaling system 
coupled to cGMP that can inhibit myocardial proliferative responses. Several studies using 
approaches that involve enhanced cGMP synthesis or prevention of its degradation have 
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been shown to blunt hypertrophy despite sustained pressure overload or neurohormonal 
stress. Interestingly, although cGMP synthesis is often increased by chronic exposure to 
such stresses, this increase appears to be ineffective to impede hypertrophy and remodeling 
progression, likely due to increase in PDE-5 expression and activity that accompany such 
stressors. For this reason, the use of PDE-5 inhibitors to reduce the catabolism may augment 
cGMP-dependent antihypertrophic effects. In the study by Takimoto et al., the authors show 
that PDE-5 inhibition with sildenafil prevents cardiac chamber, cellular and molecular 
remodeling induced by pressure overload (Takimoto et al., 2005). They next tested a more 
clinically relevant question of whether inhibition of PDE-5 can reverse pre-existing 
hypertrophy. Mice were exposed to transverse aortic constriction for 7–10 days, which 
increased heart mass by 63% (P < 0.005) without chamber dilatation. After hypertrophy was 
established, these mice were divided into 2 groups that received either sildenafil or vehicle for 
an additional 2 weeks. Cardiomyocyte hypertrophy and interstitial fibrosis were observed in 
mice exposed to 1 week of transverse aortic constriction, and both reversed to baseline with 
sildenafil treatment. Serial echocardiography also showed a gradual decline in LV mass and 
wall thickness, with preservation of systolic ejection in sildenafil-treated mice (Figure 7).  
 
Fig. 7. Sildenafil attenuates and reverses hypertrophy-induced cardiac dysfunction  
Another study by Nagayama et al. showed that delayed sildenafil treatment suppresses 
progressive cardiac dilatation, dysfunction, fibrosis, and hypertrophy in hearts subjected to 
sustained pressure-overload (Nagayama et al., 2009). In this study, following 3-week 
transverse aortic constriction, hearts had a +135% increase in LV mass, chamber end-systolic 
(+91%) and end-diastolic (+10%) dimensions, and reduced fractional shortening (−42%). 
Subsequent treatment with sildenafil fully arrested progressive remodeling, whereas control 
hearts further dilated and hypertrophied after 9-week transverse aortic constriction. Post-
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mortem analysis confirmed that both heart and lung weights, normalized to tibia length, 
were lower with sildenafil treatment. Moreover, cardiomyocyte cross-sectional dimension 
and interstitial and perivascular fibrosis was also reduced in sildenafil-treated myocardium. 
5. PDE-5 inhibitors reverse cardiac dysfunction in Duchenne muscular 
dystrophy 
Duchenne muscular dystrophy (DMD) is a degenerative, muscle-wasting disease caused by 
mutations in the dystrophin gene. The total loss of dystrophin mainly affects skeletal muscle 
and results in impaired respiratory function, primarily in older boys (Finsterer & 
Stöllberger, 2003; Adamo, 2010). Due to remarkable improvement of noninvasive 
respiratory support in the recent past, the lifespan of patients with DMD has increased. 
Unfortunately, this was also associated with an increase in the incidence of complications 
and eventual mortality from cardiomyopathy (McNally, 2008). Cardiomyopathy is a 
delayed symptom of the disease that usually develops by the second decade of life, with 
more than 90% of patients presenting clinical symptoms by 18 y of age (Finsterer & 
Stöllberger, 2003). Loss of cardiac dystrophin eventually leads to dilated cardiomyopathy, 
which manifests as congestive heart failure in at least 20% of patients (Finsterer & 
Stöllberger, 2003). Current treatment options for heart failure associated with DMD include 
angiotensin converting enzyme inhibitors and β-blockers. Despite the moderate benefits 
provided by these medications in patients with systolic heart failure, similar advantages 
have not been observed in dystrophic patients with features of systolic and diastolic 
dysfunction (Bushby, 2003). These findings highlight the need for treatments that slow the 
development of cardiomyopathy in DMD and improve cardiac function in older patients 
with established cardiomyopathy.  
It has been shown that stimulation of cGMP synthesis by overexpression of cardiac-specific 
neuronal (n)NOS reduces impulse-conduction defects in dystrophin-deficient (mdx) mice 
(Wehling-Henricks et al., 2005; Wehling et al., 2001). Similarly, increased particulate 
guanylyl cyclase activity in young mdx mice has also been shown to decrease susceptibility 
to cardiac damage during sympathetic stress (Khairallah et al., 2008). These findings clearly 
implicate reduced NO-cGMP signaling as a key contributor to myocardial pathogenesis in 
patients with DMD. Therefore, it is plausible that restoration of NO signaling, particularly 
by preservation of cGMP, may provide therapeutic benefit to dystrophic hearts. In a recent 
study, Adamo et al. tested whether chronic inhibition of PDE-5 with sildenafil would 
reverse cardiac dysfunction in the mdx mouse model of DMD (Adamo et al., 2010)  
Chronic sildenafil treatment prevented LV functional deficits in aging mdx mice. 
Furthermore, late sildenafil treatment, i.e. after developing cardiomyopathy, reversed the 
established symptoms.  
Conventional echocardiography and tissue Doppler analysis were used to monitor the 
development of LV dysfunction in aging mdx mice. Both the myocardial performance index 
(MPI) and ratios of early diastolic velocity (Ea) to peak velocity with atrial contraction (Aa) 
were calculated. MPI is a sensitive measure of left ventricular systolic and diastolic 
performance, whereas the Ea/Aa largely reflects diastolic function. The majority of patients 
with DMD exhibit diastolic dysfunction and impaired myocardial performance, which can 
be identified by increased MPI (Bahler et al., 2005). This dysfunction usually precedes the 
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onset of systolic heart failure and dilated cardiomyopathy (Markham et al., 2006). Mdx mice 
show these same echocardiographic abnormalities (Jearawiriyapaisarn et al., 2010; 
Townsend et al., 2007).  
Three different sildenafil treatment regimens were used: 1- long-term chronic sildenafil 
treatment starting at 1 month of age, 2- long-term treatment starting at 12 months with 
echocardiographic measurements taken 3 months later to assess whether established 
dysfunction could be reversed, and 3- a similar treatment starting at 12 months, but with 
multiple measurements to determine the time course of the reversal. The results showed 
impaired LV performance in mdx mice (increased MPI) by 11 to 13 months of age compared 
with treated and untreated WT controls. As mice approached 15 months of age, mdx mice 
continued to demonstrate impaired LV function whereas WT control mice began to show a 
slight age-related decline in cardiac performance. Although sildenafil did not have an effect 
on cardiac performance in WT mice, mdx mice that received chronic sildenafil treatment 
starting at 1 month of age retained a relatively normal MPI with age, indicating that 
sildenafil attenuated the cardiomyopathy in mdx mice. Furthermore, late sildenafil 
treatment following well-established cardiomyopathy at 12 months of age completely 
reversed LV dysfunction by age 15 months, as evidenced by normal MPI at that time point. 
Taken together, these results demonstrate that chronic treatment with sildenafil mitigates 
the progression of LV dysfunction and late treatment also reverses established LV 
dysfunction in mdx mice (Figure 8). 
In order to better understand the underlying cause for the improvement in the MPI by 
sildenafil, which could be a result of effects on systolic or diastolic function, the authors 
measured the Ea/Aa using tissue Doppler imaging to more directly evaluate diastolic 
function in mdx mice. This parameter largely reflects the diastolic (chamber relaxation and 
filling) capacity of the LV. As shown in Figure 8B, diastolic dysfunction (indicated by Ea/Aa 
<1) was observed in mdx mice as early as 8 months of age. Moreover, chronic sildenafil 
treatment reduced the progression of diastolic dysfunction in mdx mice through 15 months 
of age. Even when sildenafil treatment was initiated after LV dysfunction was established at 
12 months of age, it markedly reversed the diastolic dysfunction within 3 months. Based on 
this result, the authors suggest that diastolic dysfunction is a major component of the 
impaired MPI observed in 11- to 13-month-old mdx mice.  
Cardiac remodeling after injury can result in hypertrophy, increased fibrosis and systolic 
dysfunction of the heart. However, cardiomyopathy in mdx mice is characterized by slow, 
progressive cell death, followed by compensatory hypertrophy of the surviving 
cardiomyocytes. In order to study the impact of sildenafil on cardiac dimensions and 
remodeling, the authors used M-mode echocardiography to determine LV dimensions in 
conscious mdx mice. By 12 months of age, the LV wall thickness of mdx mice was increased 
and the LV mass index (LVMI) was larger compared with sildenafil-treated mdx mice. 
Taken together, the anti-hypertrophic effect of sildenafil, coupled with the prevention of 
diastolic dysfunction, suggest that sildenafil may also have protective effects on some 
aspects of cardiac remodeling. However, the authors did not find any difference in the FS of 
12-month-old, conscious mdx mice compared with WT controls or sildenafil-treated mdx 
mice, nor did they observe any effect on heart rate. This indicates a lack of major systolic 
dysfunction in these animals up to 12 month of age. Although systolic dysfunction may 
develop later in life, it appears that diastolic dysfunction plays a more prominent role in the 
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cardiomyopathy seen in the mdx mice used in this study.Overall, the findings of this study 
suggest that PDE-5 inhibitors may be an effective treatment for DMD-associated 
cardiomyopathy at early and late stages of the disease. 
  
Fig. 8. Sildenafil reverses cardiac dysfunction in the mdx model of Duchenne Muscular 
Dystrophy 
6. Clinical use of PDE-5 inhibitors in patients with heart failure 
Following years of basic research examining the cardioprotective effects of PDE-5 inhibitors 
against ischemia, a recent study by Guazzi et al. demonstrated that sildenafil improves LV 
diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart 
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failure (Guazzi et al., 2011). The study primarily focused on the effects of chronic PDE-5 
inhibition on LV diastolic function and cardiac chamber remodeling, providing the first 
human evidence that PDE-5 inhibition can be beneficial for improving the diastolic and 
structural properties of the failing LV. Transthoracic echocardiography was performed using 
IE33, Philips ultrasound machine, equipped with a software for tissue Doppler (TD), using a 
2.5- to 5.0-MHz probe (S5). Standard M-mode, 2D, and Doppler blood flow measurements 
were performed according to the current American Society of Echocardiography Guidelines 
(Quiñones et al., 2002). Chamber dimensions were obtained using standard procedures 
including left atrial volume index (LAVI) and LV mass index (LVMI) (Devereux & Reichek, 
1977). Septal and posterior wall thickness, LA, and LV end-systolic and end-diastolic 
dimensions were obtained from the parasternal long-axis view. LVEF, end-diastolic volume 
index (LVEDVI), and end-systolic volume index were evaluated with the Simpson method. 
Interestingly, E/E′, a variable repeatedly found related to LV filling pressures in a variety of 
left-sided cardiac disorders (Lester et al., 2008), significantly decreased at 6 months and 1 
year of active treatment (Figure 9). Additional study findings that support the hypothesis 
that PDE-5 inhibition may represent a novel and viable therapeutic strategy for improving 
LV relaxation were the significant shortening in both lateral and septal T E-E′, a Doppler-
derived index of LV relaxation performance validated against invasively measured negative 
dP/dT22, and the reverse remodeling effect on LV mass. Moreover, over 12 months, LAVI, 
LVEDV, and LVMI were unchanged in the placebo group and decreased in the active 
treatment group, which suggests reverse remodeling with sildenafil involving both the 
ventricle and the atrium. Over the same time period in the sildenafil group, there was a 
progressive increase in mean LVEF, from 29.5% at baseline to 34.9% and 36.3% at 6 and 12 
months, respectively (P<0.01). Changes observed with sildenafil were significantly different  
  
Fig. 9. Sildenafil significantly decreased E/E′ at 6 months and 1 year of active treatment in 
patients with stable systolic heart failure 
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compared with placebo (P<0.01). Additionally, diastolic measures of LV function 
demonstrated systematic and sustained improvement after both 6 months and 1 year of 
sildenafil treatment. The transmitral E/A ratio, isovolumic relaxation time, and both lateral 
and septal E/E′ decreased from baseline through 12 months (all P<0.01), which is indicative 
of an improvement in LV diastolic function and a decrease in LV filling pressure.  
Furthermore, septal T E-E′ was significantly reduced at 6 and 12 months of sildenafil 
treatment (P<0.01). All these changes were in agreement with the observed reverse 
remodeling on LAVI, which is viewed as morphological expression of LV end-diastolic 
pressure (Lester et al., 2008). Changes observed at 6 months and 1 year after sildenafil were 
significantly different compared with the placebo group (P<0.01).  
7. Concluding remarks 
With the advancement in the management of patients with cardiovascular disease and 
improvement in survival following cardiovascular events, the incidence of heart failure, 
especially in patients of age 65 and older is increasing. Using state-of-the-art 
echocardiography, we and others have demonstrated that treatment with PDE-5 inhibitors 
improve LV function in various models of myocardial dysfunction and heart failure. These 
studies suggest that PDE-5 inhibitors are immensely promising for further development as 
novel drug therapies for myocardial infarction, LV hypertrophy and dysfunction, 
doxorubicin-induced cardiotoxicity, and heart failure. Clinical studies of sildenafil on heart 
failure patients have reported improved exercise capacity, coupled with reduced pulmonary 
vascular resistance and better endothelial function (Lewis et al., 2007; Guazzi et al., 2007). 
Sildenafil also preserved LV function in patients with heart failure due to various etiologies 
(Guazzi et al., 2011). Several other studies indicated that PDE-5 inhibition with sildenafil has 
a therapeutic promise for stroke, neurodegenerative diseases and potentially other 
circulatory disorders (reviewed in Kukreja et al., 2007; Kukreja et al., 2011a; Kukreja et al. 
2011b). These drugs may not only delay or reduce the pathological damage or defects in 
various vital organs, but also improve the overall well-being and quality of life in patients. 
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1. Introduction  
Transesophageal echocardiography (TEE) has gained its role in perioperative use for 
congenital heart disease patients, especially with technology improvements in the past 
decades. It helps with diagnosis confirmation, real-time hemodynamic monitoring, 
evaluation the successfulness of surgical repair, and surgical planning. The use of 
intraoperative TEE has major impacts on surgery for congenital heart defects (Randolph et 
al., 2002). Even with conservative estimates, the financial benefits of TEE in pediatric 
patients with congenital heart disease are substantial and outweigh its costs (Bettex et al., 
2005). In most of the modern cardiac centers, the TEE exam is an essential part of anesthetic 
management in congenital heart disease surgery. 
2. Indication, contraindication, and complications 
TEE has proven to be an invaluable tool for patients underwent cardiac surgery and cardiac 
catheterization for congenital heart disease. More than that, TEE is useful for high risk 
congenital heart disease patients who will have non-cardiac surgeries. It can help with 
hemodynamic monitoring, and provide real-time detailed anatomic information. In 
addition, it can help assess ventricular volume and function, intracardiac shunt, valvular 
disease, right ventricle (RV) or pulmonary artery (PA) systolic pressure, and pericardial 
effusions. It is reasonable to use intraoperative TEE routinely in congenital heart surgery 
(Randolph et al., 2002). According to the “practice guidelines for perioperative TEE”, TEE 
should be used in all adult open heart procedures (Thys et al., 2010). The task force of 
American Society of Echocardiography also described surgery for congenital heart disease is 
an indication for performance of TEE (Ayres et al., 2005). 
Perioperative TEE exam cannot replace the preoperative diagnostic exam. A thorough 
imaging study must be performed before the operation. Each imaging study has its 
limitation. TEE performed before surgical incision may disclose a different diagnosis and 
even result in cancellation of the operation (Huang et al., 2009). 
However, there are some situations that TEE is contraindicated. Patients with unrepaired 
tracheoesophageal fistula, esophageal obstruction or stricture, perforated hollow organ, or 
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decades. It helps with diagnosis confirmation, real-time hemodynamic monitoring, 
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2005). In most of the modern cardiac centers, the TEE exam is an essential part of anesthetic 
management in congenital heart disease surgery. 
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TEE has proven to be an invaluable tool for patients underwent cardiac surgery and cardiac 
catheterization for congenital heart disease. More than that, TEE is useful for high risk 
congenital heart disease patients who will have non-cardiac surgeries. It can help with 
hemodynamic monitoring, and provide real-time detailed anatomic information. In 
addition, it can help assess ventricular volume and function, intracardiac shunt, valvular 
disease, right ventricle (RV) or pulmonary artery (PA) systolic pressure, and pericardial 
effusions. It is reasonable to use intraoperative TEE routinely in congenital heart surgery 
(Randolph et al., 2002). According to the “practice guidelines for perioperative TEE”, TEE 
should be used in all adult open heart procedures (Thys et al., 2010). The task force of 
American Society of Echocardiography also described surgery for congenital heart disease is 
an indication for performance of TEE (Ayres et al., 2005). 
Perioperative TEE exam cannot replace the preoperative diagnostic exam. A thorough 
imaging study must be performed before the operation. Each imaging study has its 
limitation. TEE performed before surgical incision may disclose a different diagnosis and 
even result in cancellation of the operation (Huang et al., 2009). 
However, there are some situations that TEE is contraindicated. Patients with unrepaired 
tracheoesophageal fistula, esophageal obstruction or stricture, perforated hollow organ, or 
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poor airway control should consider transthoracic echocardiography or epicardial 
echocardiography instead. Besides, patients with history of esophageal surgery, esophageal 
varices or diverticulum, gastric or esophageal bleeding, oropharyngeal pathology, severe 
coagulopathy, cervical spine injury or anomaly require extra attention for TEE probe 
insertion. Although TEE examination is semi-invasive, some people do suffer from 
complications related to TEE probe insertion (Huang et al., 2007). These include bradycardia 
due to vagal stimulation, oropharyngeal injury, and esophageal perforation (Kamra et al., 
2011). Besides, airway compromise, vascular compression, and dysphagia may be seen after 
TEE probe insertion. Physicians should respect individual differences and be vigilant to 
possible complications. 
3. Specific defects 
3.1 Atrial septal defect 
Atrial septal defects (ASD) can be classified into four types: ostium secundum, ostium 
primum, sinus venosus, and coronary sinus defects (Joffe et al., 2008). The 
pathophysiological effects of ASD are determined by the defect size and degree of left-to-
right shunting. A large defect or unrepaired defect for a long time may lead to right heart 
volume overload, and subsequent right atrium (RA), RV, and PA dilation.  
Ostium secundum ASD is the most commonly encountered ASD. It is located in the central 
portion of the interatrial septum. Mitral valve prolapse and regurgitation sometimes 
accompany this defect. With the advancement in treatment, many people now have 
transcatheter occluder placement instead of surgical patch repair. Mid-esophageal four-
chamber and bicaval views delineate the interatrial septum clearly and are used in the 
evaluation of ASD repair surgery (Figure 1). 
 
 
Fig. 1. Secundum atrial septal defect. (A) Preoperative mid-esophageal four-chamber view 
shows a defect (D) in interatrial septum. (B) The defect is repaired with a patch (P). RA, right 
atrium; RV, right ventricle; LA, left atrium.  
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Ostium primum ASD is also known as partial atrioventricular canal defects (see below). It is 
located in the inferior portion of the interatrial septum. It can be visualized in mid-
esophageal four- chamber view (Figure 2). Incomplete formation of the septum primum is 
sometimes associated with anterior mitral leaflet cleft and regurgitation.  
Sinus venosus ASD occurs near the superior vena cava (SVC) or inferior vena cava (IVC) 
entrance. This kind of defect is often associated with partial anomalous pulmonary venous 
drainage. After surgical repair, we should look not only for the residual shunt, but also the 
unobstructed flow in SVC, IVC, and pulmonary veins (Figure 3).  
Coronary sinus defects are rare, and result from a communication between the left atrium 
and coronary sinus. They are commonly associated with a persistent left side SVC. 
Preoperative TEE exam should confirm the location, size, shunt magnitude and direction, 
atrioventricular(AV) valve competence, RA and RV size, associated anomalies, and 
ventricular function. Post-bypass TEE exam should evaluate the adequacy of surgical repair, 
valvular competence, and ventricular function. 
 
Fig. 2. Mid-esophageal four-chamber view demonstrates a primum atrial septal defect 
(arrow). RA, right atrium; RV, right ventricle; LA, left atrium; LV, left ventricle. 
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poor airway control should consider transthoracic echocardiography or epicardial 
echocardiography instead. Besides, patients with history of esophageal surgery, esophageal 
varices or diverticulum, gastric or esophageal bleeding, oropharyngeal pathology, severe 
coagulopathy, cervical spine injury or anomaly require extra attention for TEE probe 
insertion. Although TEE examination is semi-invasive, some people do suffer from 
complications related to TEE probe insertion (Huang et al., 2007). These include bradycardia 
due to vagal stimulation, oropharyngeal injury, and esophageal perforation (Kamra et al., 
2011). Besides, airway compromise, vascular compression, and dysphagia may be seen after 
TEE probe insertion. Physicians should respect individual differences and be vigilant to 
possible complications. 
3. Specific defects 
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volume overload, and subsequent right atrium (RA), RV, and PA dilation.  
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portion of the interatrial septum. Mitral valve prolapse and regurgitation sometimes 
accompany this defect. With the advancement in treatment, many people now have 
transcatheter occluder placement instead of surgical patch repair. Mid-esophageal four-
chamber and bicaval views delineate the interatrial septum clearly and are used in the 
evaluation of ASD repair surgery (Figure 1). 
 
 
Fig. 1. Secundum atrial septal defect. (A) Preoperative mid-esophageal four-chamber view 
shows a defect (D) in interatrial septum. (B) The defect is repaired with a patch (P). RA, right 
atrium; RV, right ventricle; LA, left atrium.  
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Fig. 2. Mid-esophageal four-chamber view demonstrates a primum atrial septal defect 
(arrow). RA, right atrium; RV, right ventricle; LA, left atrium; LV, left ventricle. 
 




Fig. 3. Modified bicaval view shows a superior sinus venosus atrial septal defect near the 
superior vena cava and right atrial junction. RA, right atrium; LA, left atrium. 
3.2 Ventricular septal defect 
Ventricular septal defect (VSD) can be classified by its location to four groups: type I, 
doubly-committed defects; type II, perimembranous defects; type III, atrioventricular 
defects; and type IV, muscular defects. Perimembranous and muscular defects can be 
further subdivided to inlet type, trabecular type, and outlet type according to the extension 
of the defects (Penny & Vick, 2011). The pathophysiological effects are affected by the size of 
defect, the systemic and pulmonary vascular resistance, and associated defects such as ASD 
and patent ductus arteriosus (PDA). The left-to-right shunt can lead to increased left 
ventricle (LV) volume load, excessive pulmonary blood flow, and decreased systemic 
cardiac output. A long-standing pulmonary overcirculation may lead to pulmonary 
hypertension and Eisenmenger’s syndrome eventually.  
Perimembranous VSDs (Type 2) are confluent with and involve the membranous septum. 
The defects account for approximately 60-80% of VSDs. Aneurysmal transformation of 
tricuspid valve may occur and limit the shunt flow. Tricuspid regurgitation (TR) may occur 
because the tricuspid valve is deformed. Perimembranous outlet defects can associate with 
aortic cusp prolapse and even aortic insufficiency. Patients with perimembranous defects 
may develop RV hypertrophy and right ventricular outflow tract (RVOT) narrowing. When 
the hypertrophied muscular band divides the RV cavity into two chambers, the condition is 
called double-chambered RV (DCRV) (Figure 4). The outlet septum may be malaligned 
anteriorly or posteriorly which can possibly result in RVOT or left ventricular outflow tract 
(LVOT) obstruction respectively. 
 




Fig. 4. Perimembranous ventricular septal defect. The right ventricle (RV) inflow-outflow 
view demonstrates the septal defect (D) and mid-right ventricular obstruction (arrow). RA, 
right atrium;, TV, tricuspid valve. 
Doubly committed, subarterial, or supracristal defects (Type I) are roofed by the arterial 
valves in fibrous continuity. The defects account for approximately 5% and 30% of VSDs in 
western and oriental population, respectively. The defects may associate with aortic valve 
prolapse and aortic insufficiency (Figure 5).  
Muscular defects (Type IV) are completely surrounded by a muscular rim. The defects 
account for about 5-15% of VSDs. Multiple muscular defects can occur (Figure 6). The 
muscular outlet defects can also associate with aortic cusp prolapse and aortic insufficiency. 
Atrioventricular canal or inlet defects (Type III) occur close to the atrioventricular valves in 
the posterior portion of the ventricular septum. The defects account for approximately 5% of 
VSDs. 
Preoperative TEE exam should confirm the defect location, size, and numbers. Besides, the 
shunt direction and magnitude, the cardiac chamber size and PA dimension, competence of 
AV valve, presence of septal malalignment, LVOT or RVOT obstruction, evidence of 
pulmonary hypertension, and associated cardiac anomalies should be evaluated thoroughly. 
The velocity of TR jet can be used to calculate PA pressure in the absence of RVOT 
obstruction. The post-bypass TEE can offer information about the presence of residual 
shunts or outflow tract obstruction, changes in severity of valvular regurgitation, and 
ventricular function. 
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Fig. 5. Doubly-committed ventricular septal defect. Mid-esophageal long-axis view shows 
the prolapse of aortic cusp (arrow) and the septal defect (double arrow). LA, left atrium; LV, 
left ventricle; Ao, aorta. 
 
Fig. 6. Mid-esophageal four-chamber view demonstrates multiple muscular ventricular 
septal defects (arrow). RA, right atrium; RV, right ventricle; LA, left atrium; LV, left 
ventricle. 
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3.3 Atrioventricular septal defect 
Atrioventricular septal defects (AVSD), also called endocardial cushion defects, are defects 
involving atrioventricular septum. Normally, mitral valve is attached to a more cephalad 
position than tricuspid valve. However, in patients with AVSD, their mitral valve and 
tricuspid valve attach to the same level. There are two types of AVSD, partial AVSD and 
complete AVSD. In patients with partial AVSD, there is a primum type ASD and anterior 
mitral leaflet cleft. Though there are usually two orifices for the AV valve, their mitral valve 
attachment to ventricular septum is not normal, and the leaflet can be thickened, irregular, 
and dysplasic. Their mitral valve is actually part of the common AV valve and the mitral 
cleft is a commissure between anterior and posterior bridging leaflets. The attachment of 
mitral leaflet in the LVOT can cause LVOT obstruction, and poor apposition of the valve can 
cause mitral regurgitation (MR). Complete AVSD composes single orifice AV valve with 
deficiency of both atrial and ventricular septum (Figure 7). Rastelli classified this complex 
into three types according to their different degrees of bridging of superior bridging leaflet, 
its chordal attachment pattern, and the degree of associative of hypoplasia of the tricuspid 
anterorsuperior leaflet. The function of common AV valve can be quite variable, ranging 
from nearly normal function with minimal regurgitation to severely limited dysplastic valve 
with marked incompetence.  
 
Fig. 7. Complete atrioventricular septal defect. The mid-esophageal four-chamber view 
shows deficiency of both interatrial (arrow) and interventricular (double arrow) septum. 
The pathophysiology of partial AVSD is similar to simple primum ASD. The magnitude of 
left-to-right shunt is determined by the size of defect and relative ratio of systemic and 
pulmonary vascular resistance. Mitral cleft can cause significant MR and LV volume 
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overload. The MR can pass the primum ASD and results in LV to RA shunt, RA volume 
overload, and pulmonary overcirculation. In patients with complete AVSD, the presence of 
concomitant atrial and ventricular shunting can cause increased shunt flow. Pulmonary 
hypertension, secondary pulmonary vascular change, and increased pulmonary vascular 
resistance (PVR) can occur thereafter. The hemodynamic changes are affected by the 
magnitude and direction of shunt flow. There may be different directions of AV valve 
regurgitation: LV-to-left atrium (LA), RV-to-RA, LV-to RA, or RV-to-LA. 
The mid-esophageal four-chamber view of intraoperative TEE can demonstrate the defect of 
inferior part of atrial septum. Secundum ASD or patent foramen ovale (PFO) can be present 
in some patients. The broad-base MR jet not originating from the coaptation may suggest 
the presence of a cleft mitral valve (Figure 8). Cleft mitral valve may be demonstrated in 
transgastric basal short-axis view. Besides, the presence of ventricular shunting, sizes of 
both ventricle, ventricular function, magnitude and direction of AV valve incompetence, 
degree of AV valve straddling, presence of LVOT obstruction, degree of pulmonary 
hypertension, and associated cardiac anomalies must be evaluated preoperatively. The 
postoperative TEE exam should include the evaluation of ventricular function, AV valve 
competence, and the presence of residual shunt (Cohen et al., 2007). Because valvular 
regurgitation is quite pressure and load dependent, it is important that we take patient’s 
volume status and cardiac contractility into consideration when comparing preoperative 
and postoperative regurgitation severity. If prosthetic valve is replaced, it is important to 
check the function of prosthetic valve and the presence of paravalvular leak.  
 
Fig. 8. Partial atrioventricular septal defect. The mid-esophageal four-chamber view 
demonstrates a primum atrial septal defect (atrial) and mitral cleft (double arrow) with 
severe mitral regurgitation. 
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3.4 Patent ductus arteriosus and aortopulmonary window 
PDA is a postnatal communication between the main pulmonary trunk and descending 
thoracic aorta due to persistent patency of fetal ductus arteriosus (Schneider & Moore, 
2006). Shunt flow is determined by diameter of PDA and the pressure gradient. The 
preoperative TEE can demonstrate the shunt flow in the ascending aorta short-axis view 
(Figure 9). The size of left-side chambers, ventricular function, valvular regurgitation, 
degree of pulmonary hypertension, and associated cardiac anomalies must also be 
evaluated. The postoperative TEE exam can be used to detect the presence of residual 
ductal flow. 
Aortopulmonary defect, also known as aortopulmonary (AP) window, is a defect between 
ascending aorta and pulmonary artery. Without treatment, pulmonary system will be 
overloaded due to left to right shunt, and eventually develop pulmonary vascular occlusive 
disease. A significant portion of the patients have other associated cardiac anomalies. 
Preoperative TEE can detect a shunt between ascending aorta and PA (Figure 10). Evidence 
of pulmonary hypertension, ventricular function and size, defect size and shunt pressure 
gradient can be measured by intraoperative TEE. Surgical treatment usually involves aorta 
incision, defect visualization, and a patch is sutured to close the defect over the aortic side. 
The post-repair TEE exam should detect the presence of residual shunt, valvular 




Fig. 9. The upper esophageal aortic arch long-axis view demonstrates the patent ductus 
arteriosus (arrow) connecting aortic arch and left pulmonary artery. Ao, aorta. 
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Fig. 9. The upper esophageal aortic arch long-axis view demonstrates the patent ductus 
arteriosus (arrow) connecting aortic arch and left pulmonary artery. Ao, aorta. 
 




Fig. 10. Aortopulmonary window as a defect (arrow) between ascending aorta and main 
pulmonary artery. Ao, aorta; PA, pulmonary artery. 
3.5 Truncus arteriosus 
Truncus arteriosus is caused by failure of truncal ridge and aortopulmonary septum to 
develop, forming aorta and PA. There is a single great vessel arising from a common 
semilunar valve, and a VSD. The truncal valve can have variable cusps, and valvular 
incompetence is not uncommon. Further classification is dependent on the existence of 
truncal septum, and the take-off position of pulmonary arteries. The VSD is caused by 
failure of conal septum to develop and rotate. It is usually large, non-restrictive, with 
superior border adjacent to truncal valve. PA is usually of normal size, but stenosis at 
origin site or diffuse hypoplasia may happen. Other common concurrent cardiac defects 
include right aortic arch, PDA, persistent left-sided SVC, ASD, and anomalous subclaivan 
artery.  
Surgical repair encompasses separation of branched PA from truncus vessel, establishment 
of RV-PA continuity by RVOT reconstruction or RV-PA conduit, VSD closure, and repair of 
associated anomalies. Due to variable coronary anatomy, separation of PA from truncal 
vessel should be done with care. Mild to moderate truncal valve regurgitation is often 
tolerated, and will improve over time. However, severe regurgitation is a poor indicator for 
long term survival. If the truncal valve is severely incompetent, valve replacement should be 
considered.  
Intraoperative TEE should focus on truncal valve morphology and function, anatomy of the 
main and branched pulmonary arteries, size and position of the intracardiac shunting, AV 
valve competence, ventricular function and the associated cardiac abnormalities (Figure 11). 
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After repair, truncal valve function, residual intracardiac shunt and RVOT patency can be 
examined with color Doppler. Monitoring of ventricular function is important, because 
coronary artery may be compromised during pulmonary artery resection, RV-PA conduit 
reconstruction, and reimplantation of coronary arteries. Pulmonary hypertensive crisis and 
low cardiac output are potential threats for patients undergoing repair. RV function and 
severity of TR demonstrated in TEE exam can give anesthesiologist a guide for patient 
management. 
 
Fig. 11. The mid-esophageal long-axis view shows a truncal vessel overrides the left 
ventricle (LV) and right ventricle (RV) and gives rise to aorta and pulmonary artery (arrow). 
Ao, aorta; PA, pulmonary artery. 
3.6 Coarctation of aorta and interrupted aortic arch 
Coarctation of aorta (CoA) is characterized by narrowing of aortic lumen due to thickening 
or infolding of aortic media (Rosenthal, 2005). Interrupted aortic arch (IAA), on the other 
hand, is complete discontinuity between two parts of aortic arch. These lesions lie closely to 
PDA or ligament arterioum. In patients with CoA, the defect can be isolated, or associated 
with VSD or other complex cardiac disease. The LV afterload is increased in patients with 
CoA. The site and extent of the stenosis may be seen in upper esophageal level during TEE 
exam (Figure 12). However, preoperative TEE exam can offer valuable information for other 
associated anomalies, such as biscupid aortic valve, Shone’s complex, and VSD. Surgical 
treatment includes resection of stenotic area with end-to-end anastomosis, extended 
resection with primary anastomosis, subclavian flap aortoplasty, and patch augmentation. 
Some patients have balloon angioplasty and stent insertion in intervention units. 
Postoperative TEE gives a direct evidence of anatomic site patency and LV function.  
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Fig. 12. Upper esophageal aortic arch long-axis view shows coarctation of aorta (arrow). Ao, 
aorta. 
IAA is classified by its interruption location into three types: type A, interruption is distal to 
left subclavian artery; type B, interruption is between left subclavian artery and left common 
carotid artery; and type C, interruption is proximal to left carotid artery. The arterial 
circulation proximal to the interruption is supplied by the LV output. The RV output 
supplies the arterial circulation distal to the interruption via the ductus arteriosus. Patients 
usually have PDA, VSD, and aortic valve abnormalities. The VSD is usually conoventricular 
type with a posterior conal septum malalignment, which causes LVOT obstruction at either 
subvalvular or valvular level. 
Preoperative TEE can be used to evaluate the morphology of aortic arch and PDA. Other 
coexisting defects should be carefully explored. Size of LVOT and aortic valve should be 
measured. Failure to detect LVOT obstruction is likely to result in persistent heart failure 
postoperatively. Surgical treatment for IAA is more complex than simple CoA. Current 
favorable approach is one-stage repair of interruption, and total correction of intracardiac 
abnormalities. However, if LVOT obstruction prohibited one-stage correction, modified 
Norwood operation such as Damus-Kaye-Stansel connection with atrial septectomy may be 
needed. Postbyapss TEE exam should survey for anastomotic stenosis, aortic or subaortic 
obstruction, residual atrial or ventricular shunts, and signs of pulmonary hypertension. 
3.7 Anomalous pulmonary venous return 
Partial or total anomalous pulmonary venous return (PAPVR/TAPVR) indicates that some 
or all of the pulmonary veins enter systemic venous circulation instead of LA. According to 
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the connection site of pulmonary veins, anomalous pulmonary venous return (APVR) can 
be classified as supracardiac type, cardiac type, infracardiac type, and mixed type. In 
supracardiac type APVR, confluence of pulmonary veins unites to an ascending vertical 
vein and joins the innominate vein, and then drains into SVC and RA. Sometimes the 
vertical vein bypasses the innominate vein and joins SVC directly. The connection site 
between vertical vein and innominate vein or SVC is prone for pulmonary venous 
obstruction. In patients with cardiac type APVR, the pulmonary vein confluence drains into 
the coronary sinus, and then to the RA. Some of the patients will have pulmonary veins 
going directly to RA. In the infracardiac type, the pulmonary vein confluence drains into a 
descending vertical vein, goes down across diaphragm to portal vein or hepatic vein, and 
then comes back to RA with IVC. 
The pathophysiology is similar to that of ASD in patients with PAPVR. The degree of 
shunt is determined by the numbers of anomalous pulmonary venous connections. In 
TAPVR, all of the pulmonary veins drain into RA and there is no pulmonary venous 
return in LA. Blood in LA is derived from PFO or ASD, which is mixed deoxygenated 
blood, therefore the patients are cyanotic. In patients with small size or restrictive ASD, 
the systemic circulation will decrease significantly. In patients with large or nonrestrictive 
ASD, the magnitude of shunt is determined by the relative ratio of PVR and systemic 
vascular resistance (SVR).  
The pulmonary veins are in the posterior portion of the heart, which makes TEE a valuable 
tool for optimal imaging and Doppler examination. However, proper probe size should be 
considered to avoid pulmonary veins compression by probe insertion. PAPVR should be 
suspected whenever a sinus venous ASD is present. The distinguishable TEE feature of 
TAPVR includes absence of pulmonary venous connection to LA, identification of alternate 
pulmonary venous drainage site, and RV overload (Figure 13). The presence of pulmonary 
venous obstruction, pulmonary hypertension and associated cardiac anomalies must be 
evaluated. The post-repair TEE exam should check the ventricular and valvular function, 
signs of pulmonary hypertension, and presence of pulmonary venous obstruction. 
  
Fig. 13. Anomalous pulmonary venous return. (A) Cardiac type: the modified mid-
esophageal four-chamber view demonstrates the drainage of pulmonary vein (PV) into 
coronary sinus (CS) and then right atrium (RA). (B) Supracardiac type: the modified mid-
esophageal five-chamber view shows the dainage of PV into superior vena cava (SVC) 
(arrow). RV, right ventricle; Ao, aorta. 
 




Fig. 12. Upper esophageal aortic arch long-axis view shows coarctation of aorta (arrow). Ao, 
aorta. 
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Fig. 13. Anomalous pulmonary venous return. (A) Cardiac type: the modified mid-
esophageal four-chamber view demonstrates the drainage of pulmonary vein (PV) into 
coronary sinus (CS) and then right atrium (RA). (B) Supracardiac type: the modified mid-
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3.8 Tetralogy of fallot 
Tetralogy of Fallot (TOF) consists of VSD, overriding aorta, RVOT obstruction, and RV 
hypertrophy. It can be associated with right aortic arch, additional VSDs, absence of the 
pulmonic valve, coronary artery anomalies, systemic venous anomalies, AP window, and 
LVOT obstruction. Surgery involves VSD closure and repair or reconstruction of RVOT 
(Shinebourne et al., 2006).  
The pathophysiological changes in patients with TOF are related to the shunt flow across a 
large VSD and the degree of RVOT obstruction. RV pressure is increased due to large VSD 
flow and RVOT obstruction. When the RV pressure is greater than systemic pressure, a 
right-to-left shunt and arterial desaturation will ensue. There may be little or no right-to-left 
shunt if the RVOT obstruction is not severe. The common associated cardiac anomalies 
include right-sided aortic arch in 25%, ASD in 10%, and coronary anomalies in 10% of 
patients with TOF.  
Preoperative TEE exam can evaluate the degree of RV hypertrophy and aortic overriding, the 
site and severity of RVOT obstruction, size and location of VSD, direction and magnitude of 
shunt flow, ventricular and valvular function, morphology of pulmonary arteries, and 
associated cardiac lesions such as ASD. Overriding aorta and anterior malalignment of outlet 
septum can be best seen in mid-esophageal aortic valve long-axis view (Figure 14). RVOT 
obstruction and shunt across VSD can be evaluated in mid-esophageal RV inflow-outflow 
view (Figure 15). Valvular and supravalvular pulmonary stenosis can be demonstrated in 
upper-esophageal aortic short-axis view. Post-repair TEE evaluation should include the 
presence and degree of residual RVOT obstruction, residual intracardiac shunt, peripheral 
pulmonary stenosis, aortic and pulmonary regurgitation, and ventricular function.  
 
Fig. 14. Tetralogy of Fallot. The mid-esophageal aortic valve long-axis view demonstrates 
the overriding of aorta. LA, left atrium; LV, left ventricle; RV, right ventricle; Ao, aorta. 
 




Fig. 15. Tetralogy of Fallot. The right ventricle (RV) inflow-outflow view shows a ventricular 
septal defect (D) and infundibular pulmonary stenosis (arrow). Ao, aorta. 
3.9 Ebstein’s anomaly 
Ebstein’s anomaly is characterized by abnormal attachment of septal and posterior tricuspid 
leaflets in the RV, away from normal tricuspid annulus position. The anterior leaflet is 
normally attached at annulus, but morphologically enlarged, “sail-like”, and tethered to RV 
wall. The anterior leaflet may functionally obstruct the RVOT. Because tricuspid valve 
orifice is displaced downward to RV cavity at the junction of the inlet and trabecular 
components, the proximal portion of the RV is functionally integrated into RA, termed 
atrialized RV. The severity of hemodynamic compromise is related to the downward 
displacement of the leaflets, the degree of outflow tract obstruction and valvular 
regurgitation, the severity of myocardial dysfunction, and other concomitant cardiac 
abnormalities. RV output is decreased by decreased RV volume and varying degrees of 
RVOT obstruction. The most commonly accompanied disease is secundum type ASD or 
PFO. Cyanosis will occur if there is a large right-to-left shunt. Clinical presentation varied 
extremely from normal tricuspid function found incidentally on autopsy to severe cyanosis, 
compromised cardiac function, and fetal death. Appropriate surgical intervention depends 
on the age at presentation and associated anomalies. Tricuspid valve is either repaired or 
replaced depending on the extent of atrialized ventricle and morphology of tricuspid valve. 
Single ventricle repair may be performed in patients with poor RV condition. 
Considering the variety of the disease entity and different surgical approaches, 
intraoperative TEE has a significant role in preoperative evaluation and decision making. In 
mid-esophageal four-chamber view, we can calculate the displacement index, which is the 
apical displacement of tricuspid valve septal leaflet in millimeters indexed to body surface 
area. A displacement index more than 8mm/m2 is a sensitive predictor of Ebstein’s anomaly 
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(Oechslin et al. 2000). The preoperative TEE evaluation should include the RA dimension, 
size and shunt magnitude of ASD, the morphology of tricuspid leaflets, the severity of TR, 
the presence of RVOT obstruction, ventricular function, and associated cardiac anomalies 
(Figure 16). Postoperatively, we should evaluate tricuspid valve function, residual 
intracardiac shunting, residual RVOT obstruction, and RV dysfunction.  
 
Fig. 16. Ebstein’s anomaly. The mid-esophageal four-chamber view demonstrates the “sail-
like” anterior leaflet (AL) of tricuspid valve and downward attachment (arrow) of septal 
leaflet (SL) of tricuspid valve. RA, right atrium; LV, left ventricle; MV, mitral valve. 
3.10 Transposition of great arteries / congenitally corrected transposition of great 
arteries 
Dextro-transposition of great arteries (d-TGA) stands for 5-7% in congenital heart disease. It 
is characterized by concordance of the AV connection and discordance of the 
ventriculoarterial (VA) connection. Without treatment, 30% of patients will die in one week, 
50% of patients will die in one month, and 90% of patients will die in one year. Balloon atrial 
septostomy and prostaglandin E1 for PDA patency are usually given for flow 
communication. Preoperative TEE exam should include the assessment of the AV and VA 
connections, outflow tract obstruction, systemic to pulmonary communications, ventricular 
size and function, and the associated cardiac pathology (Figure 17). 
Surgical treatment for d-TGA has changed significantly through the years. Before mid 1980, 
the favored approach for infants with d-TGA is atrial switch procedure (Mustard or Senning 
operation). Surgeons will redirect the blood flow from SVC and IVC through mitral valve, 
then to LV. The heart will pump the blood from LV to PA. Pulmonary vein flow will be 
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directed to RV, aorta, and systemic circulation. This changes the parallel, non-
communicating circulation to serial connection with oxygenation. The intraoperative study 
mainly involves an assessment of systemic and pulmonary venous pathways. We should 
look for obstruction of systemic and pulmonary venous return, baffle leak, and ventricular 
function. Though atrial switch operation corrects hemodynamic abnormalities, it does not 
correct anatomical imperfections. Later complications include systemic RV failure, baffle 
obstruction, and arrhythmia. 
Arterial switch operation, the Jatene procedure, has been performed for anatomical repair 
since 1980s (Skinner et al., 2008). The great arteries are transected above the sinus valsalva 
and anastomosed to their appropriate ventricular outflows. Coronary arteries are 
translocated to the systemic outflow. Perioperative TEE should evaluate the size and flow of 
two neo-arteries, and check for any valvular stenosis or regurgitation. Because coronary 
arteries are relocated, TEE becomes an important tool for segmental and global function 
evaluation, thus providing indirect evidence of coronary perfusion.  
 
Fig. 17. Transposition of great arteries. The pulmonary artery (PA) arises from left ventricle 
(LV) and the aorta (Ao) arises from right ventricle (RV). 
Levo-transposition of great arteries (l-TGA), also commonly referred to as congenitally 
corrected transposition of the great arteries (ccTGA), is an acyanotic congenital heart 
disease. In segmental analysis, this condition is described as AV discordance and VA 
discordance, with aorta anterior and to the left of the PA. RV serves as the systemic 
ventricle. Although the physiology of blood flow is correct, systemic RV may develop 
failure progressively. 
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Double switch operation may be performed for patients with l-TGA. It is a combination of 
atrial switch operation and arterial switch operation. The preoperative TEE exam should 
evaluate the relationship of great arteries, presence of outflow tract obstruction, ventricular 
and valvular function, and associated intracardiac anomalies. The post-repair TEE exam 
should focus on the systemic and pulmonary venous return pathway, ventricular and 
valvular function, and anatomy of outflow tract and neo-great arteries. 
3.11 Double outlet right ventricle 
The key feature of double outlet right ventricle (DORV) is the two great arteries arising 
primarily from RV. For each artery, RV should contribute more than 50% of it blood flow. 
There are four types of VSD in DORV patients: subaortic VSD, subpulmonary VSD, doubly 
committed VSD, and remote VSD. DORV with subaortic VSD is the most common variety in 
DORV. The conal septum here usually deviates anterior and leftward, and sometimes 
causes subpulmonary or pulmonary valve stenosis. If there is no pulmonary stenosis, 
pulmonary blood flow is determined by the relationship of SVR and PVR. If the VSD is 
subaortic and pulmonary stenosis exists, the presentation is similar to TOF. The degree of 
cyanosis is dependent on the severity of pulmonary flow obstruction.  
DORV with subpulmonary VSD is caused by malalignment of conal septum, which should 
be differentiated from pure subpulmonary VSD. The conal septum is deviated to posterior 
and right, sometime causing subaortic narrowing. The Taussig-Bing malformation is a 
special variant of DORV with subpulmonary VSD, side by side great arteries, aorta at right 
side, and bilateral subarterial conus. The physiology of this variant is similar to d-TGA. 
Cyanosis is usually caused by inadequate mixing of systemic and pulmonary circulation, 
and improved atrial or ductal mixing by emergent balloon atrial septostomy and 
prostaglandin E1 may be needed. 
In DORV with doubly committed VSD, conal septum is deficient, and VSD is usually 
nonrestrictive. The prevalence is rare, and the hemodynamic is determined by out flow tract 
obstructions. In DORV with remote VSD or noncommitted VSD, the defects can be within 
muscular septum or AV canal septum. Because the distance of VSD and semilunar valves 
are far, surgical management is sometimes restricted. 
Different anatomical arrangements have impacts on hemodynamic presentation, and influence 
the surgical planning (Lancour-Gayet, 2008). In addition to confirming diagnosis, preoperative 
TEE should provide information that help to determine a suitable surgical procedure. The size 
and relative position of VSD to great artery locations should be evaluated by preoperative 
TEE. Color Doppler gives information of outflow tract obstruction. The presence of pulmonary 
stenosis or aortic stenosis, either valvular or subvalvular, can be imaged in multiple views. The 
relative size of both ventricles, the presence of AV valve straddling, the pulmonary valve to 
tricuspid valve distance, and presence of other associated cardiac anomalies should all be 
evaluated by preoperative TEE (Figure 18). 
In most cases, the goal of surgery is to complete biventricular repair and restore normal 
circulation. Surgeons will establish unobstructed LV to aorta continuity, establish adequate 
RV to PA continuity, and repair associated lesions. Some patients with DORV and 
subpulmonary VSD are repaired with arterial switch operation after baffling the LV to PA 
through VSD. Occasionally, in patients with unbalanced ventricle or other associated 
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anomalies, two-ventricle repair is not feasible and operation toward single ventricle 
physiology is needed.  
Postoperative complications generally fall into four groups: LV failure, RV failure, 
arrhythmia, and residual shunts. Because LV flow is baffled through VSD to great artery, 
obstruction occurs with poor configuration of the patch or insufficient enlarged VSD size. It 
is especially difficult in DORV with remote VSD. Aortic insufficiency may occur due to 
surgical damage. Residual RVOT obstruction can occur whether the repair acquired 
infundibulotomy, outflow tract patch, or some form of RV to PA conduit. Intracardiac baffle 
may compromise RVOT flow, especially in DORV with subpulmonary VSD, because the 
VSD is very close to pulmonary orifice and infundibular septal band. Tricuspid insufficiency 
may happen if chordae resection and reattachment is needed to accommodate baffle 
implantation. After arterial switch operation, neo-PA or branched PA obstruction should be 
carefully surveyed. Residual shunt may be caused by incomplete VSD repair, baffle 
detachment, and unrecognized multiple VSDs. It is prudent to carefully evaluate the repair 
by TEE before leaving operation room. 
 
Fig. 18. Double-outlet right ventricle. The mid-esophageal long-axis view demonstrates both 
aorta (Ao) and pulmonary artery (PA) arises from right ventricle (RV) and the presence of 
pulmonary stenosis (arrow) and ventricular septal defect (D). LV, left ventricle; RV, right 
ventricle. 
3.12 Single ventricular physiology 
The functionally univentricular circulation, or single-ventricle physiology, is a heterogenous 
group of cardiac abnormalities. In most patients, there is hypoplasia of either the RV or LV 
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anomalies, two-ventricle repair is not feasible and operation toward single ventricle 
physiology is needed.  
Postoperative complications generally fall into four groups: LV failure, RV failure, 
arrhythmia, and residual shunts. Because LV flow is baffled through VSD to great artery, 
obstruction occurs with poor configuration of the patch or insufficient enlarged VSD size. It 
is especially difficult in DORV with remote VSD. Aortic insufficiency may occur due to 
surgical damage. Residual RVOT obstruction can occur whether the repair acquired 
infundibulotomy, outflow tract patch, or some form of RV to PA conduit. Intracardiac baffle 
may compromise RVOT flow, especially in DORV with subpulmonary VSD, because the 
VSD is very close to pulmonary orifice and infundibular septal band. Tricuspid insufficiency 
may happen if chordae resection and reattachment is needed to accommodate baffle 
implantation. After arterial switch operation, neo-PA or branched PA obstruction should be 
carefully surveyed. Residual shunt may be caused by incomplete VSD repair, baffle 
detachment, and unrecognized multiple VSDs. It is prudent to carefully evaluate the repair 
by TEE before leaving operation room. 
 
Fig. 18. Double-outlet right ventricle. The mid-esophageal long-axis view demonstrates both 
aorta (Ao) and pulmonary artery (PA) arises from right ventricle (RV) and the presence of 
pulmonary stenosis (arrow) and ventricular septal defect (D). LV, left ventricle; RV, right 
ventricle. 
3.12 Single ventricular physiology 
The functionally univentricular circulation, or single-ventricle physiology, is a heterogenous 
group of cardiac abnormalities. In most patients, there is hypoplasia of either the RV or LV 
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which is unable to maintain a pulmonary or systemic circulation independently (Khairy et 
al., 2007). This anatomical category includes hypoplastic left heart syndrome, tricuspid 
atresia, and double-inlet LV (Figure 19). Two-ventricular repair may not be feasible in some 
complex congenital heart disease even with balanced ventricles, such as malpositioned or 
straddling AV valve, or DORV with a remote VSD, and single ventricle management 
strategy must be undertaken.  
 
Fig. 19. Single ventricle physiology. (A) Hypoplastic left heart syndrome. The mid-
esophageal short-axis view shows the mitral atresia (arrow) and hypoplasia of left ventricle 
(LV). (B) Tricuspid atresia. The mid-esophageal short-axis view demonstrates the tricuspid 
atresia (arrow) and hypoplasia of right ventricle (RV). RA, right atrium. 
In single ventricle anatomy, the functional ventricle provides a common mixing chamber, 
and must pump both the systemic and pulmonary circulations, which easily lead to volume 
overload, cyanosis, or congestive heart failure. This pathophysiology encompasses a 
complex group of diseases. The presence of systemic and pulmonary outflow tract 
obstruction both contribute to the clinical manifestation. 
Current surgical management of single ventricle is divided into 3 stages. Stage I operation 
technique is dependent on patients’ status. Surgical palliation is to achieve following goals: 
unobstructive systemic blood flow, balanced and limited pulmonary blood flow, minimal AV 
valve regurgitation, nondistorted pulmonary arteries, and unrestricted return of blood to the 
ventricle. If pulmonary flow is unrestricted, pulmonary banding is done to minimize 
ventricular overload and avoid pulmonary hypertension. If systemic obstruction is noted, 
Norwood operation or Damus-Kaye-Stansel palliation is used. A systemic to pulmonary 
shunt, such as Blalock-Taussig (B-T) shunt is placed to provide pulmonary blood flow in 
patients with obstructed pulmonary circulation. In addition, AV valve repair and atrial 
septostomy may be needed according to patients’ condition. The preoperative TEE exam 
includes the evaluation of AV and VA connections, AV valve morphology and function, 
degree of outflow tract obstruction, size and morphology of ventricles, and associated cardiac 
anomalies. The postoperative TEE exam should focus on the presence of systemic outflow tract 
obstruction, AV valve function, status of pulmonary blood flow and ventricular function. 
Stage II operation mainly aims to connect SVC to PA and eliminate or restrict other sources 
for pulmonary blood flow. Bidirectional Glenn shunt and hemi-Fontan anastomosis are 
representatives. Bidirectional Glenn shunt is built from SVC to PA. After the operation, the 
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driving force to pulmonary circulation is SVC pressure. Part of the left to right shunt is 
removed, and thus relieving the volume load from single ventricle. Perioperative TEE exam 
includes the evaluation of the anastomosis site, PA morphology,AV valve function, and 
ventricular function. 
Current approach for stage III operation is Fontan operation or total cavopulmonary 
connection. Intracardiac lateral tunnel or extracardiac conduit may be used to create 
cavopulmonary connection. In this stage, pulmonary flow is dependent on systemic venous 
pressure, and all the pulmonary flow is effective. Fontan fenestration is sometimes provided 
to offer a source to systemic circulation that is not dependent on passing through 
pulmonary circulation. The perioperative TEE exam includes evaluation of the patency of 
cavopulmonary connection, AV valve function, size and flow of fenestration, and 
ventricular function (Figure 20). 
 
Fig. 20. There is a fenestration with shunt flow (arrow) between the extracardiac conduit (C) 
and right atrium (RA) after total cavopulmonary connection in a patient with tricuspid 
atresia. 
4. Conclusion 
Congenital heart disease is a complex disease entity of various severities. Intraoperative 
TEE offers valuable information about patients’ anatomy and pathophysiology. In 
addition to diagnosis confirmation, TEE is a useful guide for surgical planning and 
anesthetic management. Intraoperative assessment by TEE images may be difficult due to 
complicated pathological presentations. A thorough understanding of anatomy, 
pathophysiology, and surgical procedure of congenital heart disease is required for 
interpretation of intraoperative TEE.  
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1. Introduction 
Kawasaki disease is an acute childhood systemic vasculitis characterised by a number of 
clinical features, with a predilection for damage to the coronary arteries. It predominantly 
affects children between the ages of 6 months to 4 years, although cases at either extreme of 
childhood are well described and are recognised to be associated with a greater risk of 
delayed diagnosis and treatment (Harnden et al., 2009; Pannaraj et al., 2004). There is a male 
predominance with a male to female ratio of 1.6 to 1. Despite important research progress 
since its first description in 1967 (Kawasaki, 1967), the aetiology remains unknown and there 
is no diagnostic test. The timely use of intravenous immunoglobulin has reduced the 
incidence of coronary artery lesions from 25% to 2-4% (Newburger et al., 2004). 
Transthoracic echocardiography is recommended in suspected cases of KD, however a 
normal study does not exclude the diagnosis.  
2. Incidence 
Kawasaki disease is the most common cause of paediatric acquired heart disease (Taubert et 
al., 1991). The incidence has been rising in both developed (Japan, Korea and United 
Kingdom) and rapidly industrialising countries such as India, which may reflect both a 
genuine increase and increased recognition (Krishnakumar & Mathews, 2006). The highest 
annual incidence is reported in Japan (218 per 100000 children <5 years of age) and Korea 
(113 per 100000 <5 years) (Nakamura et al., 2010; Park et al., 2011). The incidence is lower in 
Australia (3.7 per 100000 <5 years) but this data is 15 years old (Royle et al., 1998); given the 
rising incidence in other countries these rates may be an underestimate of true disease 
burden. Current epidemiological research is in progress in Western Australia, and these 
data will provide an updated incidence for Australia children.  
3. Aetiology  
The high incidence of Kawasaki disease in Asian populations and increased risk in families 
and siblings suggests a genetic predisposition (Fujita et al., 1989; Uehara et al., 2003). 
Seasonal patterns are well recognised, with peaks in winter and spring in Australia, the 
United States and Europe and spring to summer peaks in Korea and China (Burgner & 
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Harnden, 2005). The epidemiology of Kawasaki disease, clustering of cases, community 
outbreaks and epidemics in the 1980s, support the hypothesis that an unknown infectious 
agent (or agents) triggers an abnormal inflammatory response in genetically susceptible 
individuals. Both conventional antigens and bacterial superantigens have been implicated as 
causative triggers in Kawasaki disease, however the triggering pathogen(s) remain 
unknown. 
4. Pathogenesis 
Initially, activated inflammatory cells, particularly monocytes, macrophages, T-cells, and 
subsequently platelets, adhere to the endothelial cells that line medium-size elastic arteries. 
Other mediators contribute to destruction of the extra-cellular matrix, leading to vessel 
dilatation, and subsequent smooth muscle proliferation in the media contributes to later 
pathology. There is destruction of the intimal layer of the affected artery with inflammatory 
infiltrate during the acute phase, and histologic findings of myocarditis and fibrosis are 
found in virtually all cases with Kawasaki disease (Yutani et al., 1981). 
5. Clinical assessment 
The typical presentation is of an irritable child who has an unremitting high fever (often 
>39C) for 5 or more days, and some or all classical diagnostic of the clinical features (Table 1). 
The diagnosis can also be made by experienced clinicians on the fourth day of fever if classical 
diagnostic criteria are met.1 In most children the clinical features appear sequentially. Specific 
features for KD include perineal desquamation and erythema or crusting around the Bacille 
Calmette Guerin (BCG) inoculation site. Other extracardiac features such as respiratory or 
gastrointestinal symptoms occur frequently and make the diagnosis difficult. 
 
 
The diagnosis requires the presence of fever for at least 5 days, and at least four of the 
following five criteria: 
 
- Polymorphous rash 
- Oral mucous membrane involvement, including red fissured lips, strawberry tongue 
or injected pharynx 
- Bilateral non-exudative conjunctivitis 
- Changes with extremities including erythema or oedema of palms and soles, or 
periungal desquamation as a late sign in the subacute phase (~2 or more weeks after 
illness onset) 
- Cervical lymphadenopathy, defined as a unilateral lymph node of ≥1.5cm 
 
Table 1. The diagnostic criteria for Kawasaki disease (Newburger et al. 2004)  
Incomplete KD should be considered in children who have an unexplained prolonged 
febrile illness and have not met diagnostic criteria (Newburger et al., 2004). This occurs 
more commonly in children less than 6 months or greater than 5 years of age, with the 
younger age group more likely to present with fewer clinical features and also a higher 
incidence of coronary artery abnormalities (Genizi et al., 2003). 
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Kawasaki disease shock syndrome has been recently described and is characterised by 
hypotension and haemodynamic instability, often requiring intensive care. (Dominguez et 
al., 2008; Yim et al., 2010) These patients may be at increased risk of delayed diagnosis and 
treatment, refractory disease and more severe coronary artery involvement (Kanegaye et al., 
2009). 
6. Echocardiography in Kawasaki disease 
Transthoracic echocardiography is highly sensitive and specific for the diagnosis of 
coronary artery involvement and should be performed in confirmed or suspected cases of 
Kawasaki disease at the time of diagnosis. It is important to ensure that the timing or 
results of the echocardiogram do not delay initial treatment of Kawasaki disease, and that 
the diagnosis is made predominantly on clinical findings. On the other hand, if full 
criteria are not met and coronary artery abnormalities are present on echocardiography, 
then the child has incomplete features of Kawasaki disease and treatment with high dose 
intravenous immunoglobulin should be considered. The American Heart Association 
consensus guidelines provide a schema for the incorporation of echocardiography into the 
diagnostic process in children with possible incomplete Kawasaki disease (Newburger et 
al., 2004). 
7. Principles of echocardiographic assessment 
7.1 Optimisation of imaging modalities 
The primary aim of echocardiography is to identify coronary artery involvement, 
pericarditis and/or myocarditis. As always, optimising machine settings, using the highest 
possible frequency transducer and reducing two-dimensional gain and compression can 
achieve better image quality and resolution. B-mode cine loops and still frame images are 
necessary to assess coronary artery calibre, along with colour Doppler imaging set at a low 
Nyquist limit for evaluating normal coronary artery diastolic flow. Sedation may be 
necessary in children who are too irritable to tolerate a detailed study; our preference is to 
use 50-100mg/kg of chloral hydrate (max 1g) given orally with heart rate and peripheral 
oxygen saturation monitoring.  
7.2 Coronary artery assessment  
Coronary arteries should be assessed in multiple imaging planes before a decision is 
reached about the presence or absence of coronary artery abnormalities. The parasternal 
short axis view with or without a clockwise rotation of the transducer allows for imaging of 
the left coronary artery origin, left anterior descending artery and left circumflex artery, as 
well as the right coronary artery origin and proximal course. Parasternal long axis views 
with sweeps between the aorta and pulmonary artery will delineate the left main coronary 
artery, left anterior descending and circumflex arteries. Subcostal views are helpful for 
assessing the left circumflex artery and the mid-course of the right coronary artery. Apical 
four chamber views will show the length of the left circumflex artery and distal right 
coronary artery in the left and right atrioventricular grooves respectively. Coronary artery 
measurements should be taken from the inner edge to inner edge of the vessel wall and 
should not be measured at the level of normal branching. 
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6. Echocardiography in Kawasaki disease 
Transthoracic echocardiography is highly sensitive and specific for the diagnosis of 
coronary artery involvement and should be performed in confirmed or suspected cases of 
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Nyquist limit for evaluating normal coronary artery diastolic flow. Sedation may be 
necessary in children who are too irritable to tolerate a detailed study; our preference is to 
use 50-100mg/kg of chloral hydrate (max 1g) given orally with heart rate and peripheral 
oxygen saturation monitoring.  
7.2 Coronary artery assessment  
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reached about the presence or absence of coronary artery abnormalities. The parasternal 
short axis view with or without a clockwise rotation of the transducer allows for imaging of 
the left coronary artery origin, left anterior descending artery and left circumflex artery, as 
well as the right coronary artery origin and proximal course. Parasternal long axis views 
with sweeps between the aorta and pulmonary artery will delineate the left main coronary 
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assessing the left circumflex artery and the mid-course of the right coronary artery. Apical 
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coronary artery in the left and right atrioventricular grooves respectively. Coronary artery 
measurements should be taken from the inner edge to inner edge of the vessel wall and 
should not be measured at the level of normal branching. 
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8. Cardiovascular involvement 
8.1 Coronary artery involvement 
The main features of coronary artery involvement are dilatation, aneurysm formation, lack 
of tapering of the distal coronary vessel and perivascular brightness. Aneurysms may be 
fusiform (spindle-shaped, gradual tapering from normal to dilated segment), saccular 
(spherical, acute transition from normal to dilated segment), ectatic (uniformly dilated long 
segment) or segmented (multiple dilatations joined by normal or stenotic areas) (Figure 1). 
The common sites of coronary involvement (from highest to lowest frequency) include the 
proximal left anterior descending artery (Figure 2), proximal right coronary artery (Figure 3 
& 4), left main coronary artery (Figure 5), left circumflex branch (Figure 5), distal right 
coronary artery (Figure 6) and the junction of the right and posterior descending coronary 
artery. Takahashi et al reported that aneurysms were more likely to resolve if they were 
fusiform in nature and if the child was female and/or less than a year of age. Distal 
coronary artery aneurysms tended to regress more rapidly than aneurysms located in 





Fig. 1. Illustrative example of coronary artery abnormalities.  
 




Fig. 2. Parasternal short axis echocardiographic image at the level of the mitral valve leaflets 
demonstrating an aneurysm of the left anterior descending artery.  
 
Fig. 3. Parasternal short axis echocardiographic image showing a uniformly dilated 
proximal right coronary artery (RCA). 
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Fig. 4. Parasternal short axis image showing a giant aneurysm of the right coronary artery 
(RCA). 
 
Fig. 5. Parasternal short axis view showing a uniformly dilated left main coronary artery 
(LMCA, 4.7mm) and dilated circumflex artery (Cx, 3.4mm). Ao = aorta 
 














Fig. 6. Off-axis parasternal short axis view demonstrating a fusiform aneurysm of the mid to 
distal right coronary artery (RCA) aneurysm  
8.2 Myo-pericarditis 
Virtually all patients with Kawasaki disease develop myocarditis to varying degrees 
during the acute phase, and over half of these patients develop acute transient left 
ventricular dysfunction (Ajami et al., 2010). Systolic left ventricular function should be 
routinely assessed. Regional wall motion abnormalities may occur if there is significant 
coronary artery involvement. Pericarditis may be reflected by the presence of a pericardial 
effusion. 
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8.3 Valvar involvement 
Myocardial inflammation may also involve valve tissue and lead to mitral, tricuspid or 
aortic regurgitation that is usually mild in nature. If severe mitral regurgitation is present, 
papillary muscle dysfunction and myocardial ischaemia should be assessed (Akagi et al., 
1990). Mild aortic regurgitation is seen to persist in approximately 4% of patients with serial 
follow-up (Ravekes et al., 2001). Aortic root dilatation may occur as part of the overall 
vasculitis but is usually mild. 
9. Timing of echocardiography 
The consensus statement from the American Heart Association recommends performing 
echocardiography at diagnosis, 2 weeks and repeating at 6-8 weeks after the onset of illness 
for uncomplicated cases. In some centres the 2 week echocardiogram is not routinely 
performed. The imaging at diagnosis should provide a baseline study for serial follow-up of 
left ventricular function, coronary arterial involvement, valvar regurgitation, myocarditis 
and/or a pericardial effusion. The presence of any cardiac involvement warrants closer follow-
up. In particular, coronary aneurysms > 5mm in size require close monitoring because of an 
elevated risk of developing stenotic lesions within the vessel (Mueller, 2009). By 6-8 weeks, 
transient cardiac involvement is likely to have resolved, or if coronary artery dilation and/or 
aneurysms are present, the maximum diameter is usually reached by this time.  
10. Definitions of coronary artery involvement 
A number of definitions have been proposed to describe and quantitate coronary artery 
involvement. The Japanese Ministry of Health classification was first published in 1984. 
Aneurysms are considered to be small if their internal diameter is <5mm, medium if 
between 5-8mm, or giant if the internal diameter of the aneurysm is >8mm (Figure 5). These 
criteria are widely used and define absolute values for coronary artery dimensions and 
therefore do not account for differences in patient size or the usual caliber of different 
coronary artery branches. The American Heart Association AHA guidelines were published 
in 2004 and define coronary artery dimensions with respect to body surface area, which 
requires both weight and height measurements. These define a coronary artery as dilated if 
the intra-luminal diameter has a z-score of ≥ 2.5mm. Manlhiot et al. recently proposed a 
revision of this classification to account for differences in body size and caliber of coronary 
artery branches, and report that coronary artery abnormalities are small if the z-score is ≥ 2.5 
to <5, large if the z-score is ≥ 5 to < 10, and giant if the z-score is ≥ 10 (Manlhiot et al., 2010). 
This method is however prone to significant variation in the calculated z-score with minor 
variation in measurement of coronary size. It is therefore too early to determine whether this 
classification will be widely employed. 
11. Further imaging modalities 
As the difficulty of coronary artery imaging increases with age, further imaging options may 
be necessary. Even in experienced hands, echocardiography also has its limitations in 
detecting stenosis and thrombosis. The efficacy of other non-invasive imaging modalities 
such as magnetic resonance imaging and multi-detector computed tomography has been 
increasingly evaluated for coronary artery assessment in Kawasaki disease (Figure 7).  
 








Fig. 7. Magnetic resonance image using T2 weighted truFISP sequence demonstrating a 
dilated left anterior descending (LAD) artery with a distal fusiform aneurysm.  
12. Functional assessment 
Cardiac stress testing may be used to identify reversible ischaemia and regional wall 
motion abnormalities during increased demand. Coronary perfusion abnormalities can be 
further assessed with exercise echocardiography, pharmacologic (dobutamine, 
dipyridamole or adenosine) stress echocardiography and exercise myocardial perfusion 
scans. The stress modality employed depends on the age of the child and local expertise, 
although practically speaking, pharmacologic stress echocardiography or exercise 
myocardial perfusion scans are the preferred techniques in the paediatric age group. If 
abnormalities of coronary segmental perfusion are found, the results may assist decision-
making for further management.  
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13. Cardiac catheterisation 
Cardiac catheterisation with selective coronary angiography is considered the gold standard 
for delineation of coronary artery anatomy, and if required interventional procedures such 
balloon angioplasty, stent placement or percutaneous transluminal coronary 
revascularisation may be performed in the same setting. Cardiac catheterisation is generally 
not recommended for patients with mild coronary artery involvement, however it can 
provide useful detailed information and help with risk stratification of patients who have 
complex coronary artery lesions (Figure 8 & 9). Coronary angiography in this instance is 








Fig. 8. Lateral selective coronary angiogram demonstrating a significantly dilated left 
anterior descending (LAD) artery and proximal circumflex (Cx) artery. 
 







Fig. 9. Lateral angiographic plane with injection of contrast in the ascending aorta via a pigtail 
catheter, showing large saccular aneurysms in both the proximal right and left coronary 
arteries. (Image courtesy of Professor Mike South, Royal Children’s Hopsital, Melbourne) 
14. Natural history  
The percentage of patients developing coronary aneurysms is reduced with timely 
administration of intravenous immunoglobulin. Nearly 50% of those coronary artery 
aneurysms will show angiographic regression within 1 to 2 years following the illness, 
with smaller lesions having a greater chance of resolution (Newburger et al., 2004). The 
size of the aneurysm is a major predictor for the development of myocardial infarction 
(Yeu et al., 2008). As aneurysms remodel with time, however, the risk of coronary artery 
stenosis increases.  
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There is evidence that Kawasaki disease in childhood may increase the risk of 
cardiovascular disease in adulthood. Patients with coronary artery aneurysms have an 
increase in carotid artery intima-media thickness, and increased systemic arterial stiffness 
with higher pulse wave velocities (Cheung et al., 2007; Ooyanagi et al., 2004; Suzuki et al., 
1996). Furthermore there are data demonstrating abnormal vascular endothelial function 
and lipid profiles in patients. The exact level of increased risk is uncertain. 
15. Follow-up recommendations  
Patients with Kawasaki disease should be followed up based on risk stratification according 
to the severity of coronary artery involvement in consultation with a paediatric cardiologist 
familiar with managing the condition.  
 
 
 Kawasaki disease is a common childhood systemic vasculitis characterized by 
specific clinical features and persistent fever for at least 5 days. 
 
 Transthoracic echocardiography is recommended in suspected cases of Kawasaki 
disease, however a normal study does not exclude the diagnosis.  
 
 Treatment with high dose intravenous immunoglobulin should be initiated based 
on the clinical presentation, and should not be delayed by the timing of 
echocardiography. 
 
 The aims of echocardiography are to identify coronary artery dilatation and 
aneurysms, valvar regurgitation, myocarditis with ventricular dysfunction and 
pericarditis with effusion. 
 
 Echocardiography should be performed at diagnosis, and approximately 6-8 weeks 
after the onset of illness, with more frequent assessments required if cardiac 
involvement is present.  
 
Table 2. Kawasaki disease - Summary points  
16. Conclusion 
In summary, Kawasaki disease is an important and common systemic vasculitis of 
childhood, and the advent of intravenous immunoglobulin has significantly reduced, but 
not removed the risk of abnormal coronary artery development in affected individuals. 
There have been significant advances in our overall understanding of the condition, 
although the aetiology remains uncertain. Of concern is the emerging evidence that KD is a 
risk factor for adult coronary artery disease. Further research into pathogenesis and long 
term outcomes are required. 
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as malignant melanoma, lymphomas, leukaemias and sarcomas. Lymphatics and direct 
invasion from adjacent organs such as lung and breast cancers or mediastinal lymphomas is 
another way of spread (7, 6). 
2. Benign primary cardiac tumors 
2.1 Myxoma 
Three quarters of all primary cardiac tumors are benign and half of them are myxomas. 
These tumors occur mostly in third decade or later. Myxomas can occur as an isolated tumor 
in left atrium (the most common site of this tumor)[figure 1] or as familial form (Carney 
syndrome) which is associated with other manifestations. Most frequently it occurs in left 
atrium, then in right atrium, right ventricle and left ventricle; it can infrequently involve the 
valves. It is mostly attached to fossa ovalis via its stalk. 
 
 
Fig. 1. Parasternal long axis view. A 38 year old man with history of dyspnea. 
Echocardiography revealed left atrial mass. He underwent cardiac surgery and pathology 
showed myxoma.  
Myxoma has different clinical presentations. These include constitutional symptoms such as 
fever, weight loss, embolic events and symptoms of valvular obstruction such as the 



























Fig. 2. A 38 year old man with history of dyspnea. Myxoma can protrude through mitral 
valve and in M-mode mitral stenosis can be visualized as seen in this Echocardiograph. 
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It has also different shapes as rounded or polypoid with narrow stalk and attachment to 
interatrial septum or fossa ovalis. The mass is mostly homogenous; however, small scattered 
area of calcification may be seen. Mobile particles of this tumor describe and predict its 
tendency for embolic events (8). 
Echocardiography provides useful information about the location, size, extension and 
texture of this tumor, and one should be careful not to miss the multiple myxomas that 
could be found in other chambers. 
Definite treatment for myxoma is total excision of the mass. Follow up echocardiography to 
rule out recurrence is recommended. 
2.2 Papillary fibroelastoma 
Papillary fibroelastoma is a rare, primary benign cardiac tumor that is most frequently 
found in the cardiac valves (9). It is the third primary cardiac tumor after myxoma and 
lipoma. These tumors are mostly found incidentally on post mortem. However, because of 
high tendency for systemic emboli, prompt diagnosis and management is necessary. Other 
rare presentations such as sudden death have been reported (10-12).  
Papillary fibroelastoma represents 7.9% of benign primary cardiac tumor in adults (9). 
Approximately 90% of primary fibroelastomas arise from valves on ventricular side of 
pulmonary and aortic valve and atrial side of mitral and tricuspid valve (13-14). Aortic or 
mitral valves are mostly affected (15-16). The tricuspid valve is most affected in children; 
however, mitral and aortic valves are mostly affected in adults (17). Echocardiography 
remains the main tool for detection of this tumor. Because of involvement of cardiac valves 
other diagnosis such as infective endocarditis, degenerative changes and 0Lamble’s 
excrescences should be kept in mind. Typical echocardiographic features include round, 
oval or irregular appearance, with a homogenous texture with small stalk (18). Surgical 
removal is indicated for large mobile tumors. 
2.3 Rhabdomyoma 
It is the most frequent cardiac tumor of childhood (about 60% of cardiac tumors) which is 
frequently found by fetal echocardiography (8). This tumor occurs in both ventricles equally 
with intramural involvement; however, atrioventricular valves involvement is also seen. 
This tumor may regress spontaneously. 
2.4 Lipoma 
It is a benign cardiac tumor that is asymptomatic in many patients (3). CT scan or MRI can 
easily define the tissue characteristic of fat and make an accurate diagnosis. 
2.5 Hemangioma 
It is a benign vascular tumor which occurs equally in left and right ventricles, and in right 
atrium. When tumor is resectable, total excision is recommended. Other benign cardiac 





3. Malignant primary cardiac tumors 
Sarcomas are the most common primary malignant tumors and consist of 95% of cases. Any 
part of heart can be affected and rapid progression of disease is the usual clinical course of 
this tumor (8). 
3.1 Angiosarcoma 
Angiosarcoma is the most common primary malignant cardiac tumor (7). Men are involved 
more than female with a ratio of 2:1. Its usual location is right atrium and interatrial septum 
with involvement of pericardium and pericardial effusion [figure 3] (8). Other forms of 
sarcoma can occur in the left side of the heart and resemble the presentation of myxoma. It 
has a poor prognosis. 
 
Fig. 3. Large tumor in right atrium with invasion toward interatrial septum and left atrium 
with pericardial effusion. In a 27 year old man who presented with progressive dyspnea. 
4. Metastatic cardiac tumors 
Metastatic tumors are 20 to 40 times more common than primary malignant ones with 
prevalence of 6% in post-mortem autopsies in malignant diseases (6). 
4.1 Malignant melanoma 
For the first time the term “melanotic heart” was introduced by William Norris in 1820 (7). 
However, many cases of malignant melanoma have been described in scientific literature. 
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Malignant melanoma frequently (50-71%) metastasizes to the heart (19). It seems to have the 
highest rate of metastases to heart. When a patient presents with cardiac metastases of 
melanoma, the disease has already spread throughout the body and is rarely curable (20). 
Single metastasis is rare. Metastases could be found in right side or left side; however, 
bilateral metastasis is frequently seen (21). The way of tumor spread toward heart is mostly 
hematogenous as seen in lymphoma and leukemia. 
Previously, histologic diagnosis of malignant melanoma was made postmortem; however, 
with early detection of metastases due to availability of new imaging modalities, definite 
antemortem diagnosis and pathologic examination is frequently possible. Tissue specimen 
can be obtained by echocardiography guided transvenous biopsy or by resection of mass 
(22). 
The symptoms are nonspecific such as chronic pericarditis, congestive heart failure, 
pericardial effusion, tamponade, conduction disturbances or defects, arrhythmias such as 
ventricular or supraventricular heart rhythm disturbances (23,24), syncope, embolism events 
such as transient ischemic attack and hemodynamic changes secondary to valve 
dysfunction. 
Malignant melanoma has the highest rate of metastases to heart; however, due to 
improvement in treatment for this disease, longer survival than previous is now possible 
(25) and with newer imaging modalities early detection of metastases is possible and the 
physician should be alert of the risk of metastases. Transesophageal echocardiography has 
higher sensitivity than transthoracic echocardiography and cardiac magnetic resonance 
imaging with its ability to define the mediastinal involvement could also be used. According 
to tumor characteristics, its burden, location and size, palliative surgery or complete 
resection or adjuvant systemic therapy is recommended. 
5. Summary 
Echocardiography both transthoracic echocardiography (TTE), transesophageal 
echocardiography (TEE), is the commonly available noninvasive method for the diagnosis of 
cardiac masses. Tumor size, location and texture, and its extension to adjacent organs, its 
attachment to cardiac structures, presence or absence of pericardial effusion, interference 
with valve function, any obstruction and tumor mobility could be evaluated by 
echocardiography. In patients with poor echo window, TEE gives superior results, however, 
in some patients for better evaluation of cardiac tumor and its extension, other imaging 
modalities such as MRI is needed. Extra cardiac structures could be visualized better in TTE 
then TEE which is important for surgeons for choosing the most suitable plan for surgery(7). 
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